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ABSTRACT
Mammalian casein kinases I (CKI) belong to a family of serine/threonine protein
kinases involved in diverse cellular processes including cell cycle progression,
membrane trafficking and Wnt signalling. CKIa was identified by our laboratory as the
protein kinase from brain which phosphorylates 14-3-3C, on residue 233.
Phosphorylation of this residue in vivo negatively regulates 14-3-3^ binding to c-Raf and
may be important in Raf-mediated signal transduction. The protein kinase C-potentiated
myosin light chain phosphatase (MLCP) inhibitor, CPI-17 and the phosphatidylinositol
binding protein, centaurin-ai,were two out of six proteins which co-purified with CKIa
from brain after 4 chromatography steps, suggesting they might be forming a complex.
The aim of this study was to characterise the interaction between CPI-17 and CKIa
further and to identify new binding proteins for CPI-17 and centaurin-ai by affinity
chromatography and subsequent Western blotting and/or mass spectrometry analysis to
increase the understanding of the physiological functions CPI-17 and centaurin-ai.
PKC isoforms from all PKC classes, casein kinase I (CKI) isoforms (CKIa and
CKIs) and cyclic AMP dependent kinase (PKA) were eluted from the CPI-17 affinity
column. The site of interaction was mapped to the cysteine rich domain of PKC and to
the kinase domain ofCKI. The interaction site of CPI-17 with these two kinases was
mapped to the first 120 residues. CPI-17 was shown to be phosphorylated by PKC
isoforms from all PKC classes, but not by CKI. However, CPI-17 inhibited CKI activity.
Novel potential binding proteins ofCPI-17 were identified by mass spectrometry and
included cytoskeletal proteins and proteins involved in vesicular trafficking. These
results indicate that CPI-17 occurs in a multiprotein complex, suggesting that CPI-17
may have roles other than MLCP inhibition during smooth muscle contraction.
Novel centaurin-ai binding proteins were identified, amongst them PKC
isoforms from all PKC classes, which all phosphorylated centaurin-ai. The site of
interaction was mapped to the cysteine rich domain of PKC. The nucleolar protein,
nucleolin was identified as another centaurin-ai binding protein and the interaction was
shown to be RNA dependent. A number of potential novel centaurin-ai binding proteins
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was identified by mass spectrometry and included proteins involved in ribosome
biogenesis and RNA processing. This suggested a role for centaurin-ai and possible
involvement in other nuclear events. In summary, novel CPI-17 and centaurin-ai
binding proteins were identified and some of these interactions characterised, opening
up new potential roles for CPI-17 and centaurin-ai in cellular processes ranging from
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The introduction gives a general overview of casein kinase I (CKI), protein
kinase C-potentiated inhibitor of 17 kDa, (CPI-17), protein kinase C (PKC), centaurin-
ai and nucleolin. The objective of this study was to identify novel CPI-17 and centaurin-
oci binding proteins in order to increase the understanding of the physiological roles of
these proteins. Our laboratory has identified CPI-17 and centaurin-oci as two proteins co-
purifying with CKIa from brain after four chromatography steps suggesting they form a
complex. Originally, CPI-17 was identified as a MLCP inhibitor and the inhibition by
CPI-17 is strongly potentiated by phosphosphorylation of Thr-38 in vivo. Centaurin-ai
has been identified as a phosphatidylinositol interacting protein, whose function remains
unknown.
Data presented in this thesis demonstrate that PKC interacts with CPI-17 and
centaurin-ai and phosphorylates both proteins. CKI was identified as a novel CPI-17
binding protein. Furthermore, a number ofnovel potential CPI-17 and centaurin-ai
binding proteins were identified, and a possible role for CPI-17 in cytoskeletal re¬
arrangement and vesicular trafficking and for centaurin-ai in nuclear processes such as
ribosome biogenesis is proposed.
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1.2. CKI
The casein kinase I (CKI) family of serine/threonine kinase is highly conserved
and ubiquitously expressed in every eukaryotic organism tested so far, from yeast to
human (reviewed in Gross and Anderson, 1998). Until now, seven isoforms from
distinct genes have been identified in mammals, designed a, P, yi, 72, 73, 5 and 8. Four
isoforms are expressed in Saccharomyces cerevisiae (Hrr25, Yckl, Yck2 and Yck3) and
five in Schizosaccaromyces pombe (Ckil, Cki2, CKi3, Hhpl and Hhp2).
The CKI family is characterised by a conserved kinase domain (more than 50%
identity) and variable amino- and carboxyl-terminal tails. The diverse amino and
carboxyl termini may provide each isoform with distinct functions and regulation
mechanisms in cells (Gross and Anderson, 1998). The carboxyl-terminal extensions of
different kinase family members have been shown to be important for mediating down-
regulation of kinase activity through autophosphorylation (Cegielska et al., 1998; Graves
and Roach, 1995), for directing subcellular localisation (Wang et al., 1992) and
potentially for interaction with protein substrates (Sakanaka et al., 1999). It has been
shown that when phosphorylated, a number of the residues within their respective
carboxyl termini would generate a phosphorylated region which could act as a
pseudosubstrate and inhibit kinase activity (Gross and Anderson, 1998). A schematic
representation of mammalian CKI isoforms is shown in Figure 1.1 which has been
adapted from Gross and Anderson (1998).
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□ N-tt □ Kinase domain [I] C- terminus
0 Kinesin homology 0 Putative nuclear
domain localisation sequence
Figure 1.1 Schematic representation of the mammalian CKI isoforms.
Grey regions represent the conserved kinase domains, green and blue delineate the
variable regions in the amino and carboxyl termini, respectively. The kinesin homology
domain (pink) and nuclear localisation signal (purple) are also shown.
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CKI isoforms possess a near-consensus SV40 T-antigen putative nuclear
localisation sequence and they also contain a kinesin homology domain, that is
conserved among a number of kinesin homologues (Gross and Anderson, 1998). In
kinesins, which are microtubule associated motor proteins involved in a number of
cellular events including vesicular trafficking and mitotic spindle assembly, this domain
is thought to be involved in microtubule interactions and it has been proposed that
certain CKI isoforms could be involved in similar cellular events. The molecular weight
and tissue distribution ofmammalian CKI isoforms are summarised in the table below
(Gross and Anderson, 1998).
Table 1.1 Molecular weight s and tissue distribution of CKI isoforms
CKI isoform Molecular weight (kDa) Tissue distribution







All tissues, except heart
and spleen
5 49 Pre-dominantly testis
Number of cell lines
8 47 Tissue distribution
unknown
1.2.1. CKI substrates
CKI proteins phosphorylate substrates with a negatively charged region (i.e.
acidic amino acids like aspartate) amino-terminal to the site of phosphosphorylation
(reviewed in Vielhaber and Virshup, 2001). Some CKI isoforms have been shown to
phosphorylate tyrosine as well as serine/threonine (Braun et al., 1984; Hoekstra et al.,
1994; Pulgar et al., 1996), but it is not yet known which CKI isoforms are dual-
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specificity kinases and what the in vivo implications could be (Gross and Anderson,
1998). The consensus phosphorylation sequence for CKI has been defined as
S/T/Y(P)Xi_2S/TY or Dn-Xi_2S/T/Y where S/T/Y(P) stands for any phosphorylated
serine, threonine or tyrosine residue, X is any amino acid and D is aspartic acid
(Vielhaber and Virshup, 2001). CKI isoforms have been shown to phosphorylate a large
number of different proteins from all cellular compartments in vitro. CKI substrates
include insulin growth factor (Rapuano and Rosen, 1991; Tuazon et al., 1985), tumour
necrosis factor a (TNFa) (Beyaert et ah, 1995), [3-adrenergic receptor (Tobin et ah,
1997), cyclin-dependent kinase 5 (cdk5; Sharma et ah, 1999), cytoskeletal proteins such
as spectrin (Manno et ah, 1995; Simkowski and Tao, 1980; Tuazon et ah, 1985), a
regulatory subunit (phosphatase inhibitor-2) of protein phosphatase 1 (Agostinis et ah,
1992), translation factors (Haas and Hagedorn, 1991; Tuazon et ah, 1989) and glycogen
synthase (Flotow and Roach, 1989). Furthermore, CKIa has been shown to
phosphorylate a subset of vesicle proteins including the synaptic vesicle-specific protein
SV2 (Gross et ah, 1995). Finally, CKI phosphorylates a number of nuclear substrates
such as polymerase I and II (Dahmus, 1981), transcription factor NF-AT4 (Zhu et ah,
1998), SV40 large T antigen (Cegielska and Virshup, 1993; Grasser et ah, 1988) and
p53 (Knippschild et ah, 1997). However, only little evidence exists to link
phosphorylation by CKI with modulation of substrate function (Vielhaber and Virshup,
2001).
1.2.2. Function of CKI
Yeast CKI isoforms are involved in DNA repair (Dhillon and Hoekstra, 1994;
Ho et ah, 1997; Hoekstra et ah, 1991) and have been linked with a role in cytokinesis
(Robinson et ah, 1993 and 1999) and in vesicle trafficking, especially in endocytosis
(Feng and Davis, 2000; Friant et ah, 2000; Hicke et ah, 1998; Marchal et ah, 2002;
Panek et ah, 1997; Wang et ah, 1996). The functions of the mammalian isoforms are less
well understood, but based on high homology with their yeast counterparts they may
have similar functions (Gross and Anderson, 1998). Amongst others CKI has been
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shown to down regulate the activity of glycogen synthase (Flotow and Roach, 1989) and
the tyrosine activity ofplatelet derived growth factor (PDGF) receptor (Bioukar et al.,
1999). Furthermore, CKI phosphorylates serine 174 ofphosphatase inhibitor-2, leading
to inhibition of the phosphatase (Agostinis et al., 1987 and 1992). CKI has also been
shown to modify DARPP-32 (dopamine-and cAMP-regulated phophoprotein of 32
kDa), an inhibitor of calcineurin, a Ca2+/calmodulin dependent catalytic subunit of PP1
(PP1-C; Desdouits et al., 1995a and b). Phosphorylation ofDARPP-32 by CKI results in
activation of the inhibitor and down-regulation of calcineurin activity (Desdouits et al.,
1995b).
CKIe and CKI5 play a role in regulating the tumour suppressor protein p53
(Behrend et al., 2000a; Dumaz et al., 1999; Knippschild et al., 1997). CKIs has been
implicated in circadian rhythms in Drosophila melanogaster and in development by
transducing the Wnt (Wingless (Wg) in Drosophila)/P-catenin pathway (Liu et al., 2002;
Peters et al., 1999; Sakanaka et al., 1999). The Wnt/p-catenin pathway regulates cell
growth, developmental and oncogenic processes (reviewed in Polakis, 2000). Recently,
Mckay and co-workers have reported that the CKI isoforms a, p, y and 6 could also
activate the Wnt pathway in Xenopus laevis embryos (McKay et al., 2001).
CKIy has been proposed to play a role in cytokinesis and/or membrane
trafficking, as it has been shown that CKIyi and CKIy3 complement a yeast strain devoid
of the yeast CKI homologues, YCK1 and YCK2 (Zhai et al., 1995), which are essential
for vegetative growth, normal bud morphogenesis, cytokinesis and vesicular trafficking
(Gross and Anderson, 1998).
CKIa has been implicated in cell cycle progression in mouse oocytes (Gross et
al., 1997) and in membrane trafficking by associating with synaptic vesicles and
phosphorylating a subset of vesicle proteins including the synaptic vesicle-specific
protein SV-2 and adaptor protein AP-3 which has been implicated in the formation of
synanptic vesicles (Faundez and Kelly, 2000; Gross et al., 1995). SV-2 is a glycoprotein
which is required for normal neurotransmission and has been shown to modulate the size
of the readily releasable pool of secretory vesicles (Xu and Bajjalieh, 2001).
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Furthermore, CKI seems to be involved in the regulation of one or more steps ofmRNA
metabolism by co-localising with factors involved in pre-mRNA splicing and
associating with a complex containing splicing factors (Gross et ah, 1999).
In addition, CKIa phosphorylates 14-3-3x and C, isoforms on residue 233. 14-3-3
proteins are a family of conserved regulatory dimeric molecules expressed in all
eukaryotic cells. 14-3-3 proteins play a role in diverse cellular processes including
neuronal development, cell cycle control, cell growth control and programmed cell death
(reviewed in Aitken et al., 2002). In vivo phosphorylation of 14-3-3^ at the CKIa site
(Thr-233) negatively regulates its binding to c-Raf, and may be important for Raf-
mediated signal transduction (Dubois et al., 1997).
Furthermore, we have demonstrated that CKIa associates with the
phosphatidylinositol 3,4,5-trisphosphate-binding protein (Dubois et al., 2001), centaurin-
ai suggesting an involvement ofCKIa in membrane trafficking, actin cytoskeletal re¬
arrangement and possibly in phosphatidylinositol signalling. In addition, our laboratory
has shown that CKIa phosphorylates syntaxin-lA (Dubois et al., 2002a), a protein
involved in exocytosis (reviewed in Lin and Sheller, 2000). This could indicate a role for
CKIa in synaptic vesicle exocytosis.
Finally, our laboratory has identified novel CKIa co-purifying proteins from
brain which could represent novel CKIa binding partners. These proteins include
regulator of chromosome condensation 1 (RCC1), high mobility group protein 1 and 2
(HMG1 and HMG2), Erf (Ets2 repressor factor), centaurin-ai, synaptotagmin IX and
CPI-17 (Figure 1.2, from Dubois et al., 2002b). The seven proteins co-purified with
CKIa from brain after four chromatography steps, including a FF SP-Sepharose column,
Affi-Gel-Blue column, a Mono S column and a Sephacryl S-100 column. This suggested
that these proteins formed a tight protein complex with CKIa. However, it should be
stressed that this was not enough evidence to prove that all seven proteins directly















Figure 1.2 Co-purification of proteins with CKIa.
CKIa was purified from pig brain after four chromatography steps. The fractions
containing CKI activity were electrophoresed on 10% SDS-PAGE (lane 2) and the gel
was stained with Coomassie blue. A total of seven other proteins co-purified with CKIa
(indicated by arrows), suggesting that they may form protein complex(es). The
molecular weight markers (lane 1) are shown in kDa.
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In addition, we showed that RCC1 associated with CKIa in COS-7 cells (Dubois
et al., 2002b). Some of the functions of the CKIa co-purifying proteins are summarised
in Table 1.2. Interestingly, some of the proteins co-purifying with CKIa have previously
been implicated in CKI functions. For instance, HMG1, an architectural DNA binding
protein (Muller et al., 2001; Thomas and Travers, 2001), has recently been shown to be
phosphorylated by CKI (Okano et al., 2001). Erf is a member of the Ets family
(Mavrothalassitis and Ghysdael, 2000) and Etsl has been used as in vitro CKI substrate
(Cegielska et al., 1998). Synaptotagmin IX has been shown to associate with a mRNA
binding protein (Mizutani et al., 2000), and the association of synaptotagmin IX with
CKIa is particularly interesting in the light of evidence which suggests that CKIa may
regulate certain steps ofmRNA metabolism (Gross et al., 1999).















Ca2+ sensor in exocytosis
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(Dubois et al., 2001;
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In addition a number ofproteins were found to associate with the region of CKIa
comprising residues 217-233. These included: Importin-ai/p, a protein with similar roles
to RCC1, involved in both nuclear transport and spindle assembly (reviewed in Dasso,
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2001); protein phosphatase 2A (PP2A), tubulin, HMG1 and actin (Dubois et al., 2002b).
Interestingly, phosphorylation/dephosphorylation events by the CKI/PP2A complex
have been shown to be important in endocytosis and actin cytoskeleton organisation in
yeast (Friant et al., 2000). These data further support a role of CKIa in multiple cellular
events possibly including membrane trafficking, mRNA metabolism, mitotic spindle
assembly and actin cytoskeleton re-arrangement.
As the last point it should be added that CKI isoforms have been associated with
the pathology of Alzheimer's disease (reviewed in Vielhaber and Virshup, 2001). This
progressive, neurodegenerative disease is characterised by accumulation of a
hyperphosphorylated form of the microtubule-associated protein tau into filamentous
and granulovacuolar lesions. CKI is one of the kinases which phosphorylates tau,
inducing it to adopt an Alzheimer's like conformation. The levels of a number of CKI
isoforms (a, S, e) have been found to be elevated several fold in this disease with the
levels of CKI8 increased >30 fold. These results suggest that CKI does not only
participate in hyperphosphorylation of tau, but its overexpression could play a key role
in Alzheimer's disease progression (Vielhaber and Virshup, 2001).
1.2.3. Regulation of CKI
The presence ofCKI in a number of cellular compartments including cytosolic
vesicles and distinct nuclear structures suggests that these kinases are highly regulated.
So far little is known about the regulation ofCKI activity. Although CKI isoforms
appeared to be constitutively active and insensitive to second messengers, a number of
regulatory mechanisms have been put forward in recent years (Gross and Anderson,
1998). To date, two CKI isoforms, CKI8 and CKIs have been shown to be inhibited by
autophosphorylation, however, recent data indicate that in vivo, cellular phosphatases
continually dephosphorylate these CKI isoforms, keeping them constitutively active
(Cegielska et al., 1998; Graves and Roach, 1995; Rivers et al., 1998). Since the CKI
autophosphorylation decreases kinase activity, this dynamic
autophosphorylation/dephosphorylation cycle provides a mechanism for kinase
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regulation in vivo (Rivers et al., 1998). The association ofCKIa with native membranes
and its catalytic activity are regulated by phosphatidylinositol 4,5-bisphosphate (Ptdlns-
(4,5)-P2; Brockman and Anderson, 1991). In this study the authors show that small
increases in the membrane content of Ptdlns 4,5 P2 result in CKIa inhibition on native
membranes.
Furthermore, the CKIa homologue in Drosophila melanogaster, dmCKIa, has
been shown to be activated by y-irradiation (Santos et al., 1996). Moreover, CKI
isoforms have been reported to phosphorylate some of their substrates only if they were
previously phosphorylated by another kinase (Gross and Anderson, 1998). In this way,
the effect of CKI is dependent on other kinases and phosphatases which in many cases
are regulated by second messengers or other components of signal-transduction
pathways. Furthermore, certain CKI isoforms are also regulated at the level of
alternative mRNA splicing. CKIa and CKIy3 are alternatively spliced (Gross and
Anderson, 1998), and differently spliced CKIa isoforms have been shown to exhibit
different substrate specificities and differences in their protein-protein interactions
(Zhang et al., 1996). One of the splicing variants, CKIaL contains an insert of 28 amino
acids within the kinase domain (Rowles et al., 1991) which has been shown to alter the
substrate specificity, possibly by changing the tertiary structure of the catalytic cleft
(Zhang et al., 1996). Finally, there is evidence that the subcellular localisation ofCKI
defines both function and regulation. CKIa for example has been shown to possess a
cell-cycle-dependent subcellular distribution, including association with cytosolic
vesicles (in interphase), the centrosome (in prophase and telophase), the mitotic spindle
(in mitosis), and distinct nuclear structures (in anaphase) (Brockman et al., 1992; Gross
et al., 1997). The association ofCKIa with distinct structures throughout the cell might
therefore restrict CKI function by defining substrate access.
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1.3. CPI-17
The protein kinase C-potentiated inhibitor of 17 kDa, CPI-17, was previously
identified by our laboratory as one out of six proteins co-purifying with CKIa as part of
a protein complex from mammalian brain (Dubois et ah, 2002b) as described in section
1.2.2. In this section known properties and functions of CPI-17 will be reviewed.
1.3.1. CPI-17 as a myosin light chain phosphatase inhibitor
CPI-17 was shown to be a protein phosphatase 1 (PP1) inhibitor and specifically
to inhibit myosin light chain phosphatase (MLCP), however it should be noted that CPI-
17 is also an inhibitor of the free catalytic subunit of protein phosphatase 1 (PP1-C) in
vitro (Eto et al., 1995 and 1997).
MLCP is a trimeric protein complex consisting of a 110-130 kDa regulatory or
myosin targeting subunit (M 110-130/MYPT), a ~37 KDa catalytic (PP1-C) subunit and
a 20 kDa subunit of unknown function (reviewed in Somlyo and Somlyo, 2000). MLCP
plays a pivotal role in smooth muscle force regulation. Contractile activity in smooth
muscle is linked to an increase of intracellular [Ca2+], Ca2+ combines with calmodulin
and the Ca2+-calmodulin (CaM) complex activates MLCK which phosphorylates the 20
kDa myosin light chain (MLC20) on Ser-19 resulting in contraction (reviewed in Pfitzer,
2001). The level of phosphorylated MLC20 is governed by a balance of the activity of
• 2+ * • • • •
two counteracting enzymes: a Ca -calmodulin-dependent myosin light chain kinase and
the above described MLCP (reviewed in Brozovich, 2002). However, a membrane
potential (and therefore intracellular [Ca2+]) independent agonist induced mechanisms
can also lead to contraction. This mechanism produces Ca2+ sensitisation, or an increase
in contraction force at a constant [Ca2+] and correlates with an inhibition ofMLCP
(reviewed in Brozovich, 2002; Richards et al., 2002). The inhibition ofMLCP is thought
to occur via the small GTPase RhoA and one of its downstream targets, Rho-associated
kinase (ROK/ROCK/Rho-kinase). RhoA can bind both GDP and GTP, and is active in
the GTP bound status and inactive in the GDP bound form. Guanine nucleotide
exchange factors (GEFs) catalyze the exchange ofGDP for GTP and GTPase-activating
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proteins (GAPs) act as negative regulators by accelerating the intrinsic GTPase activity
ofRhoA and converting it back to the inactive GDP-RhoA (reviewed in Fukata et ah,
2001; Nieuw Amerongen and van Hinsbergh, 2001). Binding of Rho-associated kinase
to RhoA-GTP enhances the activity of Rho-associated kinase (Fukata et al., 2001). Rho-
associated kinase has been shown to phosphorylate MYPT at Thr-695 (Feng et al.,
1999). Phosphorylation at this site decreases MLCP activity and leads to an increase in
both MLC20 phosphorylation and contractile force (Brozovich, 2002). A HeLa zipper-
interacting protein (ZlP)-like kinase and an integrin-linked kinase (ILK) have also been
shown to phosphorylate MYPT on residue 695, decreasing MLCP activity (Borman et
al., 2002; MacDonald et al., 2001a; Muranyi et al., 2002). Another mechanism for Ca2+
sensitisation is dissociation of the subunit ofMLCP by arachidonic acid (Brozovich,
2002). Activation of guanine nucleotide-binding proteins (G proteins), increases in
intracellular [Ca2+] and activation of kinases such as mitogen activated protein kinase
(MAPK) leads to an increase in the activity of phospholipase A2 and production of
arachidonic acid from membrane glycerophospholipids (reviewed in Hirabayashi and
Shimizu, 2000), which binds to and dissociates MLCP to reduce phosphatase activity
(Brozovich, 2002). A third mechanism for Ca2+ sensitisation involves CPI-17. As
described in more detail below, CPI-17 phosphorylated by PKC (Eto et al., 1995), Rho-
associated kinase (Koyama et al., 2000), protein kinase N (PKN) (Hamaguchi et al.,
2000) or by ILK (Deng et al., 2002), has been shown to inhibit MLCP activity. A
simplified diagram summarising the possible involvement ofCPI-17 in a pathway which
could lead to cellular events mediated by MLC20 phosphorylation/dephosphorylation is
shown in Figure 1.3.
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Figure 1.3 Involvement of CPI-17 in MLCP regulation.
Agonist binding to heterotrimeric G-protein leads to RhoA activation via linked guanine
nucleotide exchange factors (GEF). RhoA activates Rho-associated kinase which then
phosphorylates the regulatory subunit ofMLCP and inhibits MLCP activity.
Phosphorylation ofCPI-17 on Thr-38 by PKC, PKN, PKA, Rho-kinase, ZIP-like kinase
or ILK also leads to inhibition of MLCP. MLCK activated by a Ca27calmodulin
complex phosphorylates myosin resulting in changes in cell morphology, cell migration
and leading to muscle contraction. Dephosphorylation of myosin by MLCP results in
muscle relaxation (based on diagram in Somlyo and Somlyo, 2000).
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MLCP is a serine/threonine phosphatase involved in many cellular functions
such as muscle contraction, cell migration, metastasis and cytokinesis (reviewed in
Matsumara et al., 2001; Somlyo and Somlyo, 2000). It should be noted that MLCP is
also expressed in non-muscle cells including human prostate cancer cells (Somlyo and
Somlyo, 2000) and therefore the identification and characterisation of proteins which
regulate its activity is of major importance.
Eto and co-workers have shown that the inhibition ofmyosin light chain
phosphatase by CPI-17 alters microfilament organisation and retards cell spreading in
fibroblasts (Eto et al., 2000). Originally, CPI-17 was thought to be smooth muscle
specific, but it is also expressed in human platelets and has been implicated in playing a
role in human platelet secretion by inhibiting the myosin light chain phosphatase
(Watanabe et al., 2001). Our laboratory has found it in brain (Dubois et al., 2002b) and
those results are supported by Eto and co-workers, who have found weak mRNA
expression ofCPI-17 in porcine brain (Eto et al., 1997).
1.3.2. Phosphorylation of CPI-17
CPI-17 is phosphorylated on Thr-38 in vivo, which increases its ability to inhibit
PP1-C by 1000-fold (Eto et al., 1995). CPI-17 was originally shown to be
phosphorylated by PKC in vitro (Eto et al., 1995). However, many other kinases were
found to phosphorylate CPI-17 on Thr-38, including the PKC-related kinase 1, PRK1 or
PKN (Hamaguchi et al., 2000), Rho-associated kinase (Koyama et al., 2000), HeLa
zipper-interacting protein (ZlP)-like kinase (MacDonald et al., 2001b) and the very
recently identified integrin-linked kinase, ILK (Deng et al., 2002). A further
phosphorylation site has been identified by MacDonald and co-workers on Ser-12. This
site has been shown to be phosphorylated by a ZIP-like kinase (MacDonald et al.,
2001b). Furthermore, our laboratory has shown that protein kinase A (PKA) and
Ca2+/calmodulin-dependent protein kinase II (CamKII) phosphorylate CPI-17 in vitro on
residues Thr-38 and Ser-130, respectively. In addition, a novel CPI-17 in vivo
phosphorylation site on Ser-128 was identified by our laboratory, however, the kinase
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which phosphorylates this residue remains unknown. A schematic representation of
known CPI-17 phosphorylation sites and the respective kinases is shown in Figure 1.4.
It is interesting to note that residues 31-120 ofCPI-17 constitute a novel domain
that is also present in the phosphatase holoenzyme inhibitor, PHI-1 (Eto et ah, 1999) and
in the serine/threonine kinase, LIM kinase-2 (LIMK-2) as our database searches
revealed. LIMK-2 is involved in stress-fibre and focal adhesion formation (Amano et ah,
2001). Interestingly, the region around Thr-38 on CPI-17 is conserved in LIMK-2 (Thr-
596), as our database searches revealed and in PHI-1 (Thr-57) (Eto et ah, 1999). The
equivalent residue in PHI-1, Thr-57 has been shown to be phosphorylated by PKC and
this results in an increase in the ability of PHI-1 to inhibit PP1 (Eto et ah, 1999). A
simplified schematic representation of the conserved domains present in CPI-17, PHI-1
and LIMK-2 is shown in Figure 1.5.
Agonist stimulation of vascular smooth muscle leads to CPI-17 phosphorylation
on Thr-38 resulting in increased vascular smooth muscle contractility (Kitazawa et ah,
2000). By contrast, CPI-17 dephosphorylation in arterial smooth muscle occurs during
nitric oxide induced relaxation (Etter et ah, 2001). Recombinant CPI-17 phosphorylated
on Thr-38 induced MLC phosphorylation and potentiated PKC-induced contraction of
arterial smooth muscle strips (Kitazawa et al., 1999; Li et ah, 1998). In addition, Eto and
co-workers showed that histamine-induced vasoconstriction involves phosphorylation of
CPI-17 and PKCa and 8, indicating that PKC may be the kinase which phosphorylates
CPI-17 on Thr-38 in vivo, since ROCK and PKN do not seem play an important role in
this process, which was shown by experiments based on sensitivity to different kinase
inhibitors (Eto et ah, 2001). This is supported by the finding that phosphorylation of
CPI-17 on Thr-38 by PKC leads to MLCP inhibition in human platelets (Watanabe et
ah, 2001).
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Figure 1.4 Schematic representation of known CPI-17 phosphorylation sites.
Schematic representation ofCPI-17 with the in vivo phosphorylation sites indicated in
bold (T38 and SI28). The in vitro phosphorylation sites are also shown (SI2 and SI30).
The kinases known to phosphorylate the in vivo sites are indicated at the top of the
figure and those that phosphorylate the in vitro sites, at the bottom of the diagram. The











Figure 1.5 Sequence conservation between CPI-17, PHI-1 and LIMK-2.
A, Schematic representation of the conserved domains present in CP1-17, PHI-1 and
LIMK-2. CPI-17 is composed mainly of a domain (black box, called "ProD domain
25745" from ProDom 2000.1 programme at http://protein.toulose.inra.fr) which is also
found in the LIMK-2 and the PP1 inhibitor PHI-1. The positions of the phosphorylated
residues are indicated. Thr-38 which is known to be phosphorylated in vivo on CPI-17 is
conserved in PHI-1 (Thr-57) and LIMK-2 (Thr-596). The corresponding residue in PHI-
I (Thr-57) is phosphorylated by PKC (Eto et al„ 1999). The C-terminal tail ofCPI-17
contains the serine that is phosphorylated in vivo (Ser-128).
B, The region containing Thr-38 in CPI-17 is conserved in PHI-1 and LIMK-2. The
residues 36-46 of CPI-1 7 containing the in vivo phosphorylation site Thr-38 (in bold) is
conserved in PHI-1 (residues 55-65) and LIMK-2 (residues 594-604).
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1.4. PKC
PKCs comprise a family of serine/threonine kinases which play an important role
in a large number of signal transduction events elicited by various extracellular stimuli
such as growth factors, hormones and neurotransmitters (reviewed in Mochly-Rosen and
Gordon, 1998). Up to 12 distinct family members have been identified in mammalian
cells and have been classified into different groups according to their structural features
and activation parameters. PKC plays fundamental roles in mitogenesis and proliferation
of cells, apoptosis, platelet activation, neurotransmission and remodelling of the actin
cytoskeleton (reviewed in Jaken and Parker, 2000; Toker 1998).
1.4.1. Structure of PKC
The structure of PKC isozymes includes conserved domains referred to as C1-C4
(reviewed in Liu and Heckman, 1998) (see Figure 1.6). These domains are interrupted
by variable regions VI-V5 whose function is not yet fully understood. However these
regions seem to mediate protein-protein interactions and regulate spatiotemporal
localisation of some PKC isoforms (Sanchez et al., 1998; Tabellini et ah, 2002;
Vallentin et ah, 2000). PKC can be divided into two functionally distinct domains: the
amino-terminal regulatory domain (C1-V3) regions, ofwhich the CI domain binds 1,2-
sn-diacylglycerol (DAG) or phorbol esters and is immediately preceded by an
autoinhibitory pseudosubstrate sequence (not in PKCp/PKD); the C2 domain which
binds calcium and acidic phospholipids (and in the case of PKCp a pleckstrin homology
(PH) domain) and the carboxyl terminal catalytic domain (C3-V5), where C3 and C4
domains form the ATP-binding and substrate binding lobes of the kinase core (reviewed
in Newton, 1995). The regulatory and catalytic domains are separated by a hinge region
that can be proteolytically cleaved when the enzyme is membrane-bound (for example in
response to apoptotic stimuli; Emoto, et ah, 1995) resulting in the release of the kinase
domain (sometimes referred to as protein kinase M) from inhibition by the
pseudosubstrate domain. Once released this way PKC is constitutively active. However,
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the free catalytic subunit is unstable and degrades quickly in cells (Murray, et al., 1987).
1.4.2. The PKC superfamily
The mammalian isoforms ofPKC have been divided into four distinct
subfamilies ifPKCp/PKD is considered as a subfamily on its own. Several non-
mammalian PKCs have also been identified (Toker, 1998). A schematic representation
of the primary structures of mammalian PKC subfamilies is outlined in Figure 1.6.
The Ca2'-dependent or conventional PKC (cPKC) isozymes (a, y, and the
alternatively spliced pi and pil) contain four conserved domains, namely, the CI domain
(which contains a tandem cysteine-rich motif, CIA and C1B), the C2 domain and the
catalytic C3 and C4 domains interspaced with variable domains (reviewed in Newton,
1995 and 2001). Conventional PKC isozymes are activated by Ca2+, DAG and
phosphatidylserine (PS), a membrane phospholipid (Liu and Heckman, 1998).
The Ca2t-independent novel PKC (nPKC) isozymes (5, s, rj, and 0) contain a
C2-like N-terminal domain and are also activated by DAG and require PS as a cofactor,
but do not require calcium (Newton 2001; Toker, 1998).
The third PKC class, atypical PKC (aPKC) (^, lA.) (i and A, are the human and
mouse homologues of the same isoform), lack the C2 domain and only contain one CI
domain. Atypical PKCs are insensitive to calcium or DAG, but require PS as cofactor
(Liu and Heckman, 1998; Toker, 1998).
In addition, PKCp/PKDl is considered by some to constitute a fourth PKC class
and by others to comprise a distinct family called protein kinase D (PKD). Other PKD
members include PKD2 and PKCv/PKD3 (reviewed in Van Lint et al., 2002; Newton,
2001). This protein kinase contains in addition to the catalytic and CI domains, a
pleckstrin homology (PH) domain and a putative signal peptide (SP) and a
transmembrane (TM) domain (Toker, 1998; Van Lint et al, 2002). This kinase does not
require calcium, but is activated by DAG and PS (Newton, 2001; Van Lint et al., 2002).
The kinase domain exhibits some similarity with members of the PKC family, but is
more related to the kinase domain of the myosin light chain kinase of Dictyostelium and
Ca2+/calmodulin-dependent kinase II (Van Lint et al., 2002). A summary of the PKC
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family is outlined in Table 1.3 which is adapted from Liu (1996) and Newton (2001).
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Cysteine rich region O Pleckstrin homology domain
Calcium-binding domain [ ! Putative signal peptide/transmembrane domain
Figure 1.6 Schematic representation of primary structures of mammalian PKC
family members.
The catalytic domains, pseudosubstrate domains (PS), the cysteine rich domains, the
pleckstrin homology domains (PH), the calcium-binding domain and the putative signal
peptide(SP)/transmembrane domain (TM) in PKCp/PKD are shown.
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1.4.3. Tissue distribution and subcellular localisation
Multiple PKC isozymes are found in any one tissue as shown in Table 1.4.
PKCa, pi, pil, 8, s, X and C, seem to be ubiquitous or expressed in most tissues. PKCy is
mainly restricted to the central nervous system and spinal cord (reviewed in Liu, 1996;
Rennecke et al., 1996). However, the expression levels of each isozyme differ
significantly (Rennecke et ah, 1996).
Table 1.4 PKC isozymes in mammalian tissue




e Ovary, skeletal muscle, platelets
PKC isozymes localise to distinct subcellular compartments including plasma
membrane, cytoskeletal elements and nuclei and are expressed differently among
various cell types (reviewed in Jaken and Parker, 2000; Liu and Heckman, 1998;
Mochly-Rosen and Gordon, 1998). PKC isoforms have different tissue distribution, are
localised to specific cellular structures (as will be described in section 1.4.4) and have
different substrate and cofactor specificity. This suggests that different PKC isoforms
control distinct cellular processes.
1.4.4. Regulation of PKC
PKC activity must be under tight structural and spatial regulation as these
enzymes are implicated in a multitude of physiological processes.
In response to extracellular stimuli, PKC isozymes undergo translocation from
one subcellular compartment or location to another. Agonist-stimulated activation of
phospholipase type C (PLC) results in the hydrolysis ofmembrane inositol
phospholipids. This leads to the generation of 1,2-sn-diacylglycerol (DAG) and soluble
inositol phosphates, including inositol-1,4,5-trisphosphate (Ins-(1,4,5)-P3), which is
1 Introduction 40
responsible for stimulating release of calcium from intracellular stores such as the
sarcoplasmic reticulum (SR) (Toker, 1998). The dogma has been that binding ofDAG
and PS results in the recruitment ofmost PKC isoforms from the cytosol where they are
maintained in an inactive conformation, to the plasma membrane, where they become
allosterically activated (Newton, 2001). However, there is increasing evidence that
suggests that individual PKC isoforms can translocate to subcellular locations other than
the plasma membrane, including membrane vesicles, nuclear structures and cytoskeletal
components (reviewed in Keenan and Kelleher, 1998).
In addition to allosteric activation by binding to second messengers,
phosphorylation has emerged as an important mechanism of regulation of all PKCs and
plays a crucial role in the activation of PKC (Newton, 2001). PKC has been shown to be
phosphorylated in vivo at three key residues in the catalytic (C4) domain (Keranen et ah,
1995; Tsutakawa et ah, 1995). Initially, PKC is phosphorylated by the phosphoinositide-
dependent kinase PDK-1 followed by subsequent autophosphorylation (Cenni et ah,
2002; Chou et ah, 1998; Dutil et ah, 1998; Le Good et ah, 1998). Interestingly the PKCp
isoform has been shown to be activated via a PKCs or PKCq dependent pathway which
could provide another regulatory mechanism (Rey et ah, 2001; Zugaza et ah, 1997). In
addition to phosphorylation as a regulatory mechanism ofPKC, there is increasing
evidence which suggests a role for protein phosphatases in controlling the
phosphorylation state of PKC (Newton, 2001).
The correct subcellular localisation of specific PKC isoforms is essential for their
biological function(s) and constitutes the third major regulatory mechanism of PKC
activity (Newton, 2001). It has been shown that many anchoring/scaffold proteins bind
PKC, target it to various cellular microdomains and position PKC isoenzymes near their
substrate or near regulators of activity such as phosphatases and kinases. One example is
the family of proteins called RACKs (Receptors for Activated C Kinase) which anchor
the active conformation of phosphorylated protein kinase C at specific cellular locations
(reviewed in Mochly-Rosen and Gordon, 1998). Another example are members of the
family of AKAPs (A Kinase Anchoring Proteins) which position phosphorylated, but
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inactive PKC near relevant substrates (Newton, 2001). Furthermore, it has been
suggested that anchoring proteins for inactive PKCs exist. It has been shown that there
are likely 5PKC-specific binding proteins that anchor inactive 5PKC at the Golgi
structures ofNG108-15 cells (reviewed in Mochly-Rosen and Gordon, 1998). These
proteins were collectively termed RICKs (Receptors for Inactive C Kinase), however, to
date, the hypothetical RICKs have not been identified (reviewed in Dorn and Mochly-
Rosen, 2002). These examples demonstrate how specific PKC isoforms can be localised
to various subcellular domains and how their activity can be spatially regulated.
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1.5. Centaurin-ai
Centaurin-ai was one out of six proteins co-purifying with CKIa from brain
after four chromatography steps (Dubois et al., 2002b) as described in section 1.2.2.
Originally, centaurin-ai was identified as a phosphatidylinositol-(3,4,5)-
trisphosphate (PtdIns-(3,4,5)-P3) and inositol-(l,3,4,5)-tetrakisphosphate (Ins-(1,3,4,5)-
P4) binding protein (Hammonds-Odie et ah, 1996; Rao et ah, 1999; Strieker et ah, 1997;
Tanaka et ah, 1999). lns-(l,3,4,5)-P4 is the soluble head group of PtdIns-(3,4,5)-P3.
Inositol phosphates and phosphoinositides, generated by the receptor-regulated
phosphoinositide 3-kinases (PI 3-Ks), play a pivotal role as second messengers in a
number of cellular processes including vesicle transport, membrane ruffling,
proliferation, regulation of cytosolic Ca2r and cell survival (reviewed in Rameh and
Cantley, 1999).
1.5.1. Structure of centaurin-ai
Centaurin-ai is a member of the centaurin family, which is comprised of several
members and includes amongst others centaurin (3m, 81.2, Y1-2, ASAP1 (ArfGAP with
SH3 ankyrin repeat and PH domains) and PAP (protein tyrosine kinase (Pyk2) C
terminus-associated protein; reviewed in Jackson et ah, 2000). Centaurins contain a
pleckstrin homology (PH) domain, ankyrin repeats and a N-terminal zinc finger motif.
The PH domains have been shown to be responsible for the binding to PtdIns-(3,4,5)-P3
and were indispensable for the PI 3-K dependent translocation of centaurin-ai to the
plasma membrane (Tanaka et ah, 1999; Venkateswarlu and Cullen, 1999;
Venkateswarlu et ah, 1999). The zinc finger motif comprises part of an ADP-
ribosylation factor (ARF) GTPase-activating proteins (GAP) domain originally
identified in ARF GAP1, a member of the ARF GAP protein family (reviewed in
Donaldson, 2000; Jackson et ah, 2000). Figure 1.7 shows a schematic representation of
the primary structure of centaurin-ai.
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Figure 1.7 Schematic representation of the primary structure of centaurin-ai.
The ArfGAP domain, the ankyrin repeats and the PH domain are shown.
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1.5.2. Centaurin-ai as an ARF GAP?
ADP-ribosylation factors (Arfs) function in cells to regulate vesicular membrane
transport and cytoskeleton (Jackson et al., 2000). Arfs are members of the Ras GTPase
superfamily and require guanine nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs) for nucleotide cycling (Jackson et al., 2000). The Arf GAP
domain has been found in several novel proteins playing a role in cytoskeleton re¬
arrangement and membrane trafficking including the phosphatidylinositol 4,5-
biphosphate-dependent Arfl GTPase-activating protein, called ASAP1 (Randazzo et al.,
2000; Brown et al., 1998) and the protein tyrosine kinase (Pyk2) C terminus-associated
protein, PAP (Andreev et al., 1999; Jackson et al., 2000). Centaurin-ai has been shown
to complement a yeast strain devoid in the ArfGAP, Gcsl, which suggested that
centaurin-ai could have an ArfGAP activity, however, such an activity has not been
reported to date (Venkateswarlu et al., 1999), indicating that centaurin-ai either requires
another co-factor or Arf partner than tested or that it is not an ArfGAP (Jackson et al.,
2000). Gcsl has been shown to be necessary for the resumption of cell proliferation
from stationary phase (Ireland et al., 1994) and to be involved in endocytosis (Wang et
al., 1996). Gcsl is also involved in the regulation of the actin cytoskeleton in vivo and
binds to actin in vitro (Blader et al., 1999). As vesicle trafficking is closely associated
with actin organisation in yeast, it has been proposed that Gcs 1 may provide a link
between vesicle trafficking and the actin cytoskeleton (Blader et al., 1999). Whether
centaurin-ai has similar roles in mammalian cells remains to be established.
1.5.3. Tissue expression and subcellular localisation of centaurin-ai
Centaurin-ai is ubiquitously expressed, with especially high levels of expression
in brain (Hammonds-Odie et al., 1996) with main localisation in the neurons of
hippocampus, cortex, cerebellum and in the hypothalamus (Kreutz et al., 1997).
Centaurin-ai has been shown to associate with membranes and vesicular
presynaptic structures (Dubois et al., 2002c; Kreutz et al., 1997). Recently, centaurin-ai
was found to be localised in the nucleus of different cell types, including the neuronal
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PC 12 cells (Venkateswarlu et al., 1999) and our laboratory has shown that centaurin-ai
localises in the nucleus of human embryonic kidney HEK293 cells (Dubois et al.,
2002c).
1.5.4. Association of centaurin-ch with CKI
As mentioned previously we found that centaurin-ai co-purified with CKIa from
brain as part of a protein complex (Dubois et al., 2001). Furthermore, our laboratory has
shown that the binding between CKI isoforms and centaurin-ai is direct and CKI was
the first centaurin-ai binding protein to be identified (Dubois et al., 2001). The binding
site was mapped to residues 217-233 within the kinase domain ofCKI. However,
centaurin-ai was not phosphorylated by CKIa and did not have an effect on CKIa
activity.
Interestingly, a CKIa-like kinase has been shown to interact with another Ptdlns-
(3,4,5)-P3 binding protein, the adaptor protein AP-3 (Faundez and Kelly, 2000). A
further link between CKI and the phosphoinositol pathway has also been demonstrated
in S. pombe. Vancurova and co-workers show that yeast CKI homologue Ckil,
phosphorylates and inhibits phosphatidylinositol 4-phosphatase 5-kinase (Vancurova et
al., 1999). The association of centaurin-ai and CKI isoforms has been further confirmed
by affinity chromatography experiments described in chapter 3, section 3.4.2 of this
study. In this section it was shown that CKIa and CKIe associated with the GST-
centaurin-ai column (Figure 3.15).
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1.6. Nucleolin
Nucleolin was identified as one of the proteins associated with the GST-
centaurin-ai affinity chromatography column as described in section 4.2.1 of this study.
Nucleolin is an abundant nucleolar phosphoprotein in exponentially growing
cells and may represent as much as 10% of total nucleolar proteins. Nucleolar proteins
structurally related to nucleolin are found in a large number of organisms, including
plants, yeasts and mammals.
Nucleolin is a nucleic acid binding protein (Herrera and Olson, 1986; Olson et
al., 1983) and has been shown to be involved in chromatin structure modulation (Erard
et al., 1988 and 1990), rDNA transcription (Borer et al., 1989; Bouche et al., 1987;
Caizergues-Ferrer et al., 1989; Herrera and Olson, 1986), rRNA maturation (Abadia et
al., 1998; Ginisty et al., 1998), ribosome assembly (reviewed in Ginisty et al., 1999),
nucleogenesis (Caizergues-Ferrer et al., 1989) and nucleocytoplasmic transport (Borer et
al., 1989). Recently, nucleolin has been implicated in genotoxis stress (DNA damage)
responses (Yang et al., 2002a), in early events in the HIV entry process (Nisole et al.,
2002a) and a role for nucleolin in mitosis and Alzheimer's disease has been proposed
(Dranovsky et al., 2001). In addition nucleolin is a calcium-binding protein and a role in
chromatin regulation, possibly during apoptosis has been proposed (Gilchrist et al.,
2002). Finally, nucleolin has been shown to repress RNA polymerase I transcription by
acting directly on the transcription machinery or on the rDNA promoter sequence and
not, as previously thought, through interaction with the nascent pre-rRNA (Roger et al.,
2002).
Nucleolin is target for regulation by proteolysis, methylation, ADP-ribosylation
(reviewed in Srivastava and Pollard, 1999), and phosphorylation by casein kinase II
(CKII; Schneider and Issinger, 1989), cell-division cycle (cdc) 2 kinase (Peter et al.,
1990), cell-surface protein kinase (ecto-PK; Jordan et al., 1994) and PKC^ (Zhou et al.,
1997). The N-terminal domain contains sites for modification by phosphorylation and
proteolysis, whereas the C-terminal domain has sites for methylation and proteolysis.
For example the idea that nucleolin function is linked to growth control by
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phosphorylation is supported by the fact that active rRNA transcription is positively
correlated with highly phosphorylated nucleolin. In addition, the phosphorylation of
nucleolin by CK2 is highly regulated during the cell cycle. Methylation of a peptide
corresponding to residues 676-692 of human nucleolin was shown to modulate its
interaction with nucleic acids (Raman et al., 2001). The exact roles ofnucleolin
regulation by proteolysis and ADP-ribosylation have yet to be determined.
1.6.1. Structure of Nucleolin
Nucleolin consists of three functional domains, the amino-terminal domain, a
RNA binding domain (RBD) and a carboxyl-terminal domain (Figure 1.8); adapted from
Ginisty et al., (1999).
The N-terminal domain contains highly acidic regions separated by basic
sequences (Ginisty et al., 1999). It has been suggested that the acidic domains bind
histone HI which would lead to chromatin decondensation (Erard et al., 1988). In
addition this domain has been shown to be involved in a number of protein-protein
interactions (Ginisty et al., 1999). It is the N-terminal domain ofnucleolin that is highly
phosphorylated by the kinases listed above. In addition, the N-terminal domain contains
a nuclear localisation signal (NLS), which is necessary for nuclear localisation, however,
it alone is not sufficient for the nucleolus localisation (Schmidt-Zachmann et al., 1993).
The central domain, the RNA binding domain (RBD), contains four RNA
binding motifs and has been shown to interact with pre-ribosomal RNA (pre-rRNA)
through the first two RNA binding motifs (Allain et al., 2000). Interestingly, a novel
nucleolin-binding ribonucleoprotein complex has been characterised recently (Yanagida
et al., 2001). Over sixty proteins were identified, out ofwhich forty were ribosomal
proteins (Yanagida et al., 2001). Yanagida and co-workers demonstrated that the RBD
ofnucleolin was sufficient to hold the entire nucleolin-binding ribonucleoprotein
complex and that nucleolin holds the ribonucleoprotein complex mainly by RNA-protein
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interaction and not by protein-protein interaction (Yanagida et al., 2001). This confirms
a suggestion that the presence of several RBDs in nucleolin enables nucleolin to interact
with multiple RNA targets (Ginisty et al., 1999).
The C-terminal domain or Arg-Gly-Gly (RGG) domain is rich in glycine,
arginine and phenylalanine (Ginisty et al., 1999). The RGG motif seems particularly
frequent in nucleolar proteins. This domain has been shown to interact non-specifically
with RNA, leading to unstacking and unfolding of this RNA, thus it has been proposed
that this domain facilitates the interaction of nucleolin RBD domains with targets
located within large and complex RNA. Furthermore, it has been proposed that this
domain might be involved in controlling nucleolar localisation (Srivastava and Pollard,
1999). Finally, the RGG domain also seems to be involved in specific protein-protein
interactions including the binding of ribosomal proteins (Ginisty et al., 1999).
1 Introduction 49





I | RNA binding domains
RGG domain
Figure 1.8 Schematic representation of the primary structure of nucleoiin.
Nucleolin contains three different domains, the N-domain, the central domain and the C-
domain. The acidic residues, the nuclear localisation signal (NLS), the RNA binding
domains and the Arg-Gly-Gly (RGG) domain are shown.
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1.6.2. Subcellular localisation of nucleolin
Although nucleolin is predominantly localised in the nucleolus, it has been
shown that nucleolin shuttles between the nucleus and cytoplasm, suggesting a role for
nucleolin in nuclear transport (Borer et al., 1989; Schmidt-Zachmann et ah, 1993). In
addition, it was demonstrated that nucleolin is localised in a phosphorylated form on the
cell surface of different cells (Pfeifle and Anderer, 1983). Hovanessian and co-workers
have shown that cytoplasmic nucleolin is found in small vesicles that appear to
translocate nucleolin to the cell surface, suggesting a role for nucleolin as a cell surface
receptor for various ligands (Hovanessian et ah, 2000). This proposal was later
confirmed: cell surface-localised nucleolin has been shown to be a receptor amongst
others for the bacterial membrane protein, intimin-y (Sinclair and O'Brien, 2002). In
addition, nucleolin has been implicated as a cell-surface receptor for HIV particles
(Callebaut et ah, 1998; Nisole et ah, 1999). Interestingly, the anti-HIV pentameric
pseudopeptide HB-19 and the cytokine midkine, have been shown to bind to cell-surface
expressed nucleolin, thus preventing anchorage ofHIV particles in the plasma
membrane (Said et ah, 2002; Nisole et ah, 2002b). Finally, nucleolin has been shown to
relocalise from the nucleolus to the nucleoplasm in response to heat shock and ionizing
radiation (Daniely and Borowiec, 2000; Daniely et ah, 2002) .
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AIMS
This study aimed to identify novel CPI-17 and centaurin-a, binding proteins and
to characterise these interactions to increase the understanding of the physiological roles
ofCPI-17 and centaurin-ai. For this purpose, affinity chromatography followed by
Western blotting and/or mass spectrometry was used. CPI-17 has previously been shown
to be phosphorylated by PKC and to co-purify with CKIa from brain and therefore the
interaction between CPI-17 and these two kinases was characterised. In addition, novel
potential CPI-17 binding proteins were identified.
Centaurin-ai was also shown to be phosphorylated by PKC and therefore a
possible interaction between centaurin-a i and PKC was investigated. Furthermore,
novel centaurin-ai binding proteins were identified one of them being nucleolin. The
interaction between centaurin-ai and nucleolin was further characterised. Finally, novel
potential centaurin-ai binding proteins were identified.
The identification of novel CPI-17 and centaurin-ai binding partners opens up




2. Materials and methods
Throughout the following methods the names of the companies used for the
purchase of specific reagents or materials are given in parentheses. Where no company




All cells were routinely cultured in 75 cm2 flasks at 37°C in 95% air/5% CO2 in a
humidified incubator. The sera used to culture these cells were obtained from Gibco
BRL (UK).
2.1.1. COS-1 and COS-7 cells
The monkey kidney cell lines, COS-1 and COS-7 were cultured as monolayers in
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% foetal bovine
serum containing 2 mM L-Glutamine, 100 pg/ml streptomycin and 100 units/ml
penicillin (Gibco BRL, UK). The adherent cells were passaged when they were~90%
confluent and were split 1:6.
2.1.2. Transient transfection of COS-1/COS-7 cells with plasmid DNA
Table 2.1 DNA amount and cell numbers used for transient transfections with
Method surface area cell number plasmid DNA amount (pg)
FuGENE 100 mm 0.25 x 106 2.5-5
Electroporation 100 mm 2 x 106 5-10
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2.1.2.1. Transfection of COS-1/COS-7 cells by electroporation
Table 2.2 Buffer used for transfection of COS-l/COS-7 cells by electroporation
HeBS 6 mM Glucose D+




Table 2.3 Clones used for transfection





COS cells (COS-1 or COS-7) were used for transfection when they were ~ 90%
confluent. The cells were harvested by trypsinisation, washed twice with HEPES
buffered saline (HeBS) and counted using a haemocytometer grid. 2 x 106 cells were
resuspended in 250 pi HeBS containing 5 pg plasmid DNA and 50 pg sonicated herring
sperm carrier DNA. The mixture was transferred into a 0.4 pm Bio-Rad electroporation
cuvette and pulsed at 250 V/125 pF using a Bio-Rad Gene Pulser. The cells were
allowed to recover for 10 min at room temperature before seeding into 100 mm tissue
culture dishes in 10 ml complete medium. The cells were incubated in a humidified
incubator for 48 h before they were used for immunoprecipitation as described under
2.17.
2.1.2.2. Transfection of COS-7 cells using FuGENE
COS-7 cells were transiently transfected using FuGENE 6 Transfection Reagent.
FuGENE 6 is a non-liposomal formulation. In general, 9xl05 cells were seeded onto 100
mm tissue culture dishes and grown under the same conditions as described under 2.1.1
for 24-48 hours prior to transfection. Immediately before transfection the culture
medium was replaced with 10 ml fresh complete growth media.
For a 100 mm plate, 15 pi of FuGENE were added carefully to 85 pi DMEM
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mixed and incubated for 5 min. 2.5-5 pg of plasmid DNA were added into a separate
Eppendorf tube and the FuGENE/DMEM mixture was added drop by drop. This mixture
was then incubated for 15 min at room temperature to allow DNA-FuGENE complexes
to form. The solution was then added into the plates which were then gently rocked to
mix the transfection solution with the growth media. The cells were incubated at 37°C
for 24-48 h until they were assayed for transient expression.
MOLECULAR TECHNIQUES
2.2. Agarose gel electrophoresis of DNA
Table 2.4 Buffers used for the se paration of )NA by agarose gel electrophoresis











DNA was separated and visualised by electrophoresis on 1% agarose gels in the
presence of ethidium bromide. The agarose gel mix was prepared as described above.
Appropriate volumes of 6x blue/orange loading dye (Promega, UK) were added to the
DNA samples to give a final concentration of lx. These samples were applied to the gel
and separated by electrophoresis in TAE running buffer at 100V. The presence of the
intercalating dye, ethidium bromide, allowed the visualisation of the separated DNA
bands under UV transillumination. The DNA fragments were sized by comparison to the
molecular weight standard XIV (Roche, UK), which contained fragments of the
following sizes: 2642, 1500, 1000, 500, 400, 300, 200 and 100 base pairs (bp).
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2.3. Transformation of Escherichia coli with plasmid DNA
2.3.1. Preparation of heat-shock competent E. coli
Table 2.5 Media and buffers used for the preparation of heat-shock competent E.
coli
LB liquid media 10g/l Select Peptone
5 g/1 Bacto-yeast
10 mM NaCl




To make Luria-Bertani (LB) broth, all the components were mixed and the
mixture was autoclaved. To make transformation buffer (TB), all the components except
for MnCl2 were added and the pH adjusted to 6.7 with KOH. After that the MnCl2 was
added and the buffer was sterilised by filtration through a 0.45 pm filter and stored at
4°C (Inoue et al., 1990). To prepare 'heat-shock' transformation-competent E. coli, an
aliquot of frozen DH5a cells was thawed and streaked on LB agar plates and grown
overnight at 37°C. Around 15 colonies were isolated with an inoculation needle, and
grown in 250 ml LB in a 21 flask at 18°C with vigorous shaking until the absorbance at
600 nm (ODeoo) reached 0.6. The flask was placed on ice for 10 min and the culture was
transferred into a 11 centrifugation bottle and centrifuged at 5000g for 10 min. The
supernatant was removed and the pellet was resuspended in 80 ml of ice-cold TB,
incubated on ice for further 10 min, and spun down as described previously. The pellet
was resuspended in 20 ml ice-cold TB and DMSO was added to a final concentration of
7%. The mixture was incubated on ice for another 10 min and the cell mixture was
aliquated by 500 pi into cryogenic vials and immediately snap frozen by immersion into
an ethanol/dry ice bath and stored at -80°C.
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2.3.2. Heat-shock transformation of competent E. coli.
Table 2.6 Media and buffers used for the transformation of competent E. coli
LB liquid media 10g/l Select Peptone (Gibco)
5 g/1 Bacto-yeast (Gibco)
10 mM NaCl
LB agar plates 10 g/1 Select Peptone
(containing ampicillin or 5 g/1 Bacto-yeast
kanamycin) 10 mM NaCl
2% (w/v) Agar
100 pg/ml Ampicillin or kanamycin
Competent E. coli were transformed with plasmid DNA using the heat shock
method described in (Sambrook et al., 1989). A sample of the plasmid DNA (3 pi) was
gently mixed with an aliquot (200 pi) of the heat-shock competent cells prepared as
described in the previous section. This mixture was incubated on ice for 15 min. It was
then heat-shocked at 42°C for 1 min 15 sec and returned on ice for a further 5 min. LB
buffer (800 pi) was then added to the cells and they were shaken at 200 rpm for 1 h at
37°C. The cells were then spread onto a LB agar plate containing 100 pg/ml ampicillin
or kanamycin and incubated overnight at 37°C in order to obtain ampicillin or
kanamycin resistant colonies (NB all the plasmids used in this study contained either
ampicillin or kanamycin resistance gene for selection).
2.4. Preparation of plasmid DNA
Plasmid DNA was prepared from transformed E. coli cultures using the
QIAGEN DNA purification system.
2.4.1. Small scale plasmid DNA preparation
QIAprep Miniprep kits (QIAGEN) were used for small-scale preparations of
plasmid DNA. DNA purifications were carried out according to the instructions
provided by the manufacturers. Briefly, an overnight E.coli culture in LB (3 ml) was
centrifuged and the pellet was resuspended in 250 pi buffer PI. In the next step the
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bacteria were lysed under alkaline conditions for 5 min by adding 250 pi buffer P2 and
gentle mixing. 300 pi Buffer N3 was added to neutralise the alkaline conditions. The
lysate was cleared by centrifugation and the DNA was adsorbed to the QIAprep
membrane. The membrane was washed and the DNA eluted with 50 pi Elution Buffer
(10 mM Tris-HCl, pH 8.5).
2.4.2. Large scale plasmid DNA preparation
QIAfilter Plasmid Maxi Kits (QIAGEN) were used for large-scale preparations
of plasmid DNA. DNA purifications were carried out according to the instructions
provided by the manufacturers. Briefly, an overnight E.coli culture in LB (100 ml) was
centrifuged and the pellet was resuspended in 10 ml buffer P1. In the next step the
bacteria were lysed under alkaline conditions for 5 min by adding 10 ml buffer P2 and
gentle mixing. The addition of 10 ml buffer P3 neutralised the alkaline conditions. The
lysate was incubated in the barrel of the QIAfilter Cartridge for 10 min. In the next step
the lysate was cleared by filtration through the QIAfilter Cartridge and the DNA was
bound to the QIAGEN Resin of the QIAGEN-tip. The QIAGEN-tip was washed with 2
x 30 ml buffer QC and the DNA was eluted with 15 ml buffer QF. The DNA was
precipitated by the addition of 10.5 ml isopropanol and centrifuged. After that the DNA
pellet was washed with 70% ethanol, air-dried for 15 min and re-dissolved in TE (pH
8.0).
2.5. DNA manipulation
2.5.1. Cloning of CP1-17 1-120 mutant
Human CPI-17 cloned into pGEX-4Tl vector (Pharmacia Biotech) was obtained
from Dr Thierry Dubois. It was cloned as described (Dubois et al., 2002d).The
expression vector pGEX-4Tl produces a glutathione S-transferase fusion protein
expressed from a tac promoter. The vector has a thrombin protease recognition site for
cleaving the protein from the fusion product.
GST-CPI-17 mutant comprising residues 1-120 was created by amplifying the
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CPI-17 cDNA by polymerase chain reaction (PCR) using two oligonucleotides (5-
'GCAGGATCCATGGCAGCTCAGCGGCTGGGC-3') to create a 5' BamRl site and
(5 '-CACGAATTCTCACCTGTGGAGGCCTTGAAGCTTTC-3') to create a 3' AcoRI
site (both are underlined in sequences). Amplified cDNA was inserted into pGEX-4Tl
vector (Pharmacia Biotech).
2.5.1.1. Polymerase chain reaction
Table 2.7 Buffers and solutions used for PCR
Pfu DNA Polymerase 200 mM Tris-HCl, pH 8.8
lOx Reaction Buffer with MgS04 100 mM KC1
(PromegaCorporation) 100 mM (NH4)2S04
20 mM MgS04
1 mg/ml nuclease-free BSA
1% Triton X-100




Two microlitres GST-CPI-17 template (250 ng) was mixed with 64 pi nuclease
free H2O, 10 pi Pfiu DNA Polymerase, lOx buffer, 2 pi dNTP mix, 50 pmol of each
primer and 1 pi ofPfu DNA Polymerase. The reaction was started by initial denaturation
at 95°C for 1 min. After that each cycle included denaturation at 95°C for 1 min,
annealing ofDNA primers at 55°C for 30 sec and DNA extension at 72°C for 1 min. A
total of 30 cycles were carried out on Hybaid Thermal Cycler. This was followed by a
final extension at 72°C for 5 min. The product was electrophoresed on a 1% TAE
agarose gel, visualised under ultra-violet illumination and purified using the QIAquick
PCR purification kit (QIAGEN). The purified DNA was subsequently subjected to
restriction enzyme digestion.
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2.5.1.2. Restriction enzyme digestion
Twenty microlitres PCR product were mixed with 2 pi BamHl (10 U/pl, Roche
Diagnostics), 2 pi .EcoRl(10 U/pl, Roche Diagnostics), 4 pi of 10 x SuRE/Cut Buffer B
(100 mM Tris-HCl, 50 mM MgCl2, 1M NaCl and 10 mM 2-Mercaptoethanol, pH 8.0 at
37°C) and 12 pi of ddH20. Two microlitres pGEX-4Tl (2 pg) were mixed with 1 pi
BamHl, 1 pi EcoRl, 2 pi of 10 x SuRE/Cut Buffer B and 14 pi of ddH20. Samples were
incubated at 37°C for 2 h and purified by running the samples on a 1% TAE agarose gel,
excising the bands and using the QIAquick gel exctraction kit (QIAGEN).
2.5.1.3. Ligation
Two microlitres pGEX-4Tl DNA (50 ng) were mixed with 6 pi CPI-17 1-120
(200 ng), 1.5 pi lOx T4 DNA buffer (660 mM Tris-HCl, 50 mM MgCl2, 10 mM DTT
and 10 mM ATP, pH 7.5), 1 pi T4 DNA ligase (1 U/pl, Roche Diagnostics) and 4.5 pi
ddH20. The ligation reaction was incubated O/N at 22°C.
2.5.1.4. Transformation
Fifteen microlitres of the ligation product was added to 200 pi of competent
E.coli DH5a cells and a transformation was performed as described under 2.3.2. 200 pi
of transformed E.coli were plated onto L-agar plates containing 100 pg/ml ampicillin.
2.5.1.5. Plasmid purification
Plasmids were purified using the QIAprep Miniprep Kit (QIAGEN) as described
under 2.4.1. To screen for positive clones, plasmids were treated with AcoRI and
BamHl, analysed on 1% TAE agarose gel and sent for sequencing to Cytomix,
Cambridge.
2 Materials and methods 61
2.5.2. Site-directed mutagenesis
Site-directed mutagenesis was used to introduce point mutations into CPI-17 in
order to study the effects of specific amino acids on the binding properties of CPI-17 to
other protein binding partners. The point mutations were also used to study the effect of
specific residues on CKI activity. Mutants ofCPI-17 were made using the
QuikChange™ site directed mutagenesis kit (Stratagene).
Table 2.8 Primers and restriction enzymes used to create CPI-17 point mutations
Mutation Primers 5'-3' Primers 3'-5' Restriction
Enzymes
CPI-17 T3 8A 5'GAAGCGGCACGC 3'CTTCGCCGTGCGC ifas'Hl site
GCGAGTCGCCGTC GCTCAGCGGCAGTT removed.
AAGTATGACC3' CATACTGG5'










The pGEX-4Tl-CPI-17 plasmid was used as DNA template. The oligonucleotide
primers, each complementary to opposite strands of the vector were extended during
temperature cycling by means ofPfuTurbo DNA polymerase. Incorporation of the
oligonucleotide primer generated a mutated plasmid. Following temperature cycling the
product was treated with Dpnl, an endonuclease which is specific for methylated and
was used to digest the parental DNA (Nelson and McClelland, 1992). DNA isolated
from almost all E.coli strains is methylated and therefore, susceptible to Dpnl digestion.
The DNA containing the desired mutation was then transformed into E.coli (using
modification of the Stratagene site-directed mutagenesis kit data sheet). To select for
mutant CPI-17 plasmids a specific restriction enzyme site was introduced into the
oligonucleotide primer containing the desired mutation
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2.5.2.1. Polymerase chain reaction
Three microlitres ofpGEX-4Tl-CPI-17 plasmid (20 ng) were mixed with the
two respective primers (125 ng each), 1 pi dNTP mix (2.5 mM each dNTP), 5 ju.1 lOx
reaction buffer (same as described in Table 2.7) and water to a final volume of 50 pi.
The reaction was started by an initial denaturation step at 95°C for 30 sec. Following
temperature cycling (15 cycles each including denaturation at 95°C for 30 sec, annealing
ofDNA primers at 55°C for 1 min and extension at 68°C for 10 min) the PCR product
was treated with 1 pi of the Dpnl restriction enzyme (10 U/pl) and incubated at 37°C for
1 h. 5 pi ofDpnl treated PCR product were transformed into E.coli DH5a cells using
the heat-shock method described under 2.3.2. The DNA was purified using the QIAprep
Miniprep kit as described under 2.4.1. To screen for positive clones, plasmids were
treated with the respective restriction enzyme, analysed on 1% TAE agarose gel and sent
for sequencing to Cytomix, Cambridge.
2.6. Over-expression and protein purification
2.6.1. Over-expression of GST-fusion proteins expressed in E. coli
Table 2.9 Clones used for protein over-ex pression in E. coli
GST (pGEX-4TI) Pharmacia Biotech
GST-centaurin-aj (pGEX-4TI) Kanamarlapudi Venkateswarlu
GST-CPI-17 (pGEX-4TI) Thierry Dubois
GST-CPI-17 SI28A (pGEX-4TI) Thierry Dubois
GST-14-3-3C (pGEX-4TI) Thierry Dubois
Table 2.10 Media and buffers used for the over-expression of GST-fusion proteins
Isopropyl P-D-thiogalactopyranoside
(IPTG)
1M stock solution (stored at -20 °C)
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GST 37°C 1 mM 4 h
GST-14-3-3 C 37°C 1 mM 4 h
GST-CPI-17 wild-
type and mutants*
37°C 1 mM 4 h
GST-centaurin ai 25°C 0.5 mM 4 h
* GST-CPI-17 mutants: T38A, T38D, S128A, S128D and GST-CPI-17 1-120.
E. coli (BL21 strain, Stratagene) was transformed with the respective
recombinant protein (GST-tagged) and grown overnight. E. coli containing the
transformed plasmid were grown overnight in 200 ml LB supplemented with 100 pg/ml
ampicillin at 37° C or 25°C. The cultures were diluted 1/10 in the same medium and
growth was continued at 37°C or 25°C until the optical density reached 0.6 (at 600 nm).
Expression of the recombinant protein was induced by adding 0.5-1 mM isopropyl p-D-
thiogalactopyranoside (IPTG) for 4 h. The bacteria were harvested by centrifugation for
15 min at 5000 g and stored at -80°C.
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2.6.2. Purification of GST fusion proteins expressed in E.coli






1/50 ml Complete TM EDTA-free protease inhibitor
cocktail (Roche Diagnostics, UK)
Elution buffer 10 mM reduced Glutathione
50 mM Tris-HCl, pH 8.0
PBS 137 mM NaCl
2.7 mM KC1
4 mM Na2HP04
0.15 mM NaH2P04 (pH 7.4)
Glutathione Sepharose 4B Amersham Pharmacia Biotech,





All the following procedures were carried out at 4°C. The pellet was resuspended
in sonication buffer. Bacteria were incubated with 0.5 mg/ml of lysozyme for 30 min.
This was followed by sonication of the bacteria 6 times for 20 sec at 5-10 pA. Bacterial
debris was then pelleted by centrifugation for 20 min at 14 OOOg at 4°C. The supernatant
was transferred to a fresh tube and filtered through a 0.45 pm filter.
Glutathione-Sepharose matrix was equilibrated by washing twice with 10 bed
volumes of ice cold sonication buffer. The filtered bacterial supernatant was loaded onto
the glutathione Sepharose matrix. The glutathione-Sepharose affinity support bound the
GST fusion protein. Unbound material was passed through the column a further two
times to increase the yield of protein bound to the column. To remove all non-specific
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binding, the matrix was washed 2x with 10 bed volumes sonication buffer containing
600 mM NaCl. To remove the NaCl the matrix was then washed 3 times with 10 bed
volumes PBS. The protein was eluted with 10 bed volumes elution buffer. Purified
fusion proteins were dialysed against 20 mM Tris and 1 mM EDTA overnight at 4°C.
Protein concentration was estimated by using the Bio-Rad protein assay and protein
purity was determined by analysis on 12.5% SDS-PAGE gel.
2.6.3. Purification of recombinant 14-3-3C and CP1-17 WT and mutants T38A,
T38D, S128A, S128Dand CPI-17 1-120
Table 2.13 Buffers and materials used for 14-3-3C WT/T233A and CPI-17
WT/mutants purification











Benzamidine Sepharose Amersham Pharmacia, UK
Similar procedures for 14-3-3^ and CPI-17 purification were followed as
described above. Instead of eluting the proteins however, the columns were washed with
3 column volumes equilibration buffer. GST was removed by digestion with thrombin
(100 U/2 ml column volumes) for 30 min at room temperature. Proteins were eluted by
washing the columns with 2 column volumes elution buffer. Fractions containing
recombinant protein were loaded onto a benzamidine Sepharose matrix (1 ml) to remove
thrombin contamination. The purity of 14-3-3^ and CPI-17 was determined by analysis
on 12.5% or 15% SDS-PAGE, respectively.
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BIOCHEMICAL TECHNIQUES
2.7. Protein assay
Protein was routinely measured by the method of Bradford (Bradford, 1976).
Protein assay dye concentrate (Bio-Rad) was diluted 1:4 with water to produce the
protein assay dye solution. Samples were diluted with water and 1 volume of diluted
sample was incubated with 4 volumes of protein assay dye solution for 5 min at room
temperature. The absorbance was then measured at 595 nm (A595). Bovine serum
albumin (BSA) was used as a standard to construct a curve ofA595 versus protein
concentration.
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2.8. SDS polyacrylamide gel electrophoresis (SDS-PAGE) of proteins






















































*Referred to as acrylamide in the text
Proteins were separated according to their size by Tris-glycine SDS PAGE,
following the method of Laemmli (Laemmli, 1970). Laemmli buffer (3x) was added to
the samples to give a final concentration of lx. These samples were boiled for 5 min
prior to storage and/or separation. Samples were separated by downward migration
through a vertical two-phase gel consisting of a stacking gel (top) and a resolving gel
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(bottom). The gel apparatus was obtained from Bio-Rad. The gel was suspended
between two separate reservoirs of Tris-glycine running buffer. A cathode and anode
were placed in the top and bottom reservoirs respectively. Proteins were separated at 40
mA constant current for 1 h (5 ml resolving gel). A 10% (w/v) acrylamide resolving gel
was used for the separation of 60-100 kDa proteins, whereas a 12.5% (w/v) acrylamide
resolving gel was used for the separation of 30-60 kDa proteins and a 15% (w/v)
acrylamide resolving gel was used to separate 10-30 kDa proteins (Sambrook et al.,
1989). The pre-stained, broad range protein molecular weight markers used were
obtained from Bio-Rad. Separated proteins were visualised by Coomassie blue staining
(20 min stain followed by 30 min destain) or were transferred onto nitrocellose
membrane for analysis by Western blotting.
2.9. Western blotting
Table 2.15 Buffers for Western blotting




TBS-Tween 137 mM NaCl
20 mM Tris-HCl, pH 7.6
0.1% Tween-20
Proteins were transferred from SDS-PAGE gels to nitrocellulose membranes
(Bio-Rad) by electroblotting in transfer buffer at 180 mA constant current for 90 min.
The nitrocellulose membranes were blocked with 10% skimmed milk in TBS-Tween for
1 h shaking at room temperature. They were then probed with primary antibody, diluted
in 10% skimmed milk in TBS-Tween, either shaking at room temperature for 2 h or at
4°C overnight. The antibody dilutions that were used are shown in Table 2.16. After six
5 min washes in TBS-Tween, the nitrocellulose membranes were incubated with
horseradish peroxidase (HRP) conjugated secondary antibody, diluted in 10% skimmed
milk in TBS-Tween, for 1 h shaking at room temperature. The membranes were washed
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in TBS-Tween as before and subjected to enhanced chemiluminescence (ECL) system
(Amersham Pharmacia Biotech, UK) following the manufacturer's instructions.
Immediately after treating the membranes with ECL reagent, they were exposed to
Kodak X-ray fdm for various lengths of time (10 sec-30 min).
Table 2.16 List of antibodies and the dilutions used for Western blotting or
immunopreci pitation












CKIa (C-19) Santa Cruz Primary Polyclonal 1/250




CKI CKI StressGen Primary Polyclonal 1/1000
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2.10. Generation of a polyclonal antiserum to CPI-17
2.10.1. Immunisation of the sheep
The following procedures were carried out by Diagnostics Scotland. For the
primary immunisation, 1.25 mg of purified CPI-17 protein were mixed with Freund's
Complete Adjuvant (FCA), an emulsifying agent containing mycobacteria which
enhance the immune response to the immunogen. The three subsequent booster
injections contained 1.25 mg ofCPI-17 protein in Freund's Incomplete Adjuvant (FIA),
an adjuvant where the mycobacteria are not included. Donations are up to 1 1 of whole
blood, which yields 200-400 ml of serum. The animal was injected every 28 days and
was not exsanguinated at the termination of procedure.
2.10.2. Affinity purification of anti-CPI-17
Table 2.17 Buffers used for affinity purification of anti-CPI-17
Buffer A 20 mM Tris-HCl, pH 7.5




Elution Buffer 3.5 M MgCl2
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Recombinant CPI-17 protein (2 mg) was covalently bound to SulfoLink
Coupling Gel column (2 ml column volume) following the manufacturer's instructions
(Pierce). The column and buffers were at room temperature for the following
procedures. The column was equilibrated with 10 column volumes. The serum (10 ml)
was dialysed against buffer A, filtered on 0.45 pm and passed through the column. The
flow-through was collected and passed through the column three more times. The
column was washed with 5 column volumes buffer A and then with 5 column volumes
Buffer B. The antibody was eluted with 5 column volumes elution buffer and dialysed
against PBS O/N. The antibody was concentrated to a final concentration of 0.5 mg/ml
and 2 mg/ml BSA were added for storage. The antibody was aliquoted and stored at -
20°C. It was used at a dilution 1/100 in Western blotting.
2.11. Chemical crosslinking of CPI-17
Table 2.18 Chemical crosslinkers (Pierce)







DMS and DTBP are water soluble homobifunctional imidoesters and possess
two identical groups which can react with primary amine groups to form stable covalent
bonds (Pierce). To determine whether CPI-17 is a dimer, crosslinking experiments with
the two crosslinkers were carried out, and 14-3-3t was used as a positive control. CPI-17
(50 pM) or 14-3-3t (50 pM) were mixed with a freshly prepared solution of the
respective crosslinker (5 mM) and the reaction was made up to 15 pi with PBS. The
reactions were incubated at room temperature for 2 h. The reactions were stopped by the
addition ofTris-HCl, pH 7.4 to a final concentration of 500 mM. Reactions were
analysed on 15% SDS-PAGE and protein bands were either visualised by staining with
Coomassie blue or analysed by Western blotting with an anti-CPI-17 antibody or 14-3-
3 C, antibody.
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2.12. Affinity chromatography of proteins that interact with CPI-17 and
centaurin-ai






2/50 ml Protease inhibitor tablets
Elution buffer Same as above +
1 M NaCl
Glutathione-Sepharose affinity columns with ~ 25mg ofGST, GST-CPI-17 or
GST-centaurin-ai were constructed as described under 2.6.2, however, the proteins were
not eluted and the buffer was equilibrated with homogenisation buffer. Sheep brain (~
80 g) (or 10 rat brains, ~ 2 g each) were homogenised in homogenisation buffer. Triton
X-100 was then added to a final concentration of 0.5% and the mixture was incubated at
4°C for 2 h with constant agitation, and clarified by centrifugation at 14000 g for 30 min
at 4°C. This was followed by ultracentrifugation at 100000 g for 1 h at 4°C. The
supernatant was filtered through a 0.45pm filter and incubated with GST for 2 h at 4°C
with constant agitation. A centrifugation at 4000 g for 5 min at 4°C followed. The
supernatant was incubated by batch with the GST, GST-CPI-17 or GST-centaurin-ai
column overnight at 4°C. Beads were then left to settle and the columns were washed
with lysis buffer containing 0.5% Triton. The columns were subsequently washed with 4
x 15 ml of homogenisation buffer. The proteins were eluted with homogenisation buffer
containing 1M NaCl, and concentrated on Centricon 10 (Millipore). Protein
concentration was determined using the Bio-Rad protein assay. Samples were analysed
by 12.5% or 10% SDS-PAGE, transferred onto nitrocellulose and Western blotting using
CamKII, CKIa, CKIe, HMG1, PKAC, PKCa, PKCs, PKCA,, PKCp, PKC^, PKN
(PRK1) and ROCK (ROKa) antibodies was performed.
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2.13. In vitro binding between purified PKC isoforms and CPI-
17/centaurin-ai
Table 2.20 Buffer used for in vitro binding studies between purified PKC isoforms
and CPI-17/centaurin-ai





0.1% Bovine Serum Albumin (BSA)
GST, GST-14-3-3 GST-CPI-17 or GST-centaurin-ai (5 p,g) were incubated
with human recombinant PKCa, 8, p, or ^ (I U) (Calbiochem) in binding buffer for 2 h
at 4°C with constant rotation. Glutathione-Sepharose beads were then added and
incubated for a further 1 h. Bead precipitates were washed 4 times with binding buffer
and bound proteins were eluted using SDS sample buffer. The samples were analysed by
10% SDS-PAGE, transferred onto nitrocellulose and Western blotted using PKC
antibodies.
2.14. In vitro CKI assays
2.14.1. In vitro binding between purified CKI and CPI-17
Table 2.21 Buffers used for in vitro binding study between purified CKI and CPI-
17





0.1% Bovine Serum Albumin (BSA)
Kinase buffer 25 mM HEPES, pH7.0
10 mM MgCl2
1 mM DTT
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GST, GST-centaurin-ai and GST-CPI-17 (5 pg) were incubated with
recombinant CKI (0.2 pg) (S.pombe skil, Upstate Biotechnology) in binding buffer for 2
h at 4°C. Glutathione-Sepharose beads were then added and incubated for a further 1 h.
Bead precipitates were then washed 4 times with binding buffer and once with kinase
buffer. The washed beads were incubated with kinase buffer (without NaCl) containing
40 pM of a CKI-specific phosphopeptide (CKRRALS(p)VASLPGL, where S(p) is a
phosphoserine; Cali Hyde, National Institute for Medical Research, Mill Hill, London)
substrate and 50 pM ATP including [y-32P]-ATP (Amersham) in a final volume of 60 pi.
Samples were incubated at 30°C for 30 min, centrifuged (10000 g) and 20 pi of the
reaction mixture was spotted in duplicate on P81 paper squares (Whatman). The papers
were washed 5 times with 1% aqueous phosphoric acid and radioactivity retained on the
papers was quantified by liquid scintillation counting.
2.14.2. Phosphorylation of 14-3-3C wt by a kinase eluted from the CPI-17
column
Table 2.22 Buffers used for phosphorylation of 14-3-3<^ by a kinase eluted from the
CPI-17 column






Kinase buffer 25 mM HEPES, pH7.0
10 mM MgCl2
1 mM DTT
Five micrograms ofGST, GST-CPI-17 or GST-centaurin-ai column eluate was
incubated with 5 pg of GST, GST-14-3-3^ or GST-14-3-3C T233A mutant (from
Thierry Dubois) in kinase buffer (as described in 2.14.1) in a final volume of 40 pi.
Reactions were performed at 30°C for 30 min. The reaction was stopped with 1 ml of
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binding buffer. 20 pi of glutathione Sepharose beads were added and the samples were
incubated for 1 h at room temperature. The beads were washed 3 times with binding
buffer and incubated with SDS sample buffer. Samples were analysed by 12.5% SDS-
PAGE. Gels were stained with Coomassie Blue and autoradiographed.
2.14.3. Phosphorylation of CP1-17 by a kinase eluted from the CPI-17 column
Five micrograms ofGST or GST-CPI-17 column eluate was incubated with 5 pg
ofGST or GST-CPI-17 in kinase buffer (as described in 2.14.1) in a final volume of 40
pi. Reactions were performed at 30°C for 30 min. The reaction was stopped with 1 ml of
binding buffer. 20 pi of glutathione Sepharose beads were added and the samples were
incubated for 1 h at room temperature. The beads were washed 3 times with binding
buffer and incubated with SDS sample buffer. Samples were analysed by 15% SDS-
PAGE. Gels were stained with Coomassie Blue and autoradiographed.
2.14.4. Kinase assay to test the effect of CPI-17 on CKI activity
CPI-17 wt, CPI-17 T38A, CPI-17 T38D, CPI-17 SI28A, CPI-17 S128D and
CPI-17 1-120 (7.5 pg) were pre-incubated with recombinant CKIa (from Dr Thierry
Dubois) (Dubois et al., 1997) for 15 min at 30°C. To test the effect of CPI-17 on CKI,
casein (5 pg) or CKI-specific phosphopeptide substrate (40 pM) were added with the
kinase buffer (as described in section 2.14.1). The reaction was started by addition of 50
pM ATP including [y-32P]-ATP. The reaction was carried out in a final volume of 60 pi.
Reactions were performed at 30°C for 30 min, 20 pi of the reaction were spotted in
duplicates on P81 paper squares (Whatman) and the papers were washed 5 times with
1% TCA. Radioactivity retained on the papers was quantified by liquid scintillation
counting. In order to measure the half-maximum inhibition/activation, recombinant
CKIa was pre-incubated with different amounts ofCPI-17 SI 28A or CPI-17 wt/S128D
(14 nM-11 mM) for 15 min at 30°C. CKI specific phosphopeptide (40 pM) was used as
substrate and the reactions were carried out as described above.
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2.14.5. Kinase assay to test the effect of CPI-17 on CKll activity
Table 2.23 Bufi 'er used for CKII in vitro assay
Kinase buffer 20 mM Tris-HCl, pH 7.5
50 mM KC1
10 mM MgCl2
CPI-17 wt, CPI-17 T38A, CPI-17 T38D, CPI-17 SI28A and CPI-17 S128D (5
pg) were pre-incubated with CKII (Upstate Biotechnology). After 15 min at 30°C,
casein (5 pg) in kinase buffer. 50 pM ATP including [y-32P]-ATP were added. The
reaction was performed in a final volume of 60 pi at 30°C for 30 min. An aliquot of the
reaction (20 pi) was spotted in duplicates on P81 paper squares (Whatman). The papers
were washed 5 times with 1% TCA and radioactivity retained on the papers was
quantified by liquid scintillation.
2.15. Phosphorylation of CPI-17 by PKC and CKIa
Kinase buffer (for PKCs, p and C) 40 mM HEPES, pH 7.4
2 mM EGTA
20 mM MgCl2
Kinase buffer (for PKCa) Same as above +
3 mM CaCl2
CPI-17 (5 pg) was incubated with 1 U ofPKCa, PKCs, PKCp or PKC£, in
kinase buffer. 0.03 mg/ml phosphatidylserine, 8 pg/ml diacylglycerol and 50 pM ATP
including [y- PJ-ATP, Amersham were added to the reactions. The reaction was
performed at 30°C for 15 min in a final volume of 40 pi. The reactions were stopped by
the addition of SDS sample buffer and analysed on 15% SDS-PAGE. Gels were stained
with Coomassie Blue and autoradiographed.
Phosphorylation ofCPI-17 (5 pg) by CKIa was performed by incubating CPI-17
with CKIa in kinase buffer (as described in 2.14.1) at 30°C for 30 min in a final volume
of 40 pi. The reactions were stopped by the addition of SDS sample buffer and analysed
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on 15% SDS-PAGE. Gels were stained with Coomassie Blue and autoradiographed.
2.16. In vitro transcription and translation (IVTT) and GST pull-down
assays
Table 2.25 Buffer used for IVTT





Table 2.26 Clones used for IVTT
Clone From
HA-CKIoc (pcDNA3) Frank McKeon








(all cloned in pcDNA3)
CKI5 Peter Roach
CKI8A317 (deleted of the carboxyl terminus)
CKIy,
CKIy3
(all cloned in pET8c)
CKIy2 (pSV2Zeo) Louise Larose
CKIs (pV405) David Virshup
PKCa (pC02) Peter Parker
PKCX. (pcDNA3) Terje Johansen





PKCC (pcDNA3.1) Feng Liu
Nucleolin (deleted of last 171 C-terminus Josee Golay
residues)
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CKIa, CKI5, CKIe, CKIy, CKIy2 CKIy3, PKC a, X, p, £ and nucleolin were
expressed in vitro using a T7 TNT coupled transcription/translation reticulocyte lysate
(Promega Corp., Madison, WI). The reactions (50 pi) were performed following the
manufacturer's instructions using [35S] methionine (Amersham) for 90 min at 30°C.
Samples were then diluted 3 fold with binding buffer and incubated for 15 min at 30°C
with 5 pg of GST, GST-centaurin-ai, GST-CPI-17, GST-CPI-17 1-120, GST-14-3-3^ or
GST-VAMP. When ribonuclease (RNase) treatment was performed, 2, 4, or 8 pi of
RNase ONE™ ribonuclease (5-10 units/ml) (Promega Corp.) were added to the reaction
before addition of the recombinant proteins and incubated for 15 min at 30°C. BSA was
added to a final volume of 0.1% to remove non-specific binding. Glutathione-Sepharose
beads (Amersham Pharmacia) and binding buffer (300 pi) were added to the reactions
and incubated at room temperature for a further 1 h. The beads were washed 5 times
with 1 ml of binding buffer, boiled in sample buffer for 5 min and electrophoresed on
12.5% SDS-PAGE. After staining/destaining, the gels were incubated for 30 min with
Amplify™ (Amersham Pharmacia), dried and exposed to film.
2.17. Co-transfection/immunoprecipitation of CPI-17 and CKI










1/50 ml protease inhibitor tablets
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COS-1 or COS-7 cell were co-transfected with 2 pg flag-CPI-17/flag-centaurin-
cti (flag2B vector) and 4 pg HA-CKIaWT/KD (pcDNA3.1) using electroporation or
FuGENE (as described under 2.1.2.1 and 2.1.2.2). After transfection the cells were
seeded into 100 mM tissue culture dishes in complete medium and cultured for 48 h.
The cells were lysed in 1 ml of lysis buffer. Lysates were incubated with Pansorbin cells
(Calbiochem) with constant agitation (final volume 10%) for 30 min at 4°C and
centrifuged at lOOOOg for 30 min. The supernatants were incubated for 2 h with constant
agitation at 4°C with anti-HA antibody (3 pg) (Sigma) to allow binding to the
transfected HA-tagged CKIa. 25 pi protein A/G Sepharose (Pharmacia Amersham)
were added and the immunoprecipitates were incubated for a further 1 h at 4°C and
washed 3 times with lysis buffer. Bound proteins were eluted from the protein-A/G
Sepharose beads with 20 pi lx sample buffer and analysed by SDS-PAGE gel. Western
blot analysis was carried out using anti-flag (1/250) (Sigma).
2.18. Mass spectrometry
To identify new protein binding partners, CPI-17 and centaurin-ai affinity
columns were constructed, and brain lysate was passed through as described in 2.12. For
CPI-17 the experiment was also repeated using rat brain lysate. 40 pg ofCPI-17 and
centaurin-ai column eluate was separated on 12.5% SDS-PAGE and stained with
GelCODE. MALDI-TOF (Matrix Assisted Laser Desorption/Ionisation Time of Flight
Mass Spectrometry) setup was used to identify the proteins. The protein bands were
excised and digested with trypsin. Samples were analysed by 0.5 ml sample digest with
0.5 ml matrix (a-Cyano-4-hydroxycinnamic acid (CHCA), Sigma) onto a 100 well
MALDI plate. Mass Spectrometry analysis was carried out using an Applied Biosystems
Voyager DE (delayed extraction) STR MALDI-TOF instrument. The instrument was set
up as follows:
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Table 2.28 MALDI-TOF instrument set up
Mode Positive Ion Reflector
Grid Voltage 66%
Accelerating Voltage 20000V
Low Mass Gate 500Da
Delay time 150nsec
Laser energy Variable from 1830-2080
Laser shots 400 per acquisition
All samples were spotted in duplicate to account for irregularities in crystallising.
This is variable from spot to spot. Where poor spectra were obtained, Zip Tipping of the
digest solution was carried out. Zip Tips (Milipore) are generally used to desalt or
concentrate samples up. The final spectra were calibrated using known trypsin peaks
visible within each spectrum. From this a list of peaks (peptide masses) was copied into
Protein Prospector http://prospector.ucsf.edu/ucsfhtml4.0u/msfit.htm orMatrix Science
http://matrixscience.com/cgi/master.
A number of different databases can be searched using the search engines MS-Fit
(Protein Prospector) or Mascot (Matrix Science): NCBI, SwissProt, Owl,
pbEST,Genpept. In this case the NCBI database was used. The search engine matches
experimental peak mass data with theoretical peptide masses from hypothetical digests
of sequenced proteins. From this, a MOWSE and/or percent coverage score is given.
This MOWSE scoring, represents a number providing a probability for a potential hit.
Typically, the higher the MOWSE score the better (For Mascot Search, scores greater
than 65 are considered to be significant). The percentage coverage represents the
matched peptides as a percentage of the total protein. For proteins under 1 OOkDa a
minimum of 20% is generally required. A minimum of 4 peptides had to be matched
before a score was given. Again, the more matches the better. The mass spectrometry
analysis, including the trypsin digestion were carried out by Dr Andy Cronshaw and
Hannah Florance (University of Edinburgh, Wellcome trust, Edinburgh Protein
Interaction Centre, (EPIC)) for identification of novel CPI-17 binding partners. Dr
Steven Howell (National Institute for Medical Research, Mill Hill, London) carried out
the identification of centaurin-ai protein partners, apart from the identification of
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nucleolin which was also done by Dr Andy Cronshaw. The experimental procedures
description is based on a summary ofMass Spectrometry Method written and developed
by Dr Andy Cronshaw.
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CHAPTER 3
Identification of novel CPI-17 binding proteins
3. Identification of novel CPI-17 binding proteins
INTRODUCTION
CKIa was identified as the kinase from brain which phosphorylates 14-3-3^ on
residue 233 (Dubois et al., 1997). The protein kinase C-potentiated inhibitor, CPI-17,
was one of seven proteins which co-purified with CKIa from brain after four
chromatography steps suggesting that they might be forming a complex (Dubois et al.,
2002b). The aim was to characterise the interaction between CPI-17 and CKIa further
and to identify new protein binding partners for CPI-17 by affinity chromatography to
increase our understanding of the functions that CPI-17 might have in cells. In this
chapter dimerisation experiments with CPI-17 and the generation of a CPI-17 antibody
(sections 3.2.1 and 3.2.2 ) will be discussed. The identification of new CPI-17 binding
proteins will be described and will focus on the characterisation of the interaction
between PKC and CPI-17 (section 3.3), because it has been shown that phosphorylation
ofCPI-17 on Thr-38 by PKC increases its potency to inhibit the catalytic subunit of PP1
(PP1-C) by 1000-fold. The second part of this chapter (section 3.4) will focus on the
characterisation of the interaction between CPI-17 and CKI since our laboratory
identified CPI-17 as one of the proteins co-purifying with CKIa from brain as
mentioned above. In the last part of this chapter the identification of novel potential CPI-
17 binding proteins by mass spectrometry will be discussed and some of the potential
functions CPI-17 might have in cells in the light of these newly identified binding
partners will be proposed (section 3.5). The diagram below shows a summary of the
three major parts of this chapter which will be discussed (Figure 3.1).
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PKC Novel partners
MLCP
Figure 3.1 Interactions with CPI-17 described in chapter 3.
CPI-17 associates with PKC (section 3.3), CKf (section 3.4) and novel binding partners
(section 3.5); these interactions are indicated by double arrows. When phosphorylated
CPI-17 is also a myosin light chain phosphatase (MLCP) inhibitor indicated by a bar.
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RESULTS AND DISCUSSION
3.1. DNA manipulation and purification of recombinant proteins
GST-CPI-17 cloned in pGEX-4TI was from Thierry Dubois. GST-CPI-17 1-120
was cloned using the PCR and sequenced to verify the nucleotide sequence of human
CPI-17 1-120 as described in the Methods section 2.5.1. GST-CPI-17 T38A, T38D,
SI28A and S128D were cloned using the site-directed mutagenesis kit as described in
the Methods section 2.5.2. GST-14-3-3^ and GST-centaurin-ai cloned in pGEX-4TI
were from Dr Thierry Dubois. The recombinant fusion proteins were expressed in E. coli
as described in the Methods section 2.6. To obtain the GST fused protein, standard
procedures were used (Figure 3.2A, C and D). Recombinant CPI-17, was obtained by
cleavage with thrombin (Figure 3.2B). Fractions containing CPI-17 were typically 2
mg/ml as measured by Bio-Rad protein assay and stored at -20°C.

















Figure 3.2 Purified recombinant proteins.
A, Coomassie blue-stained 12.5% SDS-PAGE of 5 pg each of recombinant protein
(GST-tagged). Molecular weight markers in kDa are shown on the left.
B, Coomassie blue-stained 15% SDS-PAGE of 5 pg each of recombinant CPI-17
protein. Molecular weight markers in kDa are shown on the left.
C and D, Coomassie blue-stained 12.5% SDS-PAGE of 5 pg of recombinant CPI-17
proteins (GST-tagged). Molecular weight markers in kDa are shown on the left.
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3.2. CPI-17
3.2.1. Generation of anti-CPI-17
Antiserum was raised against purified human recombinant CPI-17 in one sheep
as described in Methods section 2.10. To test the antiserum produced, 1 pg ofCPI-17
and GST-CPI-17 were separated by SDS-PAGE and transferred onto nitrocellulose. The
nitrocellulose membrane was then immunoblotted with the antiserum, or pre-immunised
serum, as primary antibody. The two sera were diluted 1:100. Both CPI-17 and GST-
CPI-17 were recognised by the antiserum (Figure 3.3). However, the antiserum only
recognised a minimum of 0.1-0.5 pg of recombinant protein (data not shown). The anti¬
serum only recognised 1 band and therefore the specificity appears to be good. The pre-
immune serum did not recognise CPI-17 or GST-CPI-17.
3.2.2. CPI-17 dimerisation
To test whether CPI-17 forms dimers, cross-linking experiments were performed
as described in Methods section 2.11. 14-3-3^ was used as a positive control. The results
show that CPI-17 is a dimer (Figure 3.4). To the best ofmy knowledge this is the first
time this has been demonstrated. These results were further confirmed by light scattering
experiments carried out by Yuan De Yang (Institute of Cell and Molecular Biology
(ICMB), University of Edinburgh; data not shown). CPI-17 dimerisation might be a
prerequisite for interactions with certain proteins. Interestingly, it has been suggested
that the PP1 inhibitor, PHI-1 is either a dimer of 46kDa or contains an extended
polypeptide that exhibits an anomalous size in solution (Eto et ah, 1999).
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Figure 3.3 Generation of anti-CPI-17.
This figure shows that the sheep had raised antibodies to CPI-17 just 28 days after the
first injection with CPI-17. The antiserum detected a band at approximately 20kDa
which is the molecular weight at which CPI-17 migrates on 15% SDS-PAGE (Eto et al.,
1995).





















Figure 3.4 CPI-17 dimerisation.
A, CPI-17 (50 pM ) was incubated in the presence (+) or absence (-) of DMS or DTBP
chemical cross-linking agents. The presence of monomeric and dimeric forms of CPI-17
was determined by Western blotting using CPI-17 antibodies.
B, As a positive control, 14-3-3<^ (50 pM ) was incubated in the presence (+) or absence
(-) ofDMS or DTBP chemical cross-linking agents . The presence of monomeric and
dimeric forms of 14-3-3^ was determined by Western blotting using 14-3-3C, antibodies.
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3.3. Characterisation of the association between CPI-17 and PKC
The next part of this chapter will focus on the identification ofnovel CPI-17
binding partners and particularly focus on the interaction between CPI-17 with PKC and
CKI. To investigate the function(s) ofCPI-17, novel CPI-17 protein partners were
identified by affinity chromatography as described in more detail in section 3.5.
CPI-17 is phosphorylated on Thr-38 in vitro by a number of kinases such as PKC
(Eto et al., 1995), PKA (Dubois et al., 2002d), ROCK (Koyama et al., 2000), PKN
(Hamaguchi et al., 2000), a ZIP-like kinase (MacDonald et al., 2001b) and ILK (Deng et
al., 2002), however the in vivo kinase that phosphorylates this residue remains unknown.
Phosphorylation of Thr-38 plays a key role in regulating CPI-17 activity (Eto et al.,
1995), therefore the interaction of some of these kinases with CPI-17 was tested, with
the ultimate aim to gather evidence which would lead to the identification of the in vivo
kinase.
3.3.1. A kinase which phosphorylates CPI-17 associates with the CPI-17 column
To determine whether a kinase associated with the GST-CPI-17 column which
could phosphorylate CPI-17 wt, 5 pg of CPI-17 wt were incubated with 5 pi CPI-17
column eluate or GST column eluate in the presence of CKI kinase buffer. Casein kinase
buffer was used because I wanted to test whether CPI-17 wt could be phosphorylated by
CKI which could be present in the CPI-17 column eluate. The results show that CPI-17
wt was phosphorylated by a kinase present in the CPI-17 column eluate (Figure 3.5),
however the identity of this kinase remains unknown. It should be pointed out that it is
very unlikely that the kinase is CKI, because in chapter 3.4.6 it will be shown that CPI-
17 is only a very weak substrate for CKI. It is possible that a number of kinases are
present in the CPI-17 eluate which phosphorylate CPI-17 in vitro on multiple
phosphorylation sites.
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GST eluate GST-CPI-17
eluate
Figure 3.5 A kinase associates with the GST-CPI-17 column which phosphorylates
CPI-17.
GST ("GST-eluate") or GST-CPI-17 ("GST-CPI-17 eluate") (5 pg) column eluate were
incubated for 30 min at 30°C with 5 pg of GST or GST-CPI-17 in the presence of 50 pM
32
[y- "P] ATP and kinase buffer. A GST pull-down assay was performed and the samples
were analysed by 15% SDS-PAGE and autoradiography. The positions of the molecular
weight markers (kDa) are indicated, as is the position of the phosphorylated GST-CPI-
17.
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3.3.2. PKC isoforms from all PKC classes bind to the CPI-17 column
PKC has been shown to phosphorylate CPI-17 on Thr-38 (Eto et al., 1995) and
therefore the association of PKC isoforms with the CPI-17 column was tested. Proteins
eluted from the GST1 and GST-CPI-17 column (10 pg) were separated on a 10% SDS-
PAGE gel, transferred onto nitrocellulose and Western blotted with anti-PKCa, s, X, p
and C, antibodies (for PKCA. and C, 5 pg of GST-CPI-17 column eluate and GST-
centaurin-ai column eluate were loaded). No PKC isoforms were detected in the eluate
from the control GST column. PKCa (conventional PKC), PKCs (novel PKC), PKCA.
and C, (atypical PKCs) and PKCp all associated with the GST-CPI-17 column, and
PKCA. and PKC^ also associated with the centaurin-ai column (Figure 3.6). The PKCC
antibody seems to recognise a lower molecular weight band in the brain lysate and in the
GST-centaurin-ai column eluate compared to the CPI-17 column eluate. This could be
explained by the fact that the PKCC isoform present in the CPI-17 eluate could be
phosphorylated and therefore migrates higher than the unphosphorylated form which
might be present in the brain lysate and GST-centaurin-ai column eluate. The other
possibility could be that the antibody against PKC^ is of low quality and might not be
very specific. One cannot conclude whether PKCa, s and p also bound to the GST-
centaurin-ai column as not enough material was available. The kinases ROCK, PKN
and PKA were also shown to phosphorylate CPI-17 on Thr-38 in vitro (Dubois, et al.,
2002d; Hamaguchi et al, 2000; Koyama et al., 2000). Therefore it was tested whether
ROCK, PKN and the catalytic unit ofPKA (PKAc) associated with the GST-CPI-17
column (Figure 3.7). Out of these kinases only PKAc associated with the CPI-17
column. Because it was not tested whether a regulatory subunit ofPKA associated with
the CPI-17 column, it was difficult to conclude whether the PKAC detected was a free,
active subunit from the cytosol or part of the inactive complex containing regulatory
1 Note that due the low concentration of proteins in the GST column eluate, it was not possible to load the
same amount of protein i.e. 5-10 pg and therefore 20 pi of the GST column eluate were loaded.
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subunits and possibly anchored via an AKAP to a specific subcellular domain.
The association ofCamKII, which phosphorylates CPI-17 on Ser-130 (Dubois et al.,
2002d), with the CPI-17 column was tested, however, no binding could be detected
(Figure 3.7). The results from the CPI-17 affinity chromatography indicated that PKC
isoforms from all PKC classes (a, s, X, p and Q and PKAC associated with the GST-
CPI-17 column. However, one cannot conclude from this experiment whether the
binding of the kinases was directly to CPI-17 or whether it was mediated by other
proteins associated with the GST-CPI-17 column.









CPI-17 Cent.-a, GST Brain
82 FKCX









Figure 3.6 PKCs associate with the CPI-17 column.
All PKC classes elute from the GST-CPI-17 column. Protein (5 pg or 10 fag) eluted
from the GST-CPI-17 ("CPI-17"), GST-centaurin-ai ("Cent.-ai") or GST column was
separated on 10% SDS-PAGE, transferred onto nitrocellulose and Western blotted with
PKCA, and C, antibodies (for GST-CPI-17 and GST column eluate also with PKCa and
PKCs antibodies; for GST-CPI-17 column eluate only also with PKCp antibodies). A
brain extract was used as a positive control for the antibodies. The positions of the
molecular weight markers (kDa) are indicated.
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Figure 3.7 PKAc associates with the GST-CPI-17 column, but ROCK, PKN and
CamKII do not.
As described for Figure 3.6, but Western blot analysis was performed with PKAc,
ROCK, PKN and CamKII antibodies.
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3.3.3. In vitro binding of all PKC isoforms to CPI-17
To further investigate whether the association ofPKCs with CPI-17 was
selective, two different in vitro experiments were carried out.
Firstly, the binding between CPI-17 and PKCs from all classes was investigated
using the in vitro transcription/translation assay (IVTT). PKCa, X, p and t, were
expressed and labelled with [35S] methionine in a reticulocyte lysate, and incubated with
GST, GST-14-3-3^ or GST-CPI-17. All these PKC isoforms were associated with GST-
CPI-17 and not with GST (Figure 3.8). GST-14-3-3<^ did not associate with PKCa, X,
and p but interacted very weakly with PKC^ (Figure 3.8). Our data show that all PKC
isoforms tested bind to CPI-17. To confirm the selectivity of the interaction between
PKC and CPI-17, PKCp and 14-3-3^ were expressed and labelled with [35S] methionine
and incubated with GST and GST-CPI-17. Only PKCp and not 14-3-3^ bound to GST-
CPI-17 (Figure 3.9). Neither PKCp nor 14-3-3^ bound to GST (negative control).
Results from Figure 3.8 and Figure 3.9 indicated that the binding between CPI-17 and
PKC was selective.
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Figure 3.8 CPI-17 associates with all PKC isoforms tested.
PKCa, X, p and C, were expressed and labelled with [35S] methionine in a reticulocyte
lysate and incubated for 15 min at 30°C with 5 pg GST, GST-14-3-3^ and GST-CPI-17
in the presence of 1% Nonidet P-40. Glutathione-Sepharose beads were added and
incubated at room temperature for 1 h. Beads were washed and samples analysed by
10% SDS-PAGE followed by autoradiography (panel "Pull-down"). An aliquot of the
lysate was loaded on the gel to visualise expressed PKCs (panel "Input"). The positions
of the molecular weight markers (kDa) are indicated.






Figure 3.9 CPI-17 interacts selectively with PKC.
PKCp and 14-3-3^ expressed in a reticulocyte lysate, were incubated with 5 pg GST and
GST-CPI-17, pulled-down with glutathione Sepharose beads and analysed as described
in Figure 3.8. The positions of the molecular weight markers (kDa) are indicated.
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To determine whether the binding between CPI-17 and PKC was direct, GST,
GST-14-3-3^, GST-centaurin-ai and GST-CPI-17 were incubated with recombinant
PKCa, PKCs, PKCfj. and PKC^, pulled-down with glutathione Sepharose beads and the
samples were analysed on a 10% SDS-PAGE gel, transferred onto nitrocellulose and
Western blotted with the respective PKC antibodies. The results showed that GST-CPI-
17, but not GST, directly bound to all PKC isoforms tested (Figure 3.10). GST-
centaurin-ai also bound to all PKC isoforms (Figure 3.10). In addition, 14-3-3^ directly
associated with PKCs and PKCp, but not with PKCa nor PKC^ (Figure 3.10). These
results were in contrast to those presented in Figure 3.8, where we could not detect any
binding between 14-3-3^ and PKCp. This might be due to the presence of other proteins
in the reticulocyte lysate that may compete with PKC for binding to 14-3-3^. However,
the results in Figure 3.10 are in agreement with a reported interaction between 14-3-3^
and PKCp (Hausser et al., 1999) and the binding between 14-3-3and PKCs has also
been confirmed (Gannon-Murakami and Murakami, 2002). The results of the binding of
14-3-3^ and PKC£, have been conflicting: van der Hoeven and co-workers show that
PKC<^ does not co-immunoprecipitate with 14-3-3(^ in COS cells (van der Houven van
Oordt et al., 2000) whereas Gannon-Murakami and co-workers suggest constitutive
binding between 14-3-3^ and PKC^ in PC12 cells (Gannon-Murakami and Murakami,
2002). However, these authors also provided evidence that the binding between PKCa
and 14-3-3^ in PC 12 cells is differentiation dependent. One possibility might be that
PKCa and 14-3-3^ need to be localised to specific subcellular compartments in
differentiated cells in order to bind. It is also possible that another factor (e.g. agonist or
protein partner) that is only present in differentiated cells is required which would allow
the two proteins to interact. This could offer an explanation why no interaction between
PKCa and 14-3-3^ could be detected in the direct binding experiments as mentioned
above. It is important to point out that purified proteins were used for this direct binding
experiment and the reaction was in vitro, therefore, it is difficult to compare these results
to experiments conducted in cells. Using two different methods, it was shown that the
association between CPI-17 and PKC was selective and direct. This suggested that CPI-
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17 associated with a domain common to all PKC isoforms, i.e. the cysteine rich domain
(CI) or the kinase domain (see Figure 1.6 for schematic representation of primary
structures ofmammalian PKC family members).
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Figure 3.10 CPI-17 directly associates with PKC isoforms from all sub-families.
5 p.g each of GST, GST-14-3-3^, GST-centaurin-ai and GST-CPI-17 were incubated
with 0.1 jLXg of human recombinant PKCa, PKCs, PKCp and PKC^. GST pull-down
assays were analysed on 10% SDS-PAGE, transferred onto nitrocellulose and Western
blotted with PKCa, s, p. and ^ antibodies as indicated. Top panels represent an aliquot of
the assays to visualise the PKCs (panels "Input"). Bottom panels represent the GST pull¬
down assays (panel "Pull-down"). The positions of the molecular weight markers (kDa)
are indicated.
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3.3.4. Binding occurs via C1 domain of PKC
PKC isoforms from all PKC classes bind directly to CPI-17 (section 3.3.3) which
suggests that the binding occurs via a common domain. The PKCp isoform was used to
map the CPI-17 binding site. PKCp wt and PKCp deletion mutants Al-340 (AC1,
Cysteine Rich Domain), A336-391 (AAD, Acidic Domain) and A417-553 (APH domain)
(see Figure 3.11A for schematic diagram) were expressed, laboratory labelled with [35S]
methionine and incubated with GST and GST-CPI-17. The results from Figure 3.1 IB
showed that PKCp wt bound to GST-CPI-17. Deletion of the acidic domain or the PH
domain ofPKCp did not affect the binding to CPI-17. However, no binding was
observed between CPI-17 and PKCp Al-340 (Figure 3.1 IB). Therefore, amino acids 1-
340 ofPKCp were necessary for the association with CPI-17, thus suggesting that the
CI domain ofPKCp represented the target region for binding with CPI-17. To further
test whether the CI domain of all PKC isoforms is involved in the binding to CPI-17,
deletion mutants of the different PKC isoforms containing only the C1 domain could
have been made and used in in vitro transcription/translation experiments as described
above. If the CI domain was sufficient for the binding, all the deletion mutants of the
different PKC isoforms should associate with CPI-17.
Since all PKC isoforms have a least one CI domain (reviewed in Toker, 1998),
these results complement those from Figure 3.6 and Figure 3.10 showing that all PKC
isoforms associated in vitro with CPI-17. These results are in agreement with previously
published data showing that a number of proteins bind to the CI domain of PKCp,
including 14-3-3x (Hausser et al., 1999) and Bruton's tyrosine kinase (BTK; Johannes et
ah, 1999). An interaction between 14-3-3C, with PKCC, and with PKCs was also found in
agreement with their association in differentiated PC 12 cells (Gannon-Murakami and
Murakami, 2002). It is interesting to note that the cysteine fingers in the CI region of
PKC provide a binding site for lipid second messengers as well as for regulatory
proteins affecting protein kinase activity (Toker, 1998). Therefore, it would be
interesting to investigate whether CPI-17 affects PKC activity.
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Figure 3.11 CPI-17 associates with the CI domain ofPKC.
A, Schematic representation of the known functional domains of PKCp.
B, CPI-17 binds to the CI domain of PKCp. PKCp wt and PKCp deletion mutants (Al-
340, AAD and APH) were expressed in a reticulocyte lysate, and incubated with 5 pg
each ofGST and GST-CPI-17 as described in Figure 3.8. GST pull-down assays were
analysed by SDS-PAGE and autoradiographed (panel "Pull-down"). An aliquot of the
lysate was loaded on the gel (panel "Input"). The positions of the molecular weight
markers (kDa) are indicated.
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3.3.5. Residues 121-147 of CPI-17 are not involved in the binding to PKC
As mentioned in the Introduction (section 1.3), CPI-17 is mainly composed of a
domain which is also present in PHI-1 (Eto et al., 1999) and LIM kinase-2 (LIMK-2).
However, residues 121-147 are specific to CPI-17 and contain Ser-128, a residue that
our laboratory has shown to be heavily phosphorylated in vivo (Dubois et al., 2002d). To
determine whether residues 121-147 were involved in the interaction with PKC, PKCp.
wt was expressed, labelled with [35S] methionine and incubated with GST, GST-CPI-17
wt or GST-CPI-17 1-120. The results showed that both GST-CPI-17 wt and GST-CPI-
17 1-120 bound to the same extent to PKCp (Figure 3.12), indicating that the region
121-147 unique to CPI-17 was not involved in the interaction with PKC. This result
suggests that PHI-1 and LIMK-2 might also be possible binding partners for PKCp and
possibly for other PKC isoforms. No interaction between PHI-1 and PKC has been
reported so far, however, PKC has been shown to phosphorylate PHI-1 on Thr-57 (Eto
et al., 1999). To the best ofmy knowledge there has also not been a reported interaction
between LIMK-2 with PKC to date.














Figure 3.12 Residues 121-147 of CPI-17 are not involved in binding to PKC.
PKCp was incubated with 5 fig ofGST, GST-CPI-17 or GST-CPI-17 1-120 as described
in Figure 3.8. PKC associated with the beads was analysed by SDS-PAGE and
autoradiography (panel "Pull-down"). The panel "Input" represents an aliquot of the
lysate. The positions of the molecular weight markers (kDa) are indicated.
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3.3.6. All PKC isoforms phosphorylate CPI-17
To test whether CPI-17 was phosphorylated by different PKC isoforms, 1 U of
PKCa, s, p and C, were incubated with 5 pg ofCPI-17 in the presence of 50 pM [y-32P]
ATP and kinase buffer. The results indicated that all PKC isoforms were able to
phosphorylate CPI-17 in vitro (Figure 3.13). From the results shown in Figure 3.13 there
would appear to be a phosphorylation preference: PKCa seems to phosphorylate CPI-17
to the greatest extent, followed by PKCs, then PKC^ and PKCp. However, this can be
explained by different PKC activities as judged by autophosphorylation and histone H
III phosphorylation which was used as control (data not shown). The activity of PKCp
towards CPI-17 and histone H III was very low. The results shown here and in section
3.3.3 demonstrate for the first time that PKC isoforms from different sub-families bound
to CPI-17 in vitro and that the PKC isoforms a, s, p and C, all phosphorylated CPI-17.
This suggests that CPI-17 may be a general substrate for all PKC isoforms, however the
interaction between the two proteins may depend on their subcellular localisation. PKCs
undergo translocation from one subcellular location to another in response to
extracellular stimuli and individual PKC isoforms possess a degree of substrate
specificity and sensitivity to different activators (reviewed in Sim and Scott, 1999).
However, since most cells synthesise a range of PKC isoforms, cell specific expression
and isotype specific activation represent only a part of the mechanism for generating
specificity of PKC-mediated signalling (Sim and Scott, 1999). It has been shown that
many anchoring/scaffold proteins bind PKC and target it to various cellular
microdomains (reviewed in Newton, 2001). One example is the family of proteins called
RACKs which anchor the active conformation of phosphorylated protein kinase C at
specific cellular locations (Newton, 2001). Another example are members of the family
ofAKAPs (A Kinase Anchoring Proteins) which position phosphorylated, but inactive
PKC near relevant substrates (Newton, 2001). Furthermore, it has been suggested that
anchoring proteins for inactive PKCs exist. These proteins were collectively termed
RICKs (Receptors for Inactive C Kinase), however, to date, the hypothetical RICKs
have not been identified (reviewed in Dorn and Mochly-Rosen, 2002). These examples
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demonstrate how specific PKC isoforms can be localised to various subcellular domain
and how their interaction with substrates can be controlled. To date the subcellular
distribution ofCPI-17 has not been studied and therefore one cannot speculate how CPI-
17 distribution in cells is regulated. However, this would be an interesting point to
investigate. Having shown that PKC isoforms from different PKC classes phosphorylate
residue Thr-38 in CPI-17, one can speculate that the equivalent residue within LIMK-2,
which is Thr-596 may also be phosphorylated by different PKC isoforms. This is
supported by the fact that the equivalent residue Thr-57 in PHI-1 is phosphorylated by
PKC resulting in an increased ability ofPHI-1 to inhibit PP1 (Eto et al., 1999).
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Figure 3.13 CPI-17 is phosphorylated by all classes of PKC.
One unit each ofPKCa, s, p and C, were incubated with 5 pg CPI-17 in the presence of
50 pM [y-32P] ATP and kinase buffer for 15 min at 30°C. The samples were analysed on
15% SDS-PAGE followed by autoradiography. The fifth panel shows as an example the
equivalent region of the gel after incubation ofPKC^ in absence ofCPI-17.
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3.4. Characterisation of the association between CPI-17 and CKI
Our laboratory has shown that CPI-17 is one of the proteins which co-purifies
with CKIa as part of a protein complex from brain (Dubois et al., 2002b). Therefore, in
order to confirm this it was investigated whether CKI associated with the GST-CPI-17
column and also which CKI isoforms were associated with the GST-CPI-17 column.
3.4.1. Association of a kinase with CKIa activity with the GST-CPI-17 column
CKIa was shown to phosphorylate 14-3-3^ and x on residue 233 (Dubois et al.,
1997). Therefore, an assay for CKI activity was devised by using 14-3-3C, wt as a
substrate and comparing its phosphorylation with a 14-3-3^ T233A point mutant. To
verify whether a kinase with CKIa-like activity eluted from the CPI-17 column, CPI-17
column eluate, GST column eluate and centaurin-ai column eluate were incubated with
14-3-3^ wt or the 14-3-3<^ T233A mutant in the presence of 50 pM [y-32P] ATP and
kinase buffer. The samples were then analysed on 12.5% SDS-PAGE and
autoradiographed. Only 14-3-3^ wt, but not the 14-3-3<^ T233A mutant, was
phosphorylated by a kinase present in the GST-CPI-17 eluate (Figure 3.14). No
phosphorylation of 14-3-3^ wt or T233A mutant was detected when 14-3-3^ wt or 14-3-
3C, T233A was incubated with the GST-centaurin-ai column eluate or GST column
eluate (Figure 3.14). This result indicated that there was a protein kinase, specifically
bound to CPI-17, which was able to phosphorylate 14-3-3^ on the CKIa site, suggesting
that CKIa from brain bound to the GST-CPI-17 column. One could expect that a kinase
which phosphorylates 14-3-3^ on the CKIa site would also elute from the GST-
centaurin-ai column as a direct association between CKIa and centaurin-ai has been
shown (Dubois et al., 2001). As described in 3.4.2, CKIa did associate with the
centaurin-ai column, however, the amount ofCKIa associated with the GST-centaurin-
ai column was significantly lower than the amount associated with the GST-CPI-17
column and therefore the CKI assay used might not have been sensitive enough to detect
any CKI activity associated with the GST-centaurin-ai column. Another explanation
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might be that there are other proteins present in the centaurin-ai eluate which are absent
from the CPI-17 column eluate and which inhibit CKIa activity.


























Figure 3.14 CKIa-like activity associates with the GST-CPI-17 column.
5 pg of protein eluted from the GST-centaurin-ai column (3 first lanes), GST-CPI-17
column (3 middle lanes) or from the GST column (3 last lanes) were incubated for 30
min at 30°C with 5 pg GST, GST-14-3-3^ wt and GST-14-3-3^ T233A in the presence
of 50pM [y-32P] ATP and kinase buffer. A GST pull-down assay was performed and the
samples were analysed by 12.5% SDS-PAGE and autoradiography. The positions of the
molecular weight markers (kDa) are indicated, as is the position of the phosphorylated
GST-14-3-3^.
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3.4.2. CKIa and s bind to the GST-CPI-17 column
To verify whether CKI bound to the GST-CPI-17 column, proteins eluted from
the GST-CPI-17, GST and GST-centaurin-ai column were separated on a 12.5% SDS-
PAGE gel, transferred onto nitrocellulose and Western blotted with anti-CKIa or anti-
CKIs antibodies. Both CKIa and s isoforms were eluted from the GST-CPI-17 and
GST-centaurin-ai column, but not from the GST column (Figure 3.15). This supports
the findings in 3.4.1 where it is shows that a kinase was present in the CPI-17 eluate
which phosphorylates the CKIa site on 14-3-3^. It was also tested whether other CKI
isoforms, including CKIy2 and CKI8 were present in the CPI-17 or centaurin-ai column
eluate, however, the antibodies were not of good quality and were not able to
specifically detect CKIy2 or 8 from brain which was used as positive control (data not
shown). The high-mobility group 1 (HMG1) protein, which also co-purified with CKIa
from brain (Dubois et al., 2002b), did not associate with the GST-CPI-17 column
(Figure 3.15), verifying the selectivity of the CKI association with CPI-17.
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Figure 3.15 CKIa and CKIs were eluted from the GST-CPI-17 column.
5 p,g ofGST-CPI-17 column eluate ("CPI-17"), GST-centaurin-ai column eluate
("Cent.-ai"), GST column eluate ("GST") and 1 pg of brain lysate ("Brain") were run
on 12.5% SDS-PAGE, transferred onto nitrocellulose and Western blotted with
CKIa (StressGen antibody and Santa Cruz antibody), CKIs (two different exposures)
and HMG1 antibodies as indicated. The positions of the molecular weight markers (kDa)
are indicated as are the positions ofCKIa, CKIs and HMG1. E and W indicate column
eluate and column wash, respectively.
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3.4.3. In vitro binding of all CKI isoforms to CPI-17
Two different in vitro experiments were used to further investigate whether the
association of CKI with CPI-17 was selective. CKIa, 5, s and yi, y2 and 73 were
expressed and labelled with [35S] methionine, then incubated with GST or GST-CPI-17.
All the CKI isoforms tested bound to CPI-17 (Figure 3.16). However, the association
was stronger with CKIa, 5, and 8 than with CKIyi.3. Therefore, it appeared that CPI-17
interacted preferentially with some CKI isoforms. This is in contrast to centaurin-ai that
we found to interact to a similar extent with all CKI isoforms (Dubois et al., 2001). This
suggests that CPI-17 may be a tissue specific substrate for different CKI isoforms and
that the interaction between the two proteins may depend on their subcellular
localisation. As mentioned in Results section 3.3.6, the subcellular localisation ofCPI-
17 is unknown. However, it has been suggested that the subcellular localisation of CKI
isoforms is essential for their the function. Mammalian CKIa for example, is not
distributed homogeneously throughout the cell, but associates with distinct structures
and factors throughout the cell (Gross and Anderson, 1998): CKIa has been
demonstrated to possess a cell-cycle-dependent subcellular distribution, including the
binding to the centrosome, cytosolic vesicles (e.g. vesicles of the trans-Golgi network),
the mitotic spindle and distinct nuclear structures. Another CKI isoform, CKI8, has been
shown to associate with different cellular targets in a cell-cycle dependent manner: CKI8
co-localises with the trans-Golgi network (TGN) and interacts with microtubules in
interphase cells (Behrend et al., 2000b). During mitosis, CKI8 is evenly distributed
throughout the cytoplasm, however, upon DNA damage CKIS specifically associates
with the mitotic spindle. These examples indicate that the function and regulation of
CKI isoforms may result from defining its localisation spatially and temporally.
Therefore, it is possible that if specific CKI isoforms and CPI-17 interact in vivo, this
association might also be dependent on the subcellular localisation of both proteins and
possibly also on the stage of the cell cycle. It is interesting to note that the expression
level and localisation of another inhibitor, PPlinhibitor-2, fluctuate during different
stages of the cell cycle (Brautigan et al., 1990; Kakinoki et al., 1997).
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3.4.3.1. Binding selectivity
To investigate binding selectivity between CPI-17 and CKI, CKIa and 14-3-3^
were expressed and labelled with [35S] methionine and incubated with GST and GST-
CPI-17. GST-CPI-17 bound to CKIa, but 14-3-3£ did not associate with GST-CPI-17
(Figure 3.17A). CKI8 was the CKI isoforms which was particularly well expressed in a
reticulocyte lysate and therefore it was used in the second binding selectivity
experiment: CKI8 was expressed and labelled with [35S] methionine and incubated with
GST (negative control), GST-CPI-17, GST-14-3-3<^ (positive control), GST-VAMP
(vesicle associated membrane protein involved in exocytosis; reviewed in Gerst, 1999)
and GST-centaurin-ai as control (Figure 3.17B). Results in Figure 3.17B confinned the
interaction between CPI-17 with CKI. Centaurin-ai also associated with CKI8
confirming previous reports (Dubois et al., 2001). GST-14-3-3^ also bound to CKI5
(Figure 3.17B). This is the first demonstration that CKI isoforms bind to 14-3-3 although
it was previously shown by our laboratory that 14-3-3^ is phosphorylated by CKIa
(Dubois et ah, 1997).
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Figure 3.16 CPI-17 associates with all CKI isoforms.
CKIa, 8, s and yi_3 isoforms (as indicated) were expressed in a reticulocyte lysate and
incubated with 5 pg GST or GST-CPI-17 as described in Figure 3.8. GST-pull-down
assays were analysed by 12.5% SDS-PAGE and autoradiography ("Pull-down"). An
aliquot of the lysate was analysed ("Input"). The positions of the molecular weight
markers (kDa) are indicated.


















Figure 3.17 Binding selectivity between CKI and CPI-17.
A, CKI associates with CKIa but not with 14-3-3^.
CKIa and 14-3-3^ were expressed in a reticulocyte lysate and incubated with 5 pg GST
or GST-CPI-17 as described in Figure 3.8. The left panel "Input" shows an aliquot of the
lysate, and the panel "Pull-down" shows the proteins bound to GST-CPI-17. The
positions of the molecular weight markers (kDa) are indicated.
B, CKI associates selectively with CPI-17. CKI8, expressed in a reticulocyte lysate was
incubated with 5 pg GST, GST-14-3-3<;, GST-CPI-17, GST-VAMP or GST-centaurin-
aj as described Figure 3.8. The upper panel "Input" shows an aliquot of the lysate, and
the panel "Pull-down" shows the proteins bound to the GST-fusion proteins. The
positions of the 36 and 48kDa molecular weight markers are indicated on the left, and
the position of CKI8 is shown on the right.
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3.4.3.2. Direct binding between CKI and CPI-17
To determine whether the association between CKI and CPI-17 was direct or
mediated through other proteins which might have been present in the reticulocyte
lysate, recombinant CKI (ski 1, S.pombe) was incubated with purified GST, GST-CPI-
17, and GST-centaurin-ai (used as a positive control; Dubois et al., 2001). The GST
fusion proteins were pulled-down with glutathione Sepharose beads and a kinase assay
was performed on the precipitated beads using the CKI phosphopeptide substrate. The
results show that CKI directly associated with GST-centaurin-ai, (confirming our
previous results) and with GST-CPI-17 (Figure 3.18). These results also indicate that
structural features necessary for this interaction exist when the proteins are expressed in
bacteria. This may suggest that the interaction between CPI-17 and CKI is not dependent
on post-translational modifications.




























Figure 3.18 CPI-17 directly binds to CKI.
Recombinant CKI (0.2 jag) was incubated with 5 )_ig ofGST, GST-centaurin-ai or GST-
CPI-17 for 2 h at 4 °C. Glutathione-Sepharose beads were then added. Beads were
washed and subjected to an in vitro kinase assay using the CKI-specific phosphopeptide
substrate. The presence of 32P incorporated into the peptide (cpm) was quantified by
liquid scintillation counting and represents CKI activity associated with the beads.
3 Identification of novel CPI-17 binding proteins 121
3.4.4. CPI-17 binds to a region within the kinase domain of CKI
Since CPI-17 bound to all CKI isoforms tested (a, 8, s, yi, 72 and 73), one can
propose that CPI-17 interacted with a region common to all members of the CKI family.
Therefore a range ofCKIa deletion mutants were tested (see Figure 3.19 for schematic
diagram) and CKI5 A317 (deleted of the C-terminal tail). CKIa wt, CKI5 A317 and a
range of CKIa deletion mutants (see Figure 3.19A) all bound to CPI-17 (Figure 3.19B).
These data demonstrated that the kinase domain ofCKI is sufficient for binding to CPI-
17. CKI isoforms are characterised by a conserved kinase domain and by variable
amino-and carboxyl-terminal tails. CKI isoforms are more than 50% identical at the
amino acid level within the catalytic domain; the catalytic domain ofCKIs for example
is more than 98% identical with the catalytic domain of CKIS (Gross and Anderson,
1998). The binding decreased significantly between the CKIa 233-325 mutant and CPI-
17. Therefore, the binding site between CKIa and CPI-17 can be narrowed down to
CKIa residues 217-233. These results are in agreement with a previous report from our
laboratory showing that centaurin-ai also binds to CKIa residues 217-233 (Dubois et
al., 2001). To further confirm the association of CPI-17 with CKIa residues 217-233, a
peptide column containing these CKIa residues could be constructed and the association
ofpurified CPI-17 with this column could be tested.
Because all CKI isoforms tested bind to CPI-17 as shown in 3.4.3, it was
assumed that the binding occurred through the kinase domain which is highly conserved
within the CKI family. However, it was found that the binding between CPI-17 to
CKI71.3 was weaker than to the other CKI isoforms. This could be due to the fact that
CKI71.3 isoforms contain a longer amino terminal domain (Gross and Anderson, 1998)
which could interfere with the binding to CPI-17. The residues corresponding to 217-
233 in CKIa, which were mapped as the binding site to CPI-17 are highly conserved
throughout all the CKI isoforms tested (see Figure 3.19C for schematic representation of
this domain).
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Figure 3.19 CPI-17 binds to a region within the kinase domain ofCKI isoforms.
A, Schematic representation ofCKIa deletion mutants.
B, CPI-17 binds to a region within the kinase domain ofCKI. CKIa wt and CKIa
mutants 17-325, 164-325, 189-325,217-325,233-325, 17-287, 164-287, 189-287 and
CKI6 A317 were expressed in a reticulocyte lysate and incubated with 5 pg ofGST or
GST-CPI-17 as in Figure 3.8. An aliquot of the lysate ("Input") and the GST pull-down
assays ("Pull-down") were analysed as in Figure 3.8.
C, Sequence alignment of human CKI isoforms of residues corresponding to residues
217-233 in CKIa.
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3.4.5. Residues 121-147 of CPI-17 are not involved in the binding to CKI
As described in the Introduction (section 1.3), CPI-17 is mainly composed of a
domain which is also present in PHI-1 (Eto et al., 1999) and LIM kinase-2. To test
whether the residues 121-147 that are unique to CPI-17 were involved in CKI binding,
the kinase domain ofCKIa was expressed and labelled with [35S] methionine and
incubated with GST, GST-CPI-17 wt or GST-CPI-17 1-120. The results showed that
both GST-CPI-17 wt and GST-CPI-17 1-120 bound to the kinase domain of CKIa
(Figure 3.20). The association between CKIa with CPI-17 1-120 seems to be stronger
compared to the association with GST-CPI-17 wt. This could indicate that the C-
terminus ofCPI-17 may possibly negatively regulate CKI binding to CPI-17. This result
also demonstrated that the region unique to CPI-17 containing Ser-128, which is heavily
phosphorylated in vivo (Dubois et al., 2002d), was not involved in the interaction with
CKI. As described for PKCp (section 3.3.5), this result further suggests that PHI-1 and
LIMK-2 might also be possible binding partners for CKIa. Combining the results from
3.3.5, where it was shown that CPI-17 residues 121-147 are not necessary for the
binding to PKCp and the results described in this section, it appears that the binding of
CPI-17 to its binding proteins occurs via the first 1-120 residues in CPI-17. Although
residues 121-147 are not involved in binding to CKIa they may have a regulatory role
conferring specificity on binding.












Figure 3.20 Residues 121-147 of CPI-17 are not involved in binding to CKI.
The kinase domain ofCKIa (CKIa KD) was incubated with 5 p,g of GST, GST-CPI-17
and GST-CPI-17 1-120 as described in Figure 3.8. An aliquot of the lysate ("Input") and
the GST pull-down assays ("Pull down") were analysed as in Figure 3.8. The position of
the molecular weight markers are indicated on the left, and the position of CKIa KD on
the right.
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3.4.6. CKI does not phosphorylate CPI-17 to any significant extent
Having shown the interaction between CPI-17 and CKI, the next step was to
determine whether CPI-17 was a substrate for CKI. Recombinant 14-3-3x (from Dr
Thierry Dubois) and CPI-17 (5 pg each) were incubated with 0.1 pg recombinant CKI in
the presence of 50 pM [y-32P] ATP and kinase buffer. The samples were analysed by
SDS-PAGE followed by autoradiography. Figure 3.21 shows that the positive control,
14-3-3t, was phosphorylated by CKI, but CPI-17 was not phosphorylated to any
significant extent by CKI. From that it was concluded that CPI-17 is probably not a
substrate for CKI in vivo. However, CKI isoforms have been shown to phosphorylate
some substrates only if they have been previously phosphorylated by another kinase two
or three residues C-terminal to the CKI site. The consensus phosphorylation sequence
for CKI has been defined as S/T/Y(P)X,.2S/TY or Dn-Xi.2S/T/Y where S/T/Y(P) stands
for any phosphorylated serine, threonine or tyrosine residue, X is any amino acid and D
is aspartic acid (Vielhaber and Virshup, 2001). Our laboratory has shown by
HPLC/mass spectrometry that CKI does phosphorylate CPI-17 very weakly within the
peptide comprising residues 126-141 (Q126PSPSHDGSLSPLQDR141). Residue 134
(underlined in sequence) represents the CKI consensus site. To test whether
phosphorylation of residue 130 or 128 would create a better consensus site for CKI,
synthetic peptides phosphorylated on these residues were used as substrates for CKI.
The results indicated that these phosphorylations did not create a better consensus site
for CKI (SpHDGS) (A. Aitken, S. Clokie and R. Wakefield, unpublished data)
confirming the results that CPI-17 is not phosphorylated by CKI to any significant
extend.
Centaurin-ai, which also directly associates with CKIa has also been shown not
to be a CKIa substrate (Dubois et al., 2001).
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14-3-3x CPI-17
Figure 3.21 CPI-17 is not a significant substrate for CKI.
Recombinant CPI-17 and 14-3-3x (5 p,g) were incubated for 15 min at 30°C with 0.1 p.g
recombinant CKI in the presence of 50 pM [y-32P] ATP and kinase buffer. The samples
were analysed on 15% SDS-PAGE followed by autoradiography. The positions of the
molecular weight markers are indicated on the left, and those of CPI-17 and 14-3-3x on
the right.
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3.4.7. CPI-17 regulates CKI activity
It was shown in section 3.4.6 that CPI-17 is not a substrate for CKIa. Therefore,
it was tested whether CPI-17 had an effect on CKIa activity. For that purpose, CPI-17
wt, CPI-17 T38A, CPI-17 T38D, CPI-17 S128A, CPI-17 S128D and CPI-17 1-120 were
incubated with CKIa in the presence of a CKI-specific phosphopeptide substrate. The
Thr-38 mutants were used, because it has been shown that phosphorylation of this
residue in vivo increases the ability of CPI-17 to inhibit PP1-C by 1000-fold (Eto et ah,
1995) and it was important to test whether a mutation to aspartate, which through its
negative charge mimicks the phosphorylated state, would have an effect on CKIa
activity. The S128D mutant has been used, because our laboratory has identified residue
S128 as a novel CPI-17 in vivo phosphorylation site (Dubois et al., 2002d) and again it
was important to test whether a mutation of this residue would modulate CKIa activity.
The results show that CKIa was inhibited by CPI-17 wt by 37% and by CPI-17
S128D by 29% (Figure 3.22). The values for CPI-17 mutants CPI-17 T38A, T38D and
CPI-17 1-120 were 103%, 99% and 104%, respectively (Figure 3.22). These mutants did
not have an effect on CKIa activity (Figure 3.22). Interestingly, the CPI-17 SI28A
mutant seemed to activate CKIa by 29% (Figure 3.22). The p-values were calculated
using the unpaired t-test calculator (GraphPad.com).
To see whether complete inhibition of CKIa could be achieved, the incubation
time ofCPI-17 wt and mutants with CKIa was increase from 15 min to 1 hour, but no
difference in CKIa activity was observed (data not shown). Because the CPI-17 1-120
mutant had no effect on CKIa activity the inhibitory effect must be due to residues 121-
147. Similar data were obtained when casein was used as a substrate (data not shown).
Since the phosphorylation of both peptide and protein substrates were affected to a
similar extent by the CPI-17 constructs, the inhibition ofCKIa is clearly not simply due
to restricted access of a relatively large protein substrate to the kinase active site. This is
supported by our finding that residues 189-287 of CKIa are sufficient for binding CPI-
17. This region comprises the C-terminal part of the kinase domain and excludes the
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ATP binding site and the active site lysine residue. It was also tested whether the CPI-17
peptides containing residues 120-135 (KQPGFPQPSPSDDPSC, from Peter Fletcher,
NIMR, Mill Hill, London), had an effect on CKIa activity. One of the peptides was
unphosphorylated on residue SI28, the other peptide was phosphorylated on SI28
(underlined in the sequence). Neither of these two peptides were capable ofmodulating
CKIa activity, using peptide concentrations from 0.1 pM to 10 pM (data not shown).
From this it can be concluded that either the region containing residues 120-147, the full
length protein or the region containing residues 135-147 is required to affect CKIa
activity. One possibility might be that residues 1-120 are required to bind to CKIa first
and that only then the C-terminus is capable of inhibition. However, this is only a
hypothesis. It should be noted that a GST-fusion ofCPI-17 wt or mutants did not
modulate CKIa activity in any way (data not shown). This may be due to steric
hindrance of the active site by the GST moiety which is fused to the N-terminal region
ofCPI-17. The lack of inhibition for the T38A and T38D mutants could be explained by
possible structural changes ofCPI-17. Ohki and co-workers have shown by solving the
NMR structure ofCPI-17 that phosphorylation of residue T38 by PKC, changes the
conformation ofCPI-17 responsible for activation and resulting in the formation of a
specific interaction with the catalytic site ofMLCP (Ohki et ah, 2001). Therefore one
can imagine that a mutation of that residue could have a similar effect. This could
account for the loss of inhibitory activity. Furthermore, it has been shown that the
phosphorylation ofCPI-17 on residue T38, induces a conformational change, resulting
in exposure of the nearby phosphorylation loop and in forming specific interactions with
the catalytic site of the phosphatase (Ohki et ah, 2001). Because the phosphorylation of
T38 plays such an important role in regulating PP1-C (Eto et ah, 1995), it was also
tested whether CPI-17 phosphorylated on T38 by PKCa would have an effect on CKIa
activity. The result was negative (data not shown) and therefore it can be concluded that
T38 does not seem to be involved in modulating CKIa activity. This supports the
hypothesis that residues 121-147 might be responsible for modulating CKIa activity. It
should be noted that preliminary results show that CPI-17 S128D had no inhibitory
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effect on PP1-C (data not shown; this work was carried out in Carol Mackintosh's
laboratory, MRC Protein Phosphorylation Unit, Dundee). This is in agreement with data
obtained by Hayashi and co-workers who show that residues 35-120 ofCPI-17 are
sufficient for PP1 inhibition (Hayashi et ah, 2001).
Intriguingly, the presence ofCPI-17 SI 28A in the kinase assay reaction leads to
an increase in CKIa activity. One possibility might be that a mutation of residue 128 to
an alanine changes the conformation ofCPI-17 and makes it a substrate for CKI. The
increased CKI activity could represent phosphorylation of CPI-17 SI28A in addition to
the CKI specific phosphopeptide because the assay method used did not distinguish
between the two. This hypothesis was tested, by incubating 5 pg ofCPI-17 wt, CPI-17
1-120 and CPI-17S128A with CKIa. However, no increased phosphorylation ofCPI-17
S128A by CKIa was detected. Neither CPI-17 wt or the mutants were substrates for
CKIa (data not shown). Therefore, this possibility does not offer an explanation for
increased CKIa activity. The alternative option could be that CPI-17 SI28A has a
different conformation compared to the CPI-17 wt and the other mutants and stabilises
CKIa, resulting in an increased concentration of active CKIa and increased substrate
phosphorylation. The effect of CPI-17 on CKI activity was selective, because CPI-17 wt
did not modulate CKII activity (Figure 3.24). The p-value for CPI-17 wt was 0.5837.
However, it is not known whether CPI-17 associates with CKII and therefore it would
have been useful to test the effect ofCPI-17 on a kinase which is known to bind to CPI-
17, for example PKC.
CPI-17 and CPI-17 S128D mutant inhibit CKIa activity by around 30%, whereas
CPI-17 SI 28A increases the activity ofCKIa by around 30%. The CPI-17 1-120 mutant
has no effect on CKIa activity. This indicates that the CPI-17 residues 121-147 could
have a regulatory role on CKIa activity as discussed earlier in section 3.4.5. CKI has
previously been shown to associate with and phosphorylate the PP1 inhibitor DARPP-
32, indicating that CKI could function as a modulator of protein phosphatase I via
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DARPP-32 (Desdouits et al., 1995a and b). In this case, however, the reverse situation
seems to apply in which the PP1 inhibitor, CPI-17, modulates CKIa activity.
In the next part of this study the CPI-17 concentrations which gave half-maximal
inhibition/activation were calculated. Different concentrations (1 nM-10 pM) ofCPI-17
wt, CPI-17 S128D and CPI-17 SI28A were incubated with CKIa and a kinase assay
was carried out using CKIa specific phosphopeptide. Prism 3 from GraphPad.com was
used to calculate the halfmaximum inhibition/activation concentrations ofCPI-17 wt,
CPI-17 S128D or CPI-17 S128A. The values for CPI-17 wt and CPI-17 S128D were 494
nM and 31 InM, respectively (Figure 3.23A and B). The concentration of CPI-17
SI 28A, which gave half maximal activation was 224 nM (Figure 3.23C). CPI-17 wt and
CPI-17 S128D both show submicromolar levels of inhibition, however, in vivo
inhibition has yet to be shown. The values which gave half-maximal inhibition were
very similar for both CPI-17 wt and CPI-17 S128D, suggesting that the mutation S128D
has no effect on CPI-17 conformation. One explanation why CPI-17 wt/S128D did not
completely inhibit CKIa activity could be that only a certain pool ofCKIa was blocked
by CPI-17 wt/S128D and the rest was not. Therefore only a partial inhibitory effect of
around 30% can be observed.
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Figure 3.22 CPI-17 regulates CKIa activity.
CPI-17 regulates CKI activity. CPI-17 wt, CPI-17 T38A, CPI-17 T38D, CPI-17 SI28A,
CPI-17 S128D and CPI-17 1-120 (7.5 pg each) were incubated with purified histidine
tagged CKIa for 15 min at 30°C. CKI-specific phosphopeptide substrate (40 pM) was
then added and the reaction was incubated for 30 min at 30°C in the presence of 50 pM
[y-32P] ATP and kinase buffer. 32P incorporated into the peptide was quantified by liquid
scintillation counting and represents CKI activity. CKIa was inhibited by CPI-17 wt by
37% (+/- 4 SEM (standard error ofmean), n=6). The p-value was 0.0001, which is
considered to be statistically significant. CKIa was inhibited by CPI-17 S128D by 29%
(+/- 1 SEM, n=6). The p-value was 0.0001. The values for CPI-17 mutants CPI-17
T38A, T38D and CPI-17 1-120 were 103% (+/- 7 SEM, n=6), 99% (+/- 4 SEM, n=6)
and 104% (+/- 1.8 SEM, n=6), respectively. The p-values were 0.885 for CPI-17 T38A,
0.7805 for CPI-17 T38D and 0.0941 for CPI-17 1-120, which is not considered to be
statistically significant.
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Figure 3.23A, B, C Determination of half-maximal inhibition by CPI-17.
CPI-17 wt, CPI-17 SI28A and CPI-17 S128D (1 nM-10 pM ) were incubated with
purified histidine tagged CKIa and a kinase assay was carried out as described above.
Prism 3 from GraphPad.com was used to calculate the halfmaximum
inhibition/activation concentrations of CPI-17 wt, CPI-17 S128D and CPI-17 S128A.
The values for CPI-17 wt and CPI-17 S128D were 494 nM (+/- 4.03 SEM, n=3) and 311
nM (+/- 4.099 SEM, n=3), respectively. The concentration ofCPI-17 S128A, which
gave half maximal activation was 224 nM (+/-4.035 SEM, n=3).



















Figure 3.24 CPI-17 has no effect on CKII activity.
CPI-17 wt (5 pg) was incubated with purified CKII for 15 min at 30°C. Casein (5 pg)
was then added and the reaction was incubated for 30 min at 30°C in the presence of
50 pM [y-32P] ATP and kinase buffer. 32P incorporated into casein was quantified by
liquid scintillation counting and represents CKII activity. The p-value was calculated
using the unpaired t-test calculator (GraphPad.com).
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3.4.8. Binding between CPI-17 and CKI in COS cells
To investigate the possibility of an interaction between CPI-17 and CKI in vivo,
flag-tagged CPI-17 and HA-tagged CKIa (wt) or CKIa (kd, kinase dead mutant) were
used. CPI-17 was flag-tagged at the N-tenninus as was HA-tagged CKIa (wt) and CKIa
(kd) (from Dr Thierry Dubois). Transient transfection studies showed that flag-tagged
CPI-17 was well expressed in mammalian COS-l/COS-7 cells, however, HA-CKIa (wt)
was very poorly expressed as it could not be detected in detergent soluble cell lysates,
nor when immunoprecipitated with the anti-HA antibody (data not shown). HA-CKIa
(kd) was weakly expressed and detection was only possible when immunoprecipitated
with the anti-HA antibody. The previous in vitro studies showed direct interaction
between CPI-17 and CKIa and therefore the ability ofCPI-17 to interact with CKIa in
COS-7 cells was tested. Flag-CPI-17 and CKIa (wt) or CKIa (kd) were co-transfected
into COS-7 cells. It should be noted that two different transfection methods were used:
Electroporation and FuGENE as described in Method section 2.1.2. CKIa (wt) or CKIa
(kd) were then immunoprecipitated using a HA-antibody and Western blot analysis was
performed using anti-flag. In contrast to the in vitro studies it has not been possible to
detect an interaction between CPI-17 and CKIa (wt) or CKIa (kd) (data not shown).
This could be explained by the very low expression levels of CKIa.
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3.5. New potential CPI-17 binding partners identified by mass
spectrometry
To investigate the function ofCPI-17, potential CPI-17 protein partners were
identified by affinity chromatography and mass spectrometry analysis. Sheep or rat brain
lysate, which had been pre-incubated with GST to remove non-specific binding, was
loaded onto a GST, GST-CPI-17 or GST-centaurin-ai column. The columns were
extensively washed and bound proteins eluted with 1M NaCl as described in the
Methods chapter 2.12. Proteins eluted from the GST2, GST-CPI-17 and GST-centaurin-
ai column (40 pg) were separated on a 12.5% or 15% SDS-PAGE gel. More than 20
different proteins eluted from the GST-CPI-17 as judged by SDS-PAGE and GelCODE
staining (Figure 3.25). More than 15 proteins eluted from the GST-centaurin-ai column
and only around 5 proteins were recovered at low level from the GST column (Figure
3.25). The profiles from the 3 columns were completely different indicating that CPI-17
selectively bound to numerous proteins from mammalian brain that did not bind to GST
or GST-centaurin-ai columns. The concentrations of the proteins eluted from the GST-
CPI-17, GST-centaurin-ai and GST column were 2.7 pg/pl, 1.4 pg/pl and 0.2 pg/pl,
respectively. It should be noted that from the same volume of brain lysate loaded on the
columns, approximately 1% of the GST-CPI-17 column eluate, 2% of the GST-
centaurin-ai eluate and 15% of the GST column eluate were loaded on the gel. The
bands are difficult to see from Figure 3.26, but the arrows with sample number give an
indication of the approximate molecular weight of the bands. The profiles of the proteins
eluted from the GST-CPI-17 and GST columns (Figure 3.26) were very similar to the
affinity chromatography results in Figure 3.25 when sheep brain lysate was used as
judged from GelCODE staining (Figure 3.25). This further strengthened the point that
the binding of the proteins to the GST-CPI-17 was selective.
2 Note that due the low concentration of proteins in the GST column eluate, it was not possible to load the
same amount of protein i.e. 40 pg and therefore 60 pi of the GST column eluate were loaded.
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MW CPI-17 Cent.-a,
Figure 3.25 Mammalian brain proteins associate with CPI-17.
Sheep brain lysate was pre-incubated with GST in the presence of 0.5% Triton and
subsequently loaded onto a GST-CPI-17 ("CPI-17"), GST-centaurin-ai ("Cent.-ai") or
GST column. Proteins bound to the columns were eluted with 1M NaCl and analysed on
12.5% SDS-PAGE and stained with GelCODE. The positions of the molecular weight
markers (kDa) are indicated. * on a 15% SDS-PAGE gel these bands ran differently
from the bands of similar apparent molecular weight on the GST-centaurin-ai column.
In any case these 2 proteins were not identified (see Figure 4.8).
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Figure 3.26 Rat brain proteins associate with CPI-17.
Rat brain lysate was pre-incubated with GST in the presence of 0.5% Triton, and
subsequently loaded onto a GST-CP1-1 7. Proteins bound to the column were eluted with
1M NaCl, analysed on 15% SDS-PAGE, stained with GelCODE and analysed by mass
spectrometry. The positions of the sample number (including sample name) are
indicated with arrows on the right. The positions of the molecular weight markers (kDa)
are indicated on the left.
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A total of 19 protein bands from the GST-CPI-17 were excised from the gel in Figure
3.26 and digested with trypsin, which cleaves the peptide bond C-terminal to lysine and
arginine residues. The proteins were identified using MALDI-TOF setup as described in
the Methods chapter 2.18. Table 3.1 shows the proteins identified by mass spectrometry.
Bands 9, 11, 13, 16, 18 and 19 were identified as contaminating E.coli proteins. The
program MS-Fit was used to identify novel CPI-17 binding proteins.
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From Table 3.1 it is clear that CPI-17 associates with numerous proteins and
some of their functions will be briefly described in the following paragraphs. It should
be pointed out however, that it has been not been investigated whether the association
between CPI-17 and the proteins identified by mass spectrometry is direct. It is possible
that only a few of the proteins directly bind to CPI-17 and that the binding of other
proteins is indirect and occurs via protein complexes. Furthermore, it would be
important to confirm the binding of the newly identified proteins to the GST-CPI-17
column by Western blotting. It should be pointed out that other proteins associated with
the GST-CPI-17 column were not identified by mass spectrometry, among them the
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kinases CKI and PKC. This could be explained by the fact that a large number of
proteins were found to associate with the column and possibly not all the bands were cut
out from the SDS-PAGE gel for mass spectrometry analysis. Furthermore, it is easier to
identify more abundant proteins by this technique (for example cytoskeletal proteins)
and any traces ofCKI or PKC might not have been picked up by this method.
3.5.1. Binding of microtubule-associated proteins to the GST-CPI-17 column
Microtubule-associated proteins (MAPs) 1 (accession number in SWISS-PROT
56619) and 2 (accession number 56625) belong to the family of structural MAPs that
bind microtubules and regulate cytoskeletal dynamics, the spacing between microtubules
and dendritic elongation and oligodendrocyte process outgrowth in neurones (reviewed
in Sanchez et al., 2000). MAP-1A and MAP-IB are distantly related heat-stable
multimeric protein complexes containing one heavy and several light chains, present
throughout the nerve cell (reviewed in Cassimeris and Spittle, 2001). Furthermore, they
are thought to play a role in regulating the neuronal cytoskeleton, MAP-IB during
neuritogenesis and MAP-1A in mature neurons. MAP-1A and MAP-IB bind to
microtubules and microfilaments, suggesting that they are involved in mediating or
regulating the interaction between axonal microtubules and actin filaments, which is
believed to be essential for neuronal morphogenesis and function. Recently, it has been
shown that the light chains ofMAP-1A and MAP-IB directly associate with actin in
vivo and in vitro (Noiges et al., 2002). One of the factors controlling MAP-1 activity is
phosphorylation. However, very little is known to date about the phosphorylation of
MAP-1A. So far it has only been shown that growth factor stimulation ofNIH-3T3 cells
results in MAP-1A phosphorylation (Erickson et al., 1990). MAP-IB on the other hand
has been shown to be phosphorylated by proline directed kinases, likely candidates
include Cdk5 and glycogen synthase kinase 3 (3 and casein kinase II. Dephosphorylation
ofMAP-IB is mainly accomplished by PP2a (Cassimeris and Spittle, 2001). The
association ofMAP-1A with the GST-CPI-17 column suggests a role for CPI-17 in
neuronal cytoskeletal re-arrangement. It should be noted that the binding between CPI-
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17 and MAP-1A might not be direct, but could be mediated by a protein complex
containing actin for instance.
MAP-2 are heat-stable phosphoproteins predominantly expressed in neurons, and
their expression is developmentally regulated. They serve as substrates for most of
protein kinases and phosphatases present in neurons (reviewed in Sanchez et al., 2000).
The kinases which phosphorylate MAP-2 include cAMP-dependent protein kinase
(PKA), Ca2+/calmodulin-dependent protein kinase II (CamKII), PKC, extracellular
signal-regulated kinases (ERKs), glycogen synthase kinase 3 (GSK3), cyclin dependent
kinases (CDKs) and microtubule-affinity regulating kinases (MARKs). MAP-2 is
dephosphorylated by PP1, PP2A, PP2B and PP2C. Phosphorylation ofMAP-2 seems to
control its association with the cytoskeleton, and a role for MAP-2 has been proposed to
act as phosphorylation dependent cytoskeletal switch. MAP-2 may perform many
functions including the nucleation and stabilisation of microtubules, the regulation of
organelle transport within axons and dendrites, regulation of synaptic plasticity as well
as the anchorage of regulatory proteins such as protein kinases which may be important
for signal transduction. It is interesting to note that two of the kinases which associate
with the GST-CPI-17 column, PKC and PKA, have been shown to phosphorylate MAP-
2 as described above. MAP-2 has been shown to directly bind the regulatory subunit of
PKA (Theurkauf and Vallee, 1982) and recently it has been shown that the catalytic
subunit ofPKA is localised to the actin and microtubule cytoskeletons in mouse
hippocampal neurons, possibly via the AKAP, gravin, which can bind to PKA and F-
actin simultaneously (Diviani and Scott, 2001; Sato et al., 2002). Therefore, it is possible
that these two kinases associate with MAP-2, and that the binding ofMAP-2 to the
GST-CPI-17 column occurs via one or both of the kinases.
The association ofMAP-2 with the GST-CPI-17 column suggests a potential role
for CPI-17 in regulating PP1 activity in appropriate subcellular domains in neurons and
to function as a molecular switch between phosphorylation and dephosphorylation and
thereby leading to changes in the neuronal cytoskeleton. However, a possible direct
association between CPI-17 with MAP-2 still remains to be established and as for MAP-
1 it should be noted that the binding ofMAP-2 to the GST-CPI-17 column could be
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mediated via other proteins associated with the column.
3.5.2. Binding of adaptor protein subunits to the GST-CPI-17 column
Adaptins are subunits of adaptor proteins (AP) complexes involved in the
formation of intracellular transport vesicles and in the selection ofprotein cargo for
incorporation into the vesicles (reviewed in Boehm and Bonifacino, 2001). Four basic
AP complexes have been described: AP-1-4. Each of these complexes is composed of
two large adaptins (one each of y/oc/S/e and pi-4, respectively, 90-130kDa), one medium
adaptin (pi-4, ~ 50kDa) and one small adaptin (a 1-4, ~ 20kDa). AP complexes are
components of protein coats that associate with the cytoplasmic face of organelles of the
secretory and endocytic pathways. AP-1, AP-3, and AP-4 mediate sorting events at the
trans-Golgi network and/or endosomes while AP-2 mediates rapid endocytosis from the
plasma membrane. Some of these processes function in conjunction with clathrin, while
others are clathrin independent. One example of clathrin-mediated endocytosis takes
place at the nerve terminal, where clathrin-coated vesicles are involved in the recycling
of synaptic vesicles. There has been recent evidence which lends support to the idea that
clathrin mediated endocytosis is controlled by cycles of
phosphorylation/dephosphorylation (Joazeiro and Weissman, 2000; Lauritsen et ah,
2000). The protein phosphatase PP2B, also known as calcineurin has been shown to be
responsible for the essential dephosphorylation of key proteins involved in endocytosis
(reviewed in Cousin and Robison, 2001; Yakel, et al., 1997).
The association of a-adaptin (accession number 49876), P-adaptin (accession
number 203087) and clathrin coat assembly protein AP 50 (or the medium subunit of
AP-2) (accession number 529580), with the GST-CPI-17 column, suggests that CPI-17
could be involved in endocytotic events in cells.
3.5.3. Binding of dynactin I and coatomer P subunit to the GST-CPI-17 column
One of the proteins identified in band six was the cytoskeletal protein dynactin I
(also called 150 kDa dynein-associated polypeptide/DP-159/DAP-150/pl50Glued)
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(accession number P28023). Dynactin I is a subunit of dynactin which consists of 11
different subunits: 8 or 9 x Arpl (actin-related protein), 4 or 5 x dynamitin, 2 x pl50GIued
(Dynactin I), 2xp24, one each ofp62, conventional actin, Arpl 1, capping protein a and
P, p27 and p25 (reviewed in Allan, 2000).
The dynactin complex is thought to mediate all dynein function in the cell,
including cytoplasmic dynein-driven retrograde movement of vesicles and organelles
along microtubules, axonal transport and the control of the microtubule cytoskeleton.
For instance dynein-dynactin interaction is essential to keep microtubules associated
with the centrosome and contributes to centrosome separation during cell division
(reviewed in Karki and Holzbaur, 1999). The function(s) of dynactin are not well
understood, but it is known that dynactin increases the distance that cytoplasmic dynein
moves along microtubule before falling off. Dynactin also participates in cargo binding
and the largest subunit pl50Glued has been shown to bind to both microtubules and the
intermediate chain of dynein (Karki and Holzbaur, 1995; Muresan et al., 2001;
Waterman-Storer et al., 1995 and 1997). The association of dynactin I with the GST-
CPI-17 column could possibly be mediated via microtubule binding proteins, such as
MAP-1A, and it could suggest a role for CPI-17 in microtubule skeleton regulation and
vesicle trafficking.
Another protein in sample 6 was identified as the coatomer p subunit or P coat
protein (P-COP) (accession number P23514). The P-COP is a subunit of the COP I (coat
protein I ) coatomer complex, which is involved in the generation and retrieval of
vesicles from the Golgi to the endoplasmic reticulum (ER) compartment (reviewed in
Roche, 1999). The COP I coat consists of coatomer, a stable 700-800 kDa complex and
ADP ribosylation factor (Arf). The coatomer is a heptameric complex comprised of a, P,
P', y, 5, s and C, subunits (Roche, 1999). Interestingly, the P'-COP was shown to be a
RACK for PKCs, suggesting a role for PKCs in vesicular trafficking (Csukai et al.,
1997). In addition it has been demonstrated that the small GTPase Rab2, which initiates
the recruitment of soluble components necessary for protein sorting and recycling from
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pre-Golgi intermediates, requires PKCA. to recruit P-COP for vesicle formation (Tisdale,
2000). However, no direct interaction between PKCA, and P-COP was found. While the
association of P-COP with the CPI-17 column strongly suggests that this could be
mediated by a PKC isoform, a direct interaction between P-COP and CPI-17 should not
be excluded.
3.5.4. Binding of qC1 qBP protein to the GST-CPI-17 column
The gClqBP (p33, p32, ClqR, TAP) is a widely expressed, multifunctional
chaperone involved in numerous ligand-mediated cellular responses (reviewed in
Ghebrehiwet et al., 2001). Originally, this 32 kDa protein has been described as a
receptor of complement component Clq (Ghebrehiwet et al., 1994), the kinogen-binding
protein p33 (Herwald et al., 1996) and splicing factor associated protein p32 (Krainer et
al., 1991). Storz and co-workers have shown that association ofPKCp, to p32 results in
inhibition of the kinase. (Storz et al., 2000). A recent paper describes p32 as a general
PKC-binding protein, but in contrast to Storz and co-workers, reports a stimulation of
PKC activity (Robles-Flores et al., 2002). This discrepancy is explained by the fact that
Storz and co-workers used a different construct from Robles-Flores and co-workers. In
summary, p32 has been reported to bind and regulate PKC activity. Therefore, the
binding of p32 (accession number 3334249) to the CPI-17 column could be mediated via
PKC.
3.5.5. Binding of Hsp70 protein to the GST-CPI-17 column
To become functionally active, newly synthesized proteins must fold to correct
three-dimensional structures. Chaperone proteins are involved in this process to avoid
protein aggregation, misfolding or partial folding (reviewed in Hartl, 1996). One of these
chaperone proteins is the heat shock protein (Hsp) 70, which amongst others, detects
proteins that are incorrectly folded or denatured (reviewed in Bruemmer-Smith et al.,
2001). Hsp70 then forms a complex with such proteins which can lead to correct
folding, compartmentalisation in organelles, or to proteolytic degradation. Hsp70 has
also been shown to play a role in protein unfolding, which is a key step in the import of
some proteins into mitochondria and in the degradation of regulatory proteins by ATP-
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dependent proteases (reviewed in Matouschek et al., 2000). The expression of heat
shock proteins is particularly increased during stress conditions, such as heat shock,
oxidative stress or inflammation (reviewed in Zylicz et al., 2001). During these
conditions heat shock proteins increase cell survival by protecting and disaggregating
stress-labile proteins, as well as the proteolysis of the damaged proteins. Because of its
chaperone function, it is not surprising that Hsp70 (accession number 304516) was
found to associate with the GST-CPI-17 column. The interaction ofHsp70 with the CPI-
17 column has been further confirmed by Western blotting (Figure 3.27). It is possible
that Hsp70 associated with a large number ofproteins bound to the GST-CPI-17 column
and therefore it is difficult to conclude whether there could be a direct interaction
between CPI-17.
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GST CPI-17 Brain
eluate eluate
Figure 3.27 Association of Hsp70 with the GST-CPI-17 column.
Protein (5 p.g) eluted from the GST-CPI-17 column ("CPI-17 eluate) and GST column
("GST eluate") was separated on 12.5% SDS-PAGE, transferred onto nitrocellulose and
Western blotted with Hsp70 antibodies. A brain extract was used as a positive control
for the antibody. The positions of the molecular weight markers (kDa) are indicated.
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3.5.6. Binding of RING finger binding protein, HAC1, to the GST-CPI-17 column
HAC1 has been identified as a RING finger protein (Yanai K., Shimamoto Y.,
Hirota K. and Fukamizu A., unpublished results), however, nothing else is known about
this protein to date. Hundreds ofRING (Really Interesting New Gene) finger proteins
have been reported so far and they are implicated in a diverse array of cellular processes,
including development, oncogenesis and apoptosis (reviewed in Borden, 2000). Over the
last few years evidence emerged that directs the role of the RING finger motif to the
ubiquitin-ligase (E3) activity (reviewed in Joazeiro and Weissman, 2000). A large
number ofRING E3 has been identified so far, however it is not know whether all RING
finger proteins are E3 (reviewed in Pickart 2001). Ubiquitination, a process in which
target proteins are covalently modified by polyubiquitin and thus labelled for
proteolysis, is understood as a major mechanism for cellular regulation (Pickart, 2001).
Therefore, the elucidation of RING finger proteins functions and their regulation should
be of great interest. The association of the RING finger protein HAC1 (accession
number 5732193) with the GST-CPI-17 column, could indicate that HAC1 might also
have an E3 activity and is therefore involved in cellular processes, by participating in
controlling protein levels by proteolysis.
3.5.7. Binding of actin and myosin I to the GST-CPI-17 column
Actin and myosin I have been identified as two cytoskeletal proteins to associate
with the GST-CPI-17 column. Myosin in connection with actin is responsible for a
variety of cellular movements in eukaryotic cells. Chemical energy is transformed into
directed movement by actin-activated ATP hydrolysis within myosin during the process
(reviewed in Volkmann and Hanein, 2000). The actin cytoskeleton provides both the
force and framework for much of cell motility, shape change and intracellular
organisation (reviewed by Machesky and Gould, 1999). A large number of cellular
processes including cytokinesis, endocytosis, exocytosis, chemotaxis, neurite outgrowth,
signal transduction and mRNA transport are mediated by polymerisation of actin
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filaments (reviewed in Carlier et al., 1999). There are three isoforms of actin in higher
eukaryotes: a actin is found in muscle cells and p and y actins are present in non-muscle
cells (reviewed by Carpenter, 2000). Actin is often the most abundant protein in a cell
and is present as a monomer and a polymer (Carpenter, 2000). The actin cytoskeleton is
regulated by members of the Rho family of small GTPases (reviewed by Frame and
Brunton, 2002). Interestingly, it has been shown that there is functional cooperation
between the microtubule and actin cytoskeletons and MAPs were shown to be capable of
cross-linking actin filaments and microtubules in vitro (reviewed by Goode et al., 2000).
In addition, PKCp and s are known to bind directly to actin (reviewed in Jaken and
Parker, 2000), and it has been demonstrated that PKC induces actin re-organisation in
vascular smooth muscle cells (Brandt et al., 2002). Furthermore it should be mentioned
that our laboratory identified actin as one of the proteins binding to the peptide column
containing residues 214-233 ofCKIa (Dubois et al., 2002b) and CKIa was able to
phosphorylate actin in vitro (Dubois T., Maciver S.K. and Aitken A., unpublished
results). From the above results it is clear that, the association of actin p and y with the
GST-CPI-17 column could be mediated via numerous proteins, including PKC, myosin
I, CKIa, MAPs or other complexes, however it is also possible that actin associates
directly with CPI-17.
Myosin I proteins, members of the unconventional myosin class, are single-
headed, actin-binding, membrane associated proteins with heavy chains in the molecular
range of 110-130 kDa (reviewed in Coluccio, 1997). Each heavy chain associates with
1-6 light chains. All members of the myosin I family, from yeast to man, have three
structural domains: a catalytic head domain that binds ATP and actin; a tail domain
thought to be involved in targeting the myosins to specific subcellular locations and a
junction or neck domain that connects them and interacts with light chains (reviewed in
Barylko et al., 2000). Myosin Is have been implicated in various motile processes,
including cortical membrane tension (Dai et al., 1999), endocytosis and endocytotic
trafficking (Geli and Riezman, 1996; Raposo et al., 1999) and membrane ruffling
(Mezgueldi et al., 2002; Tang and Ostap, 2001). It is interesting to note that myosin la,
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Ip and Iy can all be phosphorylated in vitro by PKC (reviewed in Barylko et al., 2000).
The binding of myosin I to the GST-CPI-17 column could be mediated by protein
complexes including actin or PKC, however, a possible direct interaction between CPI-
17 and myosin I cannot be excluded.
The association of actin, myosin I, other cytoskeletal proteins, adaptor protein P-
adaptin and the assembly protein AP 50 with the GST-CPI-17 column suggests a
possible role for CPI-17 in the involvement of cytoskeletal regulation and/or vesicular
trafficking.
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CONCLUSION
In this chapter the identification of new CPI-17 binding proteins has been
described. The focus has been particularly on the interaction ofCPI-17 with PKC and
CKI. PKC has been shown to phosphorylate CPI-17 on Thr-38 (Eto et al., 1995),
however, to the best ofmy knowledge no evidence has been demonstrated that PKC
binds to CPI-17. PKC isoforms from the 3 different PKC classes and PKCp were shown
in this study to directly bind to CPI-17 in vitro. The binding site has been mapped to the
catalytic domain ofPKCg and to residues 1-120 ofCPI-17. Furthermore, PKCs from the
3 different classes and PKCp. were shown to phosphorylate CPI-17 in vitro. The second
part of this chapter demonstrated that CPI-17 associates with CKI isoforms and the site
was mapped to the kinase domain of CKI and to residues 1-120 of CPI-17. Additionally,
CPI-17 was shown not to be a substrate for CKI, but it appears to regulate CKIa
activity. In the last part of this chapter the identification of new potential CPI-17 proteins
by mass spectrometry was described. A number of proteins were shown to associate
with the GST-CPI-17 column, including many cytoskeletal proteins and proteins
involved in endocytosis/organelle transport. These results indicate that CPI-17 occurs as
a multiprotein complex, suggesting that CPI-17 may have roles other than MLCP
inhibition during smooth muscle contraction.
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CHAPTER 4
Identification of novel centaurin-ai binding proteins
152
4. Identification of novel centaurm-o^ binding proteins
INTRODUCTION
Centaurin-ai was identified as one out of six proteins co-purifying with CKIa
from brain after four chromatography steps (Dubois et ah, 2001) as described in section
1.2.2. Centaurin-ai (also called centaurin-a, PIP3BP and p42IP4), a 43 kDa protein, has
been originally described as a binding partner for inositol 1,3,4,5-tetrakisphosphate and
phosphatidylinositol 3,4,5-trisphosphate (Hammonds-Odie et al., 1996; Rao et al., 1999;
Strieker et al., 1997; Tanaka et al., 1999). In spite of the presence of a putative ADP-
ribosylation factor (ARF) GTPase-activating protein domain, no ARF GAP activity has
been attributed to centaurin-ai to date (reviewed in Jackson et al., 2000). Therefore, the
function of this protein remains unknown. In order to elucidate potential intracellular
roles for centaurin-ai the aim was to identify novel centaurin-ai binding partners. Using
affinity chromatography followed by mass spectrometry and/or Western blot analysis,
novel centaurin-ai binding partners were identified (see section 3.5).
In this chapter the evidence for the identification ofPKC as a novel centaurin-ai
protein partner and the characterisation of this interaction will be described. In the
second part, the association of nucleolin, a nucleolar protein involved in RNA
biosynthesis (reviewed in Ginisty et al., 1999), with centaurin-ai will be discussed. The
final part of this chapter will focus on the identification of novel additional potential
centaurin-a i binding proteins by mass spectrometry and some of the functions
centaurin-a i might have in cell in the light of these newly identified binding partners
will be proposed. An outline of this chapter is shown in Figure 4.1.




Figure 4.1 Interactions with centaurin-ai described in chapter 4.
Centaurin-ai binds to l>KC (section 4.1), nucleolin (section 4.2) and novel protein
partners (section 4.3). The protein interactions are indicated by double arrows.
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RESULTS AND DISCUSSION
4.1. Centaurin-ai and PKC
4.1.1. PKC7, and C bind to the centauiin-on column
Our laboratory has shown that centaurin-ai is a PKC substrate (Kerai P. and
Dubois T., unpublished data). Therefore, it was important to test whether PKC
associated with centaurin-ai and bound to the affinity chromatography column. Proteins
eluted from the GST3, GST-CPI-17 and GST-centaurin-ai column (5 pg) were separated
on a 10% SDS-PAGE gel, transferred onto nitrocellulose and Western blotted with anti-
PKCA. and C, antibodies. PKCA, and C, associated with the GST-centaurin-ai column and
GST-CPI-17 column (Figure 3.6). No PKC isoforms were detected in the eluate from the
control GST column (Figure 3.6). Further analysis to see whether PKC isoforms from
other PKC classes bound to the GST-centaurin-ai column was not possible, as
insufficient centaurin-ai eluate was available. However, these were the first results
which indicated that members of the PKC family might be novel centaurin-aj protein
partners. PKN and ROCK were not found to associate with the GST-centaurin-ai
column (Figure 3.7)indicating that the binding ofPKC isoforms to the GST-centaurin-ai
column was selective.
3 Note that due the low concentration ofproteins in the GST column eluate, it was not possible to load the
same amount of protein i.e. 5 pg and therefore 20 pi of the GST column eluate were loaded.
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4.1.2. In vitro binding of all PKC isoforms to centaurin-ai
In the previous section it is shown that atypical PKC isoforms associated with the
GST-centaurin-ai and therefore it was interesting to test whether PKC isoforms from all
subfamilies associated with centaurin-ai. Furthermore, one cannot conclude whether
association of the PKC isoforms with the GST-centaurin-ai column was direct or
mediated via other proteins associated with centaurin-ai. To investigate whether PKC
isoforms from all classes were able to associate with centaurin-ai an in vitro
transcription/translation assay was used. PKCa, X, p. and C, were expressed and labelled
with [35S] methionine in a reticulocyte lysate, and incubated with GST and GST-
centaurin-ai. All PKC isoforms tested were found to associate with GST-centaurin-ai
but not with GST (Figure 4.2), indicating that the binding might occur via a domain
present in all PKC isoforms. In order to determine whether the binding between
centaurin-ai and PKC was direct, GST, GST-CPI-17, GST-14-3-3(^ and GST-centaurin-
ai were incubated with recombinant PKCa, PKCs, PKCp and PKC^, pulled-down with
glutathione Sepharose beads and Western blot analysis was performed with the
respective PKC antibodies as described in chapter 3 section 3.3.3. The results showed
that GST-centaurin-ai, but not GST, directly bound to all PKC isoforms tested (Figure
3.10). CPI-17 directly bound to all PKC isoforms (positive control). In addition, 14-3-3^
directly associated with PKCs and PKCp, but not with PKCa nor PKC(^ (Figure 3.10) as
described in chapter 3 section 3.3.3. Using two different methods, the association
between centaurin-ai and PKC was demonstrated. To the best ofmy knowledge this is
the first time a member of the centaurin family has been shown to bind directly to PKC
isoforms.







PKCa PKCX, PKCp pkc<;
Figure 4.2 Centaurin-ai associates with all PKC isoforms tested.
PKCa, X, (J. and t, were expressed and labelled with [35S] methionine in a reticulocyte
lysate and incubated for 15 min at 30°C with 5 pg GST and GST-centaurin-ai in the
presence of 1% Nonidet P-40. Glutathione-Sepharose beads were added and incubated at
room temperature for 1 h. Beads were washed and samples analysed by 10% SDS-
PAGE followed by autoradiography (panel "Pull-down"). An aliquot of the lysate was
loaded on the gel to visualise expressed PKCs (panel "Input"). The positions of the
molecular weight markers (kDa) are indicated.
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4.1.3. Binding occurs via the C1 domain of PKC
In section 4.1.2 it has been shown that PKC isoforms from all PKC classes bind
directly to centaurin-ai which suggests that the binding occurs via a common domain.
The PKCp isoform was used to map the centaurin-ai binding site. PKCp wt and PKCp
deletion mutants (Al-340 (AC1), A336-391 (AAD)) and A417-553 (APH) were
expressed, labelled with [35S] methionine and incubated with GST and GST-centaurin-
ai. As shown in Figure 4.3 PKCp wt bound to GST-centaurin-ai. Deletion of the acidic
domain (AD) or the pleckstrin homology (PH) domain of PKCp. did not affect the
binding to centaurin-ai. However, no binding was observed between centaurin-ai and
PKCp Al-340 (Figure 4.3). According to these data, amino acids 1-340 ofPKCp are
necessary for the association with centaurin-ai, indicating that the CI domain ofPKCp
represented the target region for binding to centaurin-ai. This is not unexpected as
several proteins have been described to be associated with the CI region ofPKCp,
including CPI-17 (positive control), 14-3-3C, (Hausser et al., 1999) and Bruton's tyrosine
kinase (BTK) (Johannes et al., 1999). Since all PKC isoforms have a least one CI
domain, these results complement those from Figure 4.2 showing that all PKC isoforms
associated in vitro with centaurin-ai.
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Figure 4.3 Centaurin-aj binds to the CI domain of PKCp.
PKCp wt and PKCp deletion mutants (Al-340, AAD and APH) were expressed in a
reticulocyte lysate, and incubated with 5 pg each of GST and GST-centaurin-ai as
described in Figure 4.2. GST pull-down assays were analysed by SDS-PAGE and
autoradiographed (panel "Pull-down"). An aliquot of the lysate was loaded on the gel
(panel "Input"). The positions of the molecular weight markers (kDa) are indicated.
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4.1.4. PKC phosphorylates centaurin-ai
Since PKCs bind to centaurin-ai it was important to determine whether
centaurin-ai served as a substrate for these kinases. Our laboratory has shown that PKC
phosphorylates centaurin-ai (Kerai P. and Dubois T., unpublished data).We therefore
tested which PKC isoforms were responsible. For that purpose, 1 U of PKCa, s, p and C,
was incubated with 5 pg of centaurin-ai in the presence of 50 pM [y-32P] ATP and
kinase buffer (kinase assay using PKCp was carried out by Sam Clockie). The results
indicated that all PKC isoforms tested were able to phosphorylate centaurin-aj in vitro
(Figure 4.4A).
Although it may appear that PKCa is more potent in phosphorylation of
centaurin-ai than PKCs, C, and p, this was not the case as there was a difference in
activity between the different PKC isoforms as judged by the levels of
autophosphorylation and ofhistone H III phosphorylation used as control (Figure 4.4B).
This is the first centaurin family member that has been shown to be phosphorylated by
PKC.
Phosphorylation of centaurin-ai by PKC could regulate centaurin-ai activity and
therefore it would be important to clarify whether centaurin-ai has an ArfGAP activity
and to test whether PKC phosphorylation has any effect on the regulation of centaurin-
ai. It is interesting to note that centaurin-ai has been shown to associate with CKIa,
however, CKIa does not phosphorylate centaurin-ai, (Dubois et al., 2001).
Having demonstrated for the first time that PKC isoforms from different sub¬
families bind to centaurin-ai in vitro and that the PKC isoforms a, 8, p and C, all
phosphorylated centaurin-ai suggests that centaurin-ai may be a tissue specific substrate
for different PKC isoforms and that the interaction between the two proteins may depend
on their subcellular localisation.
At this point it should be noted that novel and atypical PKC isoforms have been
shown to be activated by lipid second messengers including the PI 3-K products Ptdlns-
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(3,4)-P2 and PtdIns-(3,4,5)-P3 (reviewed in Toker, 1998). This could link PKCs to the
phosphoinositide signalling pathway and also provide another link between PKC
isoforms and centaurin-ai. As mentioned previously in the Introduction (section 1.5.1),
centaurin-ai contains two PH domains which comprise the PtdIns-(3,4,5)-P3 binding site
and are necessary for the PI 3-K dependent translocation of centaurin-ai from the
nucleus and cytosol to the plasma membrane (Tanaka et al., 1999; Venkateswarlu and
Cullen, 1999; Venkateswarlu et al., 1999). Therefore PKC and centaurin-ai could be
regulated by PtdIns-(3,4,5)-P3.
Centaurin-ai is ubiquitously expressed with especially high expression levels in
brain (Hammonds-Odie et al., 1996) and PKC isoforms are also widely distributed in
different tissues including brain (Liu, 1996). Furthermore, it has been demonstrated that
centaurin-ai is mainly found in the nucleus of different cell lines, but it has also been
shown to associate with the plasma membrane and to be present in the cytosol (Dubois
et al., 2002c; Tanaka et al, 1999; Venkateswarlu and Cullen, 1999; Venkateswarlu et al.,
1999). Centaurin-ai contains a putative nuclear localisation signal (NLS) at its N-
terminal that was found to be critical for its targeting to the nucleus (Tanaka et al.,
1999). Intriguingly, our laboratory showed that a mutant deleted of the first residues
containing the putative NLS still localised in the nucleus to the same extent as centaurin-
ai wild type (Dubois et al., 2002c). A recent report has shown the importance of the zinc
finger motif for the nuclear localisation of centaurin-ai (Sedehizade et al., 2002). This
could explain why a the centaurin-ai mutant deleted of the NLS still localised to the
nucleus.
Most PKC isoforms have also been identified in the nucleus and increasing
evidence has implicated a role for PKC in nuclear functions, such as cell proliferation,
cell differentiation and apoptosis (reviewed in Martelli et al., 1999). As both centaurin-
ai and PKC isoforms localise in the nucleus (as well as plasma membrane and cytosol)
one can speculate that centaurin-ai could be involved in cellular processes which take
place in the nucleus. In support of these data, centaurin-ai has been found to associate
with the nucleolar protein, nucleolin, which will be discussed in the next part of this
4 Identification of novel centaurin-ai binding proteins 161
chapter.
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Figure 4.4 Centaurin-ai is phosphorylated by all classes of PKC.
A, One unit each of PKCa, s, p and C, were incubated with 5 pg centaurin-ai in the
presence of 50 pM [y-32P] ATP and kinase buffer for 15 min at 30°C. The samples were
analysed on 12.5% or 10% (for PKCp phosphorylation) SDS-PAGE followed by
autoradiography. The positions of phosphorylated centaurin-ai and autophosphorylated
PKC isoforms are indicated on the right.
B, One unit each of PKCa, s, and C, were incubated with 5 pg histone H3 in the
presence of 50 pM [y-32P] ATP and kinase buffer for 15 min at 30°C as a positive
control for PKC activity. The samples were analysed on 15% SDS-PAGE followed by
autoradiography. The position of phosphorylated histone H III is indicated on the right.
The positions of the molecular weight markers (kDa) are indicated on the left.
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4.2. Centaurin-oci and nucleolin
4.2.1. Nucleolin associates with the GST-centaurin-ai column
One of the proteins that associated with the GST-centaurin-ai column was
nucleolin (SWISS-PROT accession number PI9338, MW 76kDa) which is a
phosphoprotein abundant in the nucleolus and can represent as much as 10% of total
nucleolar protein (Ginisty et al., 1999). Nucleolin was identified as a centaurin-ai
binding protein by mass spectrometry analysis and the band corresponding to nucleolin
on a SDS-PAGE gel is indicated in Figure 4.5A. GST-centaurin-ai column eluate was
separated by SDS-PAGE gel and stained with GelCODE and analysed as described in
Method section 2.18 (Figure 4.5A). The results were confirmed using a nucleolin
specific antibody (Figure 4.5B). It is evident from Figure 4.5A that nucleolin was one of
the major proteins associated with the GST-centaurin-ai column. No nucleolin was
identified in the GST-CPI-17 column eluate, confirming the selectivity of this
interaction.
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Figure 4.5 Nucleolin elutes from the GST-centaurin-ai column.
A, (as second column in Figure 3.25). Nucleolin associates with the GST-centaurin-ai
column (detection by mass spectrometry). Sheep brain lysate was pre-incubated with
GST in the presence of 0.5% Triton, and subsequently loaded onto a GST-centaurin-ai
column. Proteins bound to the columns were eluted with 1M NaCl and analysed on
12.5% SDS-PAGE and stained with GelCODE. The band corresponding to nucleolin is
indicated on the right and the positions of the molecular weight markers (kDa) are
indicated on the left.
B, Nucleolin associates with the GST-centaurin-ai column (detection by Western
blotting). Protein (5 pg) eluted from the GST-CPI-17 ("CPI-17 eluate") or GST-
centaurin-ai ("Cent.-ai eluate") column was separated on 10% SDS-PAGE, transferred
onto nitrocellulose and Western blotted with nucleolin antibodies. A brain extract was
used as a positive control for the antibodies. The positions of the molecular weight
markers (kDa) are indicated.
4 Identification of novel centaurin-ai binding proteins 165
4.2.2. Nucleolin binds to centaurin-ai shown by IVTT
In section 4.2.1 it is shown that nucleolin associates with the GST-centaurin-ai
column. To determine whether the binding between nucleolin and centaurin-ai is
independent of other proteins binding to the GST-centaurin-ai column, an in vitro
transcription/translation assay was used. Nucleolin was expressed and labelled with [35S]
methionine in a reticulocyte lysate, and incubated with GST, GST-CPI-17, GST-14-3-3<^
and GST-centaurin-ai. Nucleolin associated with GST-centaurin-ai, but not with GST,
GST-CPI-17 or GST-14-3-3^. This confirmed that the binding between centaurin-ai and
nucleolin is selective, since nucleolin was not found to bind to any other proteins tested.
Furthermore, this result showed that the binding between centaurin-ai and nucleolin was
not mediated via other proteins associated with the GST-centaurin-ai column. In
addition the nucleolin construct used in the assay lacked the last 171 C-terminal residues
ofnucleolin which includes the RGG domain and the last RBD (Serin et ah, 1997; Ying
et ah, 2000), demonstrating that this terminal region is not involved in the interaction.
This interaction has been further confirmed in our laboratory by the association between
centaurin-ai and endogenous nucleolin in HEK293 cells (Dubois et ah, 2002c).
Nucleolin, belongs to a large family ofRNA binding proteins. It contains 707
residues and its actual calculated mass is 77 kDa (reviewed in Srivastava and Pollard,
1999). However, nucleolin runs on SDS-PAGE gel with an apparent molecular mass of
105 kDa, which can be explained by the high content ofnegatively charged amino acids
in the amino-terminal domain. Nucleolin has been shown to be involved in cellular
functions such as ribosomal DNA (rDNA) transcription, chromatic decondensation,
nucleocytoplasmic transport and ribosome biogenesis (Srivastava and Pollard, 1999).
The association of centaurin-ai with nucleolin could reveal novel exciting roles for
centaurin-ai in the nucleus.
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Figure 4.6 Nucleolin associates with centaurin-ai.
Nucleolin was expressed in a reticulocyte lysate, and incubated with 5 pg each ofGST,
GST-CPI-17, GST-14-3-3^ and GST-centaurin-ai as described in Figure 4.2. GST pull¬
down assays were analysed by SDS-PAGE and autoradiographed (panel "Pull-down").
An aliquot of the lysate was loaded on the gel (panel "Input"). The positions of the
molecular weight markers (kDa) are indicated.
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4.2.3. RNA is necessary for the binding of nucleolin to centaurin-g-i
Because nucleolin is a rRNA binding protein (Ginisty et al., 1999), and a smear
was observed which could be due nucleic acids on a gel containing the proteins eluted
from the GST-centaurin-ai column (see Figure 4.5), the effect ofRNase treatment was
tested on the association between centaurin-ai and nucleolin. It should be noted that we
did not test whether nucleic acids, i.e. DNA or RNA were eluted from the GST-
centaurin-oti column, which would be of interest for further studies.
Nucleolin was expressed and labelled with [35S] methionine in a reticulocyte
lysate, and incubated with different amounts ofRNase as described in Methods section
2.16. This was followed by incubation with GST-centaurin-ai. Interestingly, the binding
between nucleolin and centaurin-ai decreased with increasing amounts ofRNase
(Figure 4.7), suggesting that RNA was involved in the formation of the complex
between nucleolin and centaurin-ai and that they might be part of a ribonucleoprotein
complex. These results were confirmed by demonstration that binding between nucleolin
and centaurin-ai in HEK293 cells decreased upon treatment of cell lysate with RNase
before centaurin-ai immunoprecipitation (Dubois et al., 2002c). As a control cell lysate
treated with DNAse did not impair the binding between centaurin-ai and nucleolin,
further supporting a role for RNA in the association between centaurin-aj and nucleolin
(Dubois et al., 2002c). It is possible that the binding between nucleolin and centaurin-ai
is mediated via RNA or that binding ofRNA to nucleolin changes its conformation
allowing it to bind centaurin-ai.
Interestingly, a novel nucleolin-binding ribonucleoprotein complex has been
characterised recently (Yanagida et al., 2001). Over sixty proteins were identified as part
of the ribonucleoprotein which associated with nucleolin, out ofwhich forty were
ribosomal proteins. These authors demonstrated that the RBD of nucleolin was sufficient
to hold the entire nucleolin-binding ribonucleoprotein complex and that nucleolin holds
the ribonucleoprotein complex mainly by RNA-protein interactions and not by protein-
protein interactions. This further strengthens the proposal that presence ofRNA is
necessary for the binding between nucleolin and centaurin-ai.
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Nucleolin has been shown to be involved in different steps of ribosome
biogenesis including rRNA transcription, rRNA maturation and ribosome assembly
(Ginisty et al., 1999). Interestingly, nucleolin is able to shuttle between the nucleus and
the cytoplasm, which has raised the possibility that nucleolin could also be involved in
the nuclear import of ribosomal components (for example ribosomal proteins), or in the
nuclear export of the ribosomal subunits (Borer et al., 1989; Schmidt-Zachmann et al.,
1993).
Another important discovery was that nucleolin is a substrate for PKC^, which is
required for nerve growth factor (NGF) induced differentiation in PC 12 cells (Zhou et
al., 1997). NGF treatment of PC12 cells resulted in translocation ofPKC^ from the
cytoplasm to the nucleus and in phosphorylation of nucleolin. Perander and co-workers
showed that PKC^ contains a nuclear localisation signal (NLS) and a nuclear export
signal (NES) which is responsible for the shuttling of PKCA and PKC^ between
cytoplasm and the nucleus (Perander et al., 2000). Interestingly, nucleolin was only
phosphorylated by PKC^ when in the nucleus, but not in the cytoplasm (Zhou et al.,
1997). From these results, it has been suggested that nucleolin serves to relay NGF
signals from cell surface to the nucleus in PC 12 cells. Phosphorylation of nucleolin by
PKC^ provides a link between the three proteins, nucleolin, PKC and centaurin-ai. Both
nucleolin and centaurin-ai can serve as PKC substrates. However, in vivo nucleolin has
been shown to be phosphorylated only by PKC^, whereas data presented here show that
centaurin-ai can be phosphorylated by PKC isoforms from all PKC classes (it should be
noted that it remains to be established whether centaurin-ai is a substrate for PKC
isoforms in vivo). This could indicate that centaurin-ai could be involved in signalling
pathways mediated by different PKC isoforms, whereas nucleolin might only be
involved in a very specific pathway signalling to the nucleus mediated by PKCC
Because RNA was necessary for the binding between centaurin-ai and nucleolin, the
findings described above suggest a possible role for centaurin-ai in ribosome
biogenesis. However, as nucleolin is mainly expressed in the nucleolus (Ginisty et al.,
1999), and centaurin-ai throughout the nucleus (Dubois et al., 2002c; Tanaka et al.,
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1999), this suggests that centaurin-ai might have other binding partners in the nucleus
and potentially other functions. The identification ofnovel, mainly nuclear, potential
centaurin-ai protein partners will be discussed in the last part of this chapter.













Figure 4.7 RNA is necessary for the binding between nucleolin and centaurin-ai.
Nucleolin was expressed in a reticulocyte lysate, and incubated for 15 min at 30°C with
5 pg GST, GST-CP1-17, GST-14-3-3^ and GST-centaurin-ai in the presence of 1%
Nonidet P-40 and RNase. Glutathione-Sepharose beads were added and incubated at
room temperature for 1 h. Beads were washed and samples analysed by 10% SDS-
PAGE followed by autoradiography (panel "Pull-down"). An aliquot of the lysate was
loaded on the gel to visualise expressed PKCs (panel "Input"). The positions of the
molecular weight markers (kDa) are indicated.
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4.3. New potential centaurin-ai binding proteins identified by mass
spectrometry
To investigate the function of centaurin-ai, potential novel binding proteins were
identified by affinity chromatography and mass spectrometry analysis. Sheep brain
lysate, which had been pre-incubated with GST to remove non-specific binding, was
loaded onto a GST, GST-CPI-17 or GST-CPI-17 column as described in chapter 3
section 3.5. The columns were extensively washed and bound proteins eluted with 1 M
NaCl as described in the Methods chapter 2.12. More than 15 different proteins eluted
from the GST-centaurin-ai as judged by SDS-PAGE and GelCODE staining (Figure
4.8). Only around 5 proteins were recovered at low level from the control GST-column
and more than 20 proteins eluted from the GST-CPI-17 column. This further
strengthened the point that the binding of the proteins to the GST-centaurin-ai was
selective. A total of 10 proteins were identified by mass spectrometry as described in
Method chapter 2.18. Table 4.1 shows their identification by mass spectrometry.















9 Protein similar to ribosomal protein S9
10 Polymerase II TF4
Figure 4.8 Mammalian brain proteins associate with centaurin-aj.
Sheep brain lysate was pre-incubated with GST in the presence of 0.5% Triton, and
subsequently loaded onto a GST-centaurin-ai. Proteins bound to the column were eluted
with 1M NaCl, analysed on 12.5% SDS-PAGE, stained with GelCODE and analysed by
mass spectometry. The positions of the molecular weight markers (kDa) are indicated.
The approximate positions of the identified proteins are indicated on the right.
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Table 4.1 Proteins binding to the GST-centaurin-ai column identified by mass
spectrometry








































































From Table 4.1 it is clear that centaurin-ai associates with numerous proteins
and some of their functions will be briefly described in the following paragraphs. It
should be pointed out however, that the direct association between centaurin-ai and the
proteins identified by mass spectrometry has not been investigated. It is possible that
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only a few of the proteins directly bind to centaurin-ai and that the binding ofother
proteins is indirect and occurs via protein or RNA complexes. It would be important to
confirm the newly identified proteins (apart from nucleolin) by Western blotting.
4.3.1. Centaurin-ai associates mainly with nuclear proteins
Centaurin-ai was mainly found to associate with nuclear proteins with the
exception of the P2 and p subunits (or adaptins) of the adaptor-related protein complex 3
(accession number in SWISS-PROT: 4758760). Interestingly, CPI-17 was also found to
associate with adaptins as mentioned in chapter 3 (section 3.5.2). As discussed
previously, adaptins are subunits of adaptor proteins (AP) complexes involved in the
formation of intracellular transport vesicles and in the selection of protein cargo for
incorporation into the vesicles (reviewed in Boehm and Bonifacino, 2001; see also
section 3.5.2). The association of centaurin-ai with adaptins suggests a role for
centaurin-aj in vesicular trafficking. In addition, it has been shown that centaurin-ai is
also found in cell fractions containing membranes (Dubois et al., 2002c) and the
neuronal form ofAP-3 has been associated with a role in synaptic vesicle formation
(Blumstein et al., 2001), suggesting that centaurin-ai might also be involved in this
cellular event. A CKIa -like activity has been shown to associate with AP-3, and
therefore it is possible that the binding ofAP-3 to the GST-centaurin-ai column could
be mediated via CKIa. Furthermore, PI3-K and its product phosphatidylinositol-3-
phosphate have been shown to be essential in early endosome fusion (de Renzis, et al.,
2002; Zerial and McBride, 2001). This provides a further link between the
phosphatidylinositol signalling pathway, centaurin-ai and vesicular trafficking.
Two other proteins which associated with the centaurin-ai column were, SC35
(accession number: 6755478) and SF3a (accession number : 5803167), both splicing
factors involved in pre-mRNA splicing (reviewed in Hastings and Krainer, 2001; Nesic
and Kramer, 2001). Pre-mRNA splicing, an essential step for the expression ofmost
genes in higher eukaryotic cells, occurs in the nucleus in a large multicomponent
ribonucleoprotein complex called the spliceosome, which is composed of small nuclear
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ribonucleoprotein particles (snRNP; Ul, U2, U4, U5 and U6) and many non-snRNP
protein splicing factors (reviewed in Hastings and Krainer, 2001; Sureau et al., 2001;
Wang et al., 2001). One group ofnon-snRNP proteins belongs to a conserved family of
structurally and functionally related phosphoproteins called serine/arginine-rich (SR)
proteins (Sureau et al., 2001). These proteins share a similar primary protein structure
characterized by one or two RNA recognition motifs (RRMs) and an arginine/serine
(RS) domain, which functions as a protein interaction domain (reviewed in Graveley,
2000). SR proteins are involved in multiple functions of the pre-mRNA splicing
reaction, including early steps of spliceosome assembly, removal of spliced introns and
regulation of alternative splicing. The latter is the formation of different mRNA isoforms
from a single gene and a fundamental process controlling genetic expression in higher
eukaryotes (Sureau et al., 2001).
The second splicing factor found to associate with the GST-centaurin-ai column
was SF3a. The 17S U2 snRNP represents the active form ofU2 snRNP that binds to the
pre-mRNA during spliceosome assembly (Nesic and Kramer, 2001). U2 snRNP forms
by association of the splicing factors SF3b and SF3a with the 12S U2 snRNP and it has
been demonstrated that SF3a is required for the formation of the active 17S U2 and
assembly of the prespliceosome. The association of proteins involved in mRNA splicing
with the GST-centaurin-ai column gives rise to the possibility that centaurin-ai might
be involved in mRNA splicing in the nucleus. However, it is also possible that the two
splicing factors identified bind to the GST-centaurin-ai column via RNA or other
proteins associated the GST-centaurin-ai column.
Another nucleic acid binding protein, Pur a (accession number 6679573)
associated with the GST-centaurin-ai column. Pur a is a ubiquitous, sequence specific
DNA and RNA-binding protein which is highly conserved in eukaryotes (reviewed in
Gallia et al, 2000). This protein has been implicated in numerous cellular functions
including transcriptional activation and repression, translation, cell growth and
proliferation. Interestingly, RNA molecules have been shown to modulate the activity of
Pur a. The association of Pur a with the GST-centaurin-ai column could therefore be
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mediated by RNA molecules. However, an association with centaurin-ai or other
proteins bound to the GST-centaurin-ai with Pur a should not be excluded.
A protein similar to ribosomal protein S9 (accession number 12654005)
associated with the GST-centaurin-ai column. Ribosomes, the molecular machines that
manufacture proteins, are composed of ribosomal RNA and ribosomal proteins
(reviewed in Maguire and Zimmermann, 2001). They consist of a large and small
subunit, which in E. coli are the S50 and S30 subunits, respectively. The large subunit
contains the peptidyl transferase activity responsible for catalysing peptide bond
formation during protein synthesis (reviewed in Doudna and Rath, 2002). The small
subunit of the ribosome is responsible for binding and decoding messenger RNAs.
Protein S9 is an E.coli 30S ribosomal protein (reviewed in Koc et al., 2001). It has been
proposed that RNA molecules catalyse the crucial reactions on a ribosome, while the
proteins play an active role in functions that may have evolved to streamline the process
ofprotein synthesis (Maguire and Zimmermann, 2001). The association of a protein
similar to ribosomal protein S9, with the GST-centaurin-oci column suggests that either a
protein involved in the mRNA translation process is bound to the GST-centaurin-ai
column and mediates this interaction or that the protein similar to ribosomal protein S9
associates via RNA molecules to the GST-centaurin-ai column. Another possibility is
that centaurin-ai is indeed involved in ribosome biogenesis and binds to ribosome
components.
Sample number 9, the leucine-rich acidic nuclear protein (LANP; accession
number 5453880), was identified as another protein binding to the GST-centaurin-ai
column. LANP has been identified as a cerebellar protein, particularly expressed in
Purkinje cells and a role for LANP in a signal transduction pathway that directs
differentiation of cerebellar neuron has been proposed, but not confirmed (Matsuoka et
al., 1994). Leucine-rich domains appear to mediate protein-protein interactions
(reviewed in Kobe and Kajava, 2001). Interestingly, LANP associates with the protein
ataxin-1, the SCA1 gene product, which has been implicated in the pathology of
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spinocerebellar ataxia type 1 (SCA1; Matilla et al., 1997). The features of the interaction
between ataxin-1 and LANP, led these authors to propose a role for LANP in SCA1
pathogenesis. However, the precise function of this nuclear protein remains unknown.
Association of LANP with the GST-centaurin-ai column further supports the fact that
mainly nuclear proteins seem to associate with centaurin-ai. To the best ofmy
knowledge no other binding partners of LANP apart from ataxin-1, have been identified
and therefore it is difficult to speculate through which protein the interaction between
LANP and the GST-centaurin-aj column could be mediated, if the binding between
LANP and centaurin-ai proves to be indirect.
The last protein identified which associated with the GST-centaurin-ai column
was identified as the RNA polymerase II transcription cofactor 4 (also called PC4;
accession number: 5729968). In eukaryotic cells the essential components of the
transcription apparatus include RNA polymerase II and a set of general factors which are
responsible for initiating promoter-dependent transcription (reviewed in Woychik and
Hampsey, 2002). In addition, activator-dependent transcription in mammalian cells
requires upstream stimulatory activity (USA)-derived cofactors including positive
cofactors (PCs) (reviewed in Ge and Roeder, 1994; Ge et al., 1994; Kretzschmar et al.,
1994). One of these positive cofactors, PC4 has been identified as a 127 residue,
phosphorylation-regulatable DNA binding protein, that mediates functional interactions
between upstream activators and the transcriptional machinery and enhances activator-
dependent transcription. It was later shown that PC4 could act as a repressor of basal
(activator-independent) transcription (Malik et al., 1998; Werten et al., 1998).
Interestingly, PC4 also inhibits cyclin-dependent protein kinase (cdk) mediated
phosphorylation of the largest subunit ofRNA polymerase II (RNAPII) which correlated
with its transcriptional inhibitory activity (Schang et al., 2000). Furthermore, Calvo and
co-workers have provided evidence that links PC4 with mRNA termination (Calvo and
Manley, 2001). The identification of PC4 in the GST-centaurin-ai eluate, suggests that
this protein either bound directly to GST-centaurin-ai or that the association was
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mediated by other proteins linked to RNA transcription or by nucleic acids possibly
present on the GST-centaurin-ai column.
From the above described results it is evident that mainly nuclear proteins
involved in ribosome biogenesis (nucleolin and a protein similar to ribosomal protein
S9), in mRNA transcription (Pur a and PC4), mRNA splicing (splicing factors SF3 and
SC35) and mRNA translation (Pur a and protein similar to ribosomal protein S9)
associated with the GST-centaurin-ai column.
Most of the newly identified proteins binding to the GST-centaurin-ai column
have one thing in common: They bind RNA or components involved in RNA
processing. Therefore, it remains unclear whether these proteins constitute real
centaurin-ai binding partners or whether their binding to the GST-centaurin-ai column
was mediated via RNA/DNA or other proteins associated with the column. In support of
the second option, RNA was shown to be necessary for the binding between nucleolin
and GST-centaurin-ai and therefore a role for centaurin-ai in cellular events involving
RNA is plausible. In addition, Yanagida and co-workers characterised a novel nucleolin-
binding ribonucleoprotein complex. In their study, they identified over sixty proteins,
out ofwhich forty were ribosomal proteins, as part of the ribonucleoprotein which
associated with nucleolin (Yanagida et al., 2001). They demonstrated that the RBD of
nucleolin was sufficient to hold the entire nucleolin-binding ribonucleoprotein complex
and that nucleolin holds the ribonucleoprotein complex mainly by RNA-protein
interaction and not by protein-protein interaction. Interestingly, none of the proteins that
were identified as part of the nucleolin-binding ribonucleoprotein complex were
identical to proteins which eluted from the GST-centaurin-ai column. This suggests that
some of the proteins bound to the GST-centaurin-ai column, might in fact be true
centaurin-ai binding proteins, however, it is also possible that proteins eluted from the
GST-centaurin-ai column are nucleolin or RNA binding proteins which have not been
previously identified by the study of Yanagida et al., (2001).
It remains to be confirmed by other experiments whether centaurin-ai is a RNA
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binding protein and if so, which domains within centaurin-ai could function as RNA
binding domains.
CONCLUSION
In this chapter the identification of new centaurin-ai binding partners has been
described. This focused particularly on the interaction of centaurin-aj with PKC and
nucleolin. However, no interaction between centaurin-ai and PKC had been
demonstrated. PKC isoforms from the 3 different PKC classes and PKCp directly bound
to centaurin-ai in vitro and the binding site was mapped to the catalytic domain of
PKCp/PKD. In addition, PKCs from the 3 different classes and PKCp have been shown
to phosphorylate centaurin-ai in vitro. The interaction between centaurin-ai and the
nucleolar protein nucleolin has been characterised in the second part of this chapter. The
binding between these two proteins is probably independent of other proteins. However
RNA seems to be necessary for this interaction. The final part of this chapter focused on
the identification of novel potential centaurin-ai binding proteins identified by affinity
chromatography and subsequent mass spectrometry analysis, including many proteins
involved in ribosome biogenesis and RNA processing. This suggests a novel role for
centaurin-ai in these nuclear events.




The aim of this investigation was to identify novel CPI-17 and centaurin-ai
binding partners in order to increase our understanding of the functions of these two
proteins in cells. Affinity chromatography in combination with Western blotting and
mass spectrometry were used for this purpose. Affinity chromatography is a useful
technique to identify potential protein partners very quickly. However, this technique
does not allow one to distinguish between proteins that interact directly with the protein
of interest and proteins which associate with the column through complex formation.
Therefore, it is necessary to confirm potential protein-protein interactions by other
techniques. Furthermore, proteins which are more abundant in the specific tissue lysate
used, are generally the ones to be identified, therefore it is easy to overlook other
potential protein partners. The 1 M NaCl should elute most proteins associated with the
affinity chromatography column, however, to check whether any proteins remained
bound to the column, the glutathione-Sepharose beads can be boiled with sample buffer,
run on a SDS-PAGE gel and stained with Coomassie Blue.
In chapter 3 the identification of novel CPI-17 partners was discussed. PKC
isoforms from all PKC classes were shown to interact with CPI-17, probably via their
CI domain. Furthermore, it was shown that CPI-17 is a substrate for PKCa, s, C, and p.
In the second part of that chapter the characterisation of the interaction between CPI-17
and CKI isoforms was discussed. CPI-17 was shown to bind to all CKI isoforms, via the
kinase domain. However, CPI-17 was not shown to be a significant CKIa substrate but
instead appeared to modulate CKI activity. The final part of chapter 3 focused on the
identification of novel CPI-17 partners by mass spectrometry. A number ofproteins
were shown to associate with the CPI-17 column, including many cytoskeletal proteins
and proteins involved in endocytosis/organelle transport. Therefore, in the next part of
this discussion, evidence will be discussed which supports a novel role ofCPI-17 in
cytoskeletal re-arrangement and vesicular trafficking, by outlining the involvement of
CPI-17 binding partners in these cellular events.
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CPI-17 associates with PKC and is phosphorylated by PKC isoforms from all
classes. Members of the PKC family have been shown to be involved in a large number
of cellular processes, including roles in cytoskeletal re-organisation and vesicular
trafficking: PKC(3 and myristoylated alanine-rich C kinase substrate (MARCKS) have
been shown to be essential for vesicular trafficking in brain neurons (Yang et al.,
2002b); Berglund and co-workers have demonstrated that secretion from neurons is
increased by activation ofPKC and results from an increase in the pool size of releasable
synaptic vesicles (Berglund et al., 2002); in chromaffin cells PKC enhances exocytosis
both by increasing the number of readily releasable vesicles and by shifting vesicles to a
highly Ca2+ sensitive state, enabling exocytosis at sites relatively distant from Ca2+
channels (Yang, et al., 2002); phosphorylation of synaptosome-associated protein
(SNAP) of 25 kDa at Ser-187 by PKC has been shown to potentiate vesicle recruitment
(Nagy, et al., 2002); in brain nerve terminals PKC is involved in a kiss-and-run like
mechanism of synaptic vesicle recycling (Cousin and Robinson, 2001); PKCs has been
shown to associate with actin and myosin IIA, suggesting a role in cell spreading
(England et al., 2002); PKCi/A, has been implicated in microtubule dynamics in the early
secretory pathway by phosphorylating glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Tisdale, 2002) and PKCp has been shown to regulate the fission of cell
surface destined transport carriers from the trans-Golgi network (Liljedahl et al., 2001).
Amongst the many functions of CKI, there is evidence that members of the CKI
family are involved in endocytotic trafficking and neurotransmitter release. CKIa has
been shown to associate with cytosolic vesicles of the trans-Golgi network including
small synaptic vesicles and to be capable ofphosphorylating certain synaptic vesicle-
associated proteins (Gross et al., 1995). In addition, it has been demonstrated that CKI8
is mainly cytoplasmic and particularly enriched within Golgi and ER-Golgi transport
vesicles supporting a role in vesicular trafficking (Milne et al., 2001). A recent report
links CKI to the control of a late step in the endocytotic trafficking of yeast uracil
permease (Marchal et al., 2002).
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Interestingly, it has been shown that CKI phosphorylates the phosphatase 1
modulator subunit (inhibitor-2, from rabbit skeletal muscle), resulting in activation of
the inhibitor and inhibition of the phosphatase (Agostinis et al., 1992). CKI has also
been shown to associate with and phosphorylate the PP1 inhibitor DARPP-32, indicating
that CKI could function as a modulator ofprotein phosphatase I via DARPP-32
(Desdouits et ah, 1995a and b).
The association ofCKI, PKC, numerous cytoskeletal proteins and proteins such
as P-COP, dynactin and AP-2 which are all involved in endocytotic trafficking or
cytoskeletal re-arrangement, with the GST-CPI-17 column, suggests that CPI-17 could
be involved in cytoskeletal re-arrangement, vesicle transport, endocytosis and/or
exocytosis in brain and that its role might not be limited to regulating MLCP activity
during smooth muscle contraction. In support of these findings a role for PP1 in synaptic
transmission, actin cytoskeleton regulation and protein synthesis has been proposed
(reviewed in Cohen, 2002). In addition, Eto and co-workers demonstrated a role for CPI-
17 in microfilament organization and cell spreading via the inhibition ofmyosin
phosphatase (Eto et ah, 2000). Furthermore, it should be pointed out that the
phosphorylation of myosin regulatory chain in smooth and non-muscle cells leads to
contraction, cell migration and metastasis (reviewed in Somlyo and Somlyo, 2000).
Therefore, it is ofmajor importance to investigate proteins which are involved in the
phosphorylation and dephosphorylation process of the myosin regulatory light chain. For
example, inhibition ofMLCP by CPI-17, blocks (at least partially) the
dephosphorylation of the myosin regulatory light chain (Somlyo and Somlyo, 2000).
Therefore, if an inhibitor specific for CPI-17 could be identified it could have potential
implications in controlling cell migration and metastasis ofmalignant cells with highly
important pathological consequences in diseases like cancer. However, one should
remember that inhibition ofMLCP by CPI-17 plays only a partial role in controlling this
phosphatase (Somlyo and Somlyo, 2000). At this point it should be again stressed that
CPI-17 inhibits the myosin-bound PP1 complex as well as the free PP1 catalytic subunit
(PP1-C) in vitro (Eto et al., 1997). Therefore it is possible that CPI-17 could function as
a general PP1-C inhibitor during the above suggested cellular events, leading to an
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enhanced effect of kinases such as PKC and CKI.
Furthermore, in support of data presented here, our laboratory has shown that
CKIa associates with cytoskeletal protein, including actin and tubulin (Dubois et al.,
2002b), indicating that CKIa could also play a role in cytoskeletal re-arrangement, thus
further supporting a possible involvement ofCPI-17 in these cellular events.
In chapter 4 the identification of new centaurin-ai binding partners was
described. This chapter was particularly focused on the interaction of centaurin-ai with
PKC and nucleolin. PKC isoforms from the conventional, novel, atypical PKC
subfamilies and PKC p. were found to directly bind to centaurin-ai in vitro and the
binding site was mapped to the catalytic domain of PKCp. In addition, PKCs from the 3
different classes and PKCp/PKC have been shown to phosphorylate centaurin-ai in
vitro. The interaction between centaurin-ai and the nucleolar protein nucleolin was
discussed in the second part of this chapter. The binding between these two proteins
appeared to be RNA dependent suggesting a role for centaurin-ai in a number of cellular
processes involving RNA molecules e. g. ribosome biogenesis.
The final part of chapter 4 focused on the identification of novel potential
centaurin-ai binding proteins by affinity chromatography and subsequent mass
spectrometry analysis. This analysis identified many proteins, including proteins
involved in ribosome biogenesis, RNA processing, but also in vesicular trafficking.
Thus, in the following discussion a role for centaurin-ai in these cellular events will be
proposed, by examining the involvement of the newly identified centaurin-ai partners in
a number of cellular reactions including ribosome genesis and RNA processing.
Interestingly, novel and atypical PKC isoforms have been shown to be activated
by lipid second messengers including the PI 3-K products PtdIns-(3,4)-P2 and Ptdlns-
(3,4,5)-P3 (reviewed in Toker, 1998). This could link PKCs to the phosphoinositide
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signalling pathway and also provide a link between PKC isoforms and centaurin-ai. As
both centaurin-ai and PKC isoforms localise in the nucleus (as well as plasma
membrane and cytosol) one can speculate that centaurin-ai could be involved in cellular
processes which take place in the nucleus and involve PKC isoforms. However, it should
be noted that both proteins have also been shown to be localised in the cytosol and to the
plasma membrane, which suggests a role for centaurin-ai in signalling events between
the plasma membrane and the nucleus, possibly mediated by phosphatidylinositol
phosphates. Interestingly, nucleolin has been shown to interact with the regulatory
subunit p85 ofPI 3-K, thus linking nucleolin with the phosphatidylinositol pathway
(Barel et al., 2001). Figure 5.1 shows a simplified diagram of how centaurin-ai, CKI,
PKC and nucleolin could all be linked by the phosphatidylinositol pathway. This figure
is modified from Rameh and Cantey (1999).
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Figure 5.1 Phosphatidylinositol pathway linking centaurin-ai, PKC, CKI and
nucleolin.
The phosphatidylinositol lipids are indicated. Nucleolin associates with PI 3-K. CKI is
negatively regulated by PtdIns-(4,5)-P2. Centaurin-ai binds PtdIns-(3,4,5)-P3 and Ins -
(1,3,4,5)-P4. Novel and atypical PKC isoforms are activated by PtdIns-(3,4)-P2 and
PtdIns-(3,4,5)-P3 (indicated by blue arrows). CPI-17 associates with and is
phosphorylated by PKC (indicated by a grey arrow). In addition, CPI-17 binds to CKI
and leads to inhibition ofCKI activity (indicated by a grey bar). PLC hydrolyses Ptdlns-
(4,5)-P2 to produce DAG and Ins-(1,4,5)-P3 (indicated by black arrows). DAG activates
PKC (indicated by a black arrow). PTEN (phosphatase and Tensin homology deleted on
chromosome Ten) dephosphorylates PtdIns-3,4,5-P3.
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In addition, members of the Arf-GAP family are involved in membrane
trafficking and actin cytoskeletal re-arrangement (reviewed in Donaldson, 2000; Jackson
et al., 2000). These are cellular events in which PKC plays a role (reviewed in Keenan
and Kelleher, 1998; Toker 1998) and therefore it is possible that centaurin-ai is also
involved as it is a member of the Arf-GAP family, however with no shown Arf-GAP
activity to date (reviewed in Donaldson, 2000). In support of this possibility, centaurin-
ai has been shown to associate with CKIa (Dubois et al., 2001) which has been
implicated in membrane trafficking (Faundez and Kelly, 2000; Gross et al., 1995) and
actin in vitro phosphorylation (Dubois T., Maciver S.K. and Aitken A., unpublished
results). Furthermore, the P2 and p subunits of the AP-3 complex bind to the GST-
centaurin-ai column. AP complexes are involved in the formation of intracellular
transport vesicles and in the selection of protein cargo for incorporation into the vesicles
(reviewed in Boehm and Bonifacino, 2001). The interaction between AP-3 subunits and
centaurin-ai remains to be confirmed by other methods. Flowever, if confirmed, it
would further support a role for centaurin-ai in membrane trafficking.
In the next part the interaction between centaurin-ai and novel, mainly nuclear
proteins which bind to the GST-centaurin-ai column was discussed. The interaction
between nucleolin and centaurin-ai was selective and probably RNA dependent.
Therefore, the association ofnucleolin with the GST-centaurin-ai column might not be
direct but could be mediated via RNA. A number of additional RNA/DNA binding
proteins were identified in the GST-centaurin-ai column eluate, suggesting that the
interaction between these proteins and the GST-centaurin-ai column could indeed be
mediated via RNA/DNA and that a large protein complex might be present. The
presence of numerous RNA binding proteins on the GST-centaurin-ai column and the
fact that RNA seems to be necessary for the binding between nucleolin and centaurin-ai
suggests that centaurin-ai could be a RNA binding protein involved in nuclear events
such as ribosome biogenesis, mRNA transcription, mRNA splicing and translation.
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However, these potential roles for centaurin-ai in the nucleus remain to be confirmed.
On the other hand it is also possible that centaurin-aj does not bind RNA, but that
association ofRNA with nucleolin changes the conformation of nucleolin allowing it to
bind centaurin-ai as mentioned previously.
The identification of potential novel centaurin-ai binding partners suggests
multiple roles for this protein in different cellular compartments, ranging from
membrane trafficking in the cytosol and plasma membrane to ribosome biogenesis in the
nucleus. The direct interaction between these proteins and centaurin-ai remains to be
confirmed. However, if centaurin-ai proves to be a RNA binding protein, it will clearly
be involved in fundamental cellular processes and further investigation of its potential
roles should be ofmajor interest.
CONCLUSION
In conclusion, novel potential CPI-17 and centaurin-ai binding proteins have
been identified. Most of the newly identified proteins were selective for CPI-17 and
centaurin-ai respectively, suggesting distinct roles for both proteins in cells. However,
some proteins associated with CPI-17 as well as with centaurin-ai, thus the possibility
exists that some of the functions of the two proteins could converge in specific cellular
compartments and both proteins might for instance be involved in vesicular trafficking.




The present study has identified novel CPI-17 and centaurin-ai binding proteins
and has proposed potential roles for these proteins in cells. However, a number of
questions remain to be answered. The association of CPI-17 with CKI and PKC in vivo,
should be subject of further study to provide clues to the physiological relevance of
these interactions. Co-transfection of COS-7 cells with PKC and CPI-17 could be used
to study potential in vivo binding between these two proteins.
Novel potential CPI-17 have been identified, however their identity should first
be confirmed by Western blotting. Once confirmed, one should test whether these
proteins bind directly to CPI-17 or whether their interaction with the GST-CPI-17
column is mediated by protein complexes. This would provide a more direct link to the
potential physiological functions ofCPI-17.
The identification of the kinase which phosphorylates CPI-17 on SI 28 in vivo
could provide more answers in understanding the functions of CPI-17.
It would be ofmajor interest to identify the subcellular localisation ofCPI-17 by
immunofluorescence, and perform co-localisation studies with CKI and PKC,
respectively. It would be interesting to test whether activation of PKC leads to changes
in localisation ofCPI-17, which could provide further clues for potential roles ofCPI-
17. To narrow down the binding site between CPI-17 and PKC or CKI, further deletion
mutants ofCPI-17 could be created and the binding to the two kinases could be tested.
To understand the mechanism ofbinding to CPI-17 it would be of great interest to obtain
the crystal structure ofCPI-17.
To further investigate the role of the association between centaurin-a and PKC,
the in vivo association between centaurin-ai and PKC should be investigated. The
subcellular localisation of centaurin-ai has been investigated, however, it would be
interesting to study whether centaurin-ai co-localises with PKC and if changes in
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localisation of centaurin-a can be observed upon stimulation of PKC.
It would be of great interest to identify the phosphorylation site of centaurin-a i
by PKC, an investigation which is underway. The exact roles of centaurin-ai remain to
be established, however, once identified it would be interesting to see whether
phosphorylation by PKC modulates the functions of this protein. Furthermore, it remains
to be elucidated what role the binding between centaurin-ai and nucleolin has in cells.
An important study would be to determine whether centaurin-ai is a RNA binding
protein, which could for instance be investigated by Northwestern blotting.
As for CPI-17, novel potential centaurin-ai binding proteins have been identified
by mass spectrometry, but their identity remains to be confirmed by Western blotting.
The next study would test whether the proteins associated with centaurin-a i directly or
whether the binding was mediated by protein complexes or via ribonucleoprotein
complexes. Finally, it would be of great importance to study the interaction of centaurin-
ai and these novel binding proteins.
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Abstract
Proteins that interact with 14-3-3 isoforms are
involved in regulation of the cell cycle, intra¬
cellular trafficking/targeting, signal transduction,
cytoskeletal structure and transcription. Recent
novel roles for 14-3-3 isoforms include nuclear
trafficking the direct interaction with cruciform
DNA and with a number of receptors, small G-
proteins and their regulators. Recent findings
also show that the mechanism of interaction is also
more complex than the initial finding of the novel
phosphoserine /threoninemotif. Non-phosphoryl-
ated binding motifs that can also be of high
affinity may show a more isoform-depen dent
interaction and binding of a protein through two
distinct binding motifs to a dimeric 14-3-3 may
also be essential for full interaction. Phos¬
phorylation of specific 14-3-3 isoforms can also
regulate interactions. In many cases, they show a
distinct preference for a particular isoform(s) of
14-3-3. A specific repertoire of dimer formation
may influence which of the 14-3-3-interacti ng
proteins could be brought together. Mammalian
and yeast 14-3-3 isoforms show a preference for
dimerization with specific partners in vivo.
Introduction
The name 14-3-3 was given to an abundant
mammalian brain protein family due to its par¬
ticular migration pattern on two-dimensional
Key words: phosphorylation, protein-interaction motif, signalling.
Abbreviations used: PKC, protein kinase C; AANAT, arylalkyl-
amine N-acetyltransferase.
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DEAE-cellulose chromatography and starch gel
electrophoresis [1]. The first function ascribed to
this family of proteins was activation of tyrosine
and tryptophan hydroxylases, the rate-limiting
enzymes involved in catecholamine and sero¬
tonin biosynthesis, essential for the synthesis
of dopamine and other neurotransmitters [2].
Subsequently we showed that 14-3-3 could regu¬
late (inhibit) activity of protein kinase C (PKC)
[3,4]. 14-3-3 was then implicated as a novel type
of chaperone protein that modulates interactions
between components of signal-transduction path¬
ways [5]. A large number of publications began to
appear in the mid-1990s showing that 14-3-3
proteins could interact with a range of protein
kinases, phosphatases and other signalling pro¬
teins. This implied a role for the 14-3-3 family of
proteins to mediate the formation of protein
complexes involved in signal transduction, traf¬
ficking and secretion, perhaps to bind to different
signalling proteins on each subunit of the dimer, as
a novel type of 'adapter protein'. It is now clear
that 14-3-3 isoforms are involved in many other
cell functions and this is only one of their many
roles. A number of intrinsic enzymic activities
have been ascribed to 14-3-3, but none have been
substantiated in the literature.
The five major mammalian brain 14-3-3
isoforms are named (X-rj in order of their respective
elution positions on HPLC [2,6] and we showed
that a and S are the phosphoforms of /? and f
respectively [7]. Two other isoforms, r and <7, are
expressed in T-cells and epithelial cells respect¬
ively, although the former is also widely expressed
in other tissues, including brain.
Muslin and co-workers [8] showed that tar¬
get-protein phosphorylation is important for
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14-3-3 binding via a novel phosphoserine se¬
quence motif. It has subsequently been shown
that while many 14-3-3-interacti ng proteins con¬
tain this motif, many others do not, indicating
that additional sequences and modes of inter¬
action/contacts also allow 14-3-3 binding. Co-
crystal structures with non-phosphorylated motifs
suggest that the same binding pocket or 'groove'
is involved [9]. Not only can phosphorylation of
the motif be an important regulatory component
of the interaction but dephosphorylation can also
lead to creation of an interaction motif. Waterman
et al. [10] showed that ionizing radiation led to
dephosphorylation of Ser-376 in the sequence
KGQS376TS378RH/G in the p53 tumour-
suppressor protein (see Table 1), creating a con¬
sensus binding site for 14-3-3 proteins which led
to association of p53 with 14-3-3. This in turn
increased the affinity of p53 for sequence-specific
DNA.
i 4-3-3 isoforms and sequence
conservation
The 14-3-3 family is highly conserved over a wide
range of mammalian species, where the individual
isoforms /?, e, tj, y, r (also called 9), £ and a are
either identical or contain a few conservative
substitutions. Homologues of 14-3-3 proteins
have also been found in a broad range of eukaryotic
organisms and are probably ubiquitous (reviewed
in [11,12]). In every organism studied, at least two
isoforms of 14-3-3 have been observed.
The chromosomal location of 14-3-3 isoforms
has been deduced from the human genome data¬
base. The haemopoietic e sequence variant, ...
VELDVE ..., where the underlined D replaces T
in this most highly conserved 14-3-3, is on
chromosome 2 in the current draft genome se¬
quence. No variants in the amino acid sequence of
e are otherwise known in any mammalian species.
We have identified this haemopoietic tissue e
variant in human, ovine, bovine and rodent
e 14-3-3, in the same individual animal ([13] and
A. Aitken, A. Toker and Y. Soneji, unpublished
results). This form may also be present at low
levels in keratinocytes. Structure analysis of the
variation on the outer surface of e 14-3-3 suggests
this may have an important effect on interaction
with other proteins. The most striking finding in
the genome analysis is a large number of sequences
matching the £ isoform; at least nine protein
translations in a number of chromosomes, most of
which are presumably pseudogenes.
14-3-3 proteins are quite distinct in sequence
and structural topology from other protein fami¬
lies in the database. Exceptions may be tertiary
structure similarity with tetratricopeptide repeat
('TPR') helices [14] and primary structure
similarity with a-synuclein in particular regions
[15].
14-3-3 dimers, binding motifs and
their interactions
Crystal structures of both the T and f isoforms of
14-3-3 [16,17] show that they are highly helical,
dimeric proteins. Each monomer is composed of
nine anti-parallel a-helices, organized into an
N-terminal and a C-terminal domain. The dimer
creates a large negatively charged channel. Those
regions of the 14-3-3 protein which are invariant
throughout all the isoforms are mainly found
lining the interior of this channel, while the
variable residues are located on the surface of
the protein.
This channel would recognize common
features of target proteins, so the specificity of
interaction of 14-3-3 isoforms with diverse tar¬
get proteins may involve the outer surface of the
protein. The N-terminal residues of all 14-3-3
homologues are variable, and as these residues are
important for dimer formation there may be a
limit to the number of possible homo- or hetero-
dimer combinations. Residues involved in dimer-
ization are 5-21 in the A-helix of one subunit and
residues 58-89 of the C and D helices of the other
(see Figure 1).
After the demonstration by Muslin and co¬
workers [8] that a novel phosphoserine-containing
motif initially identified in Raf kinase was im¬
portant for interaction, the motif was further
refined into two subtypes and the structural details
of the interaction with 14-3-3 were elucidated
[18,19], The binding site for the phosphoserine
consists of a basic pocket composed of Lys-49,
Arg-56 and Arg-127, as well as Tyr-128, within
the C and E helices (see the underlined residues in
Figure 1).
The proline residues are in different confor¬
mations in the two classes of phosphopeptide con¬
sensus motif. In the mode 1 phosphopeptide [18]
the proline is in a ds-conformation while in the
mode 2 phosphopeptide [19] the proline has a
frarcr-conformation. Nevertheless, both proline
conformations result in a sharp alteration in chain
direction, allowing the peptide to exit the binding
groove. This is also clear in the recent deter-
4 2002 Biochemical Society 354
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mination of the arylalkylami ne N-acetyltrans-
ferase (AANAT)/14-3-3 co-crystal structure [20].
The ligand-binding groove runs in opposite
directions in the two subunits of the dimer and a
highly stable and isoform-specific interaction may
result, distinct from the involvement of 14-3-3
dimer in binding two distinct target proteins
together in a chaperone-like role.
Many of the 14-3-3-interacti ng proteins con¬
tain either one or both of two consensus motifs,
R(S/Ar)( + )pSXP and RX(Ar)( + )pSXP [18]
where pS is phosphoserine, Ar is an aromatic
residue (particularly Tyr or Phe in mode 2) and +
is a basic amino acid. Residue X following the
phosphoserine is commonly Leu, Glu, Ala or Met.
The phosphorylated residue may also be a thre¬
onine. Although most motifs contain Ser some
well-characterized ones, e.g. AANAT, have Thr
and there seem to be no structural reasons why this
residue could not fit equally well into the cleft.
Other motifs that are listed in Table 1 may be
categorized as RSXpS motifs, RX1_2SX2_3S motifs
and non-phosphorylated motifs.
When phosphopeptide libraries were tested
on six of the 14-3-3 isoforms and the yeast BMH1
and BMH2, all the isoforms were found to have
very similar preferences for the individual residues
within each consensus motif. There are seven
mammalian isoforms of 14-3-3 that are all highly
conserved and one supposes that each isoform
would have a distinct function or subset of func¬
tions. For example, several isoforms of 14-3-3
are involved in the G2/M cell-cycle checkpoint:
14-3-3 a is responsible for sequestering the Cdc2-
cyclin B1 complex in the cytoplasm, while the ft
and 8 isoforms bind Cdc25C [21].
The complete sequence conservation in the
observed ligand-binding regions of 14-3-3 would
support the hypothesis that there may be little
isoform specificity in the interaction between
14-3-3 and protein ligands; therefore many iso¬
form-specific functions of 14-3-3 observed in vivo
may result either from subcellular localization or
transcriptional regulation of particular isotypes
rather than from inherent differences in their
ability to bind to particular ligands. However,
the finding that phosphorylated 14-3-3 negatively
regulates the interaction with the Raf N-terminal
domain [22] suggests that additional interactions
may occur on the outer surface of 14-3-3 or its
dimer. A number of publications in the literature
confirm recently that for full functionality in at
least some cases the dimer of 14-3-3 is essential
[23],
Figure i
Human £ 14-3-3 phosphorylation sites and motifs
The positions ofthe known phosphorylation sites on various isoforms are shown in large type and the phosphopeptide-binding residues are
underlined. Ac denotes the N-terminus of the monomer (this is N-acetylmethionine, residue I in most isoforms). The numbering
is that of the alignment of the correctly processed longer members of the family (i.e. e and longer form of /? that commence at
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Recent findings relating to the structures and
mechanism of interaction of 14-3-3 with its part¬
ners strengthen the evidence that interaction is
not simply mediated by the canonical phospho-
serine-containing motif. Some well-characterized
interacting proteins such as Raf kinase have been
shown to have additional binding site(s) for 14-3-3
on their cysteine-rich regions. Bcr and Ksr also
bind via serine-rich regions. The interaction be¬
tween 14-3-3 and Raf is complex and the exact role
of 14-3-3 remains controversial. The fact that Raf
contains a third interaction domain in the cys¬
teine-rich region would add further complexity.
This could also confer isoform specificity. It has
also been suggested that due to the very common
occurrence of two binding sites or motifs on one
polypeptide chain of an interacting protein, the
synergy between the two may also lead to isoform
preference of interaction. Interaction motifs that
are near the optimum, as determined by surface
plasmon resonance spectroscopy [18], show no
specificity but less optimal ones do. The binding
of a protein in both (lower) affinity sites may
greatly increase target-protein specificity of rec¬
ognition and affinity. This suggests a dual site-
recognition mechanism in which, for example, a
14-3-3 ( dimer interacts with both glycoprotein I
(GPI)ba(unph osphorylated motif) and GPIb/f
(with a phosphorylation-dependent binding site),
resulting in high-affinity binding (see Table 1).
The 14-3-3 phosphoserine-binding motif is
also a common feature in plant and other eukary-
otic species [24]. The plant plasma membrane
H+-ATPase motif, QQYpT947V-COOH, is note¬
worthy in that it has so far been found only in
plant proteins [25].
Around 100 proteins have been shown to
interact with 14-3-3. The well-characterized
14-3-3-interacting proteins and the motif(s) that
have been identified are listed in Table 1. Some
target proteins contain more than one motif that
has been shown to be involved in 14-3-3 binding
and they are listed only once. In many cases the
actual residue numbers will be different in mam¬
malian species other than the one(s) that were
studied, although the site will be equivalent; for
example, Ser-178 is the most important in mouse
HDAC7. The equivalent residues in the human
sequence are Ser-156, Ser-318 and Ser-446 in the
motif RAQS446SP.
In addition to those listed in Table 1, mam¬
malian proteins that have been shown to interact
include the following, (a) Protein kinases; CKla,
Chkl kinase, MEKK1, -2 and -3, type I PKC
(a,/?,y), PKCe, PKC0 and PKUa. (b) Phos¬
phatase Cdc25B ; see also (g). (c) Receptors; a2-
adrenergic, y-aminobutyric acid (GABA) (B),
glucocorticoid, adrenergic, (X and /? oestrogen,
nuclear receptor co-repressor RIP140 and small
G-proteins and their regulators, Rad and Rem.
(d) Proteins involved in apoptosis including
a-synuclein and the neurotrophin receptor
(p75NTR)-associated cell death executor NADE.
(e) Adaptor/scaffolding molecules pl30Cas, Grb2
and She (p66). (f) Transcription factors and other
proteins involved in transcriptional control,
TATA box-binding proteins TBP and TFIIB,
histone acetyltransferase 1, Msn2p and 4p, other
forkhead family members, the co-activator YAP
(Yes-associated protein), myocyte enhancer bind¬
ing factor 2 (MEF2D) proteins in the MADS
[MCM1, AGAMOUS, DEFICIENS and SRF
(where SRF is serum response factor)] box family
of transcription factors, FKBP12-rapamycin-
associated protein (FRAP), primary response
gene BRF1, PHDfinger-HD, topoisomerase I la,
initiation factor EIF2a, integrin CD18 chain,
TLX-2 homeodomain transcription factor and
histones. (g) Enzymes and others including tryp¬
tophan hydroxylase, catalytic subunit (pi 10) of
phosphoinositide 3-kinase, calmodulin, mito¬
chondrial uncoupling protein (UCP) and CMP-
NeuAc:GMl a-2,3-sialyltransferase; structural
and cytoskeletal proteins including keratin K8,
KiflC, Tau and vimentin; proteins involved in
cell-cycle control including cell-cycle phosphat¬
ase Cdc25B and telomerase catalytic subunit
(TERT).
14-3-3-binding motif kinases
Kinases that have been shown to phosphorylate
the phosphoserine or threonine in the phos-
phorylated binding motifs include protein kinase
B (also called Akt), cAMP-dependent protein
kinase, p21-activated protein kinase 1 (PAK), Ras-
mitogen-activated protein kinase (RSK1, also
known as MAPKAP-K1), MAP kinase-activated
protein kinase-2 (MAPKAP-K2) and PKC, as
would be expected from their substrate specificity.
In most cases the physiological kinases(s) have not
been demonstrated but those that co-localize in
the cell would be prime candidates; e.g. Cdc25C
has been reported to be phosphorylated by a
number of kinases such as Cds-1 /Chk2, Chkl
and Cdc25C-associated kinase 1 (C-TAK1). The
first two are nuclear-located. In addition, Ca2+-
calmodulin-depend ent kinase II (CAM kinase II),
p90 ribosomal S6K, protein kinase D (also known
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as PKC/i) and casein kinase II (CKII) have also
been implicated in phosphorylation of the motifs.
14-3-3 isoform phosphorylation
Our sequence analysis of brain 14-3-3 separated
by reversed-phase HPLC failed to show any
differences between a and /? on the one hand and <5
and f on the other [26], We subsequently showed
by mass spectrometri c analysis that a and S were
the phosphorylated forms of /? and ( respectively
and we identified the site as Ser-185 [7] using the
numbering of the generic mammalian 14-3-3.
The acetylation at the N-terminus of 14-3-3 iso-
forms, with or without removal of the initiator
methionine, has been verified by mass spectro¬
metry for all isoforms except a [26].
/? 14-3-3 is expressed at alternate start sites,
40% of which is co-translationally processed,
resulting in an additional threonine residue at the
N-terminus. There is no evidence that this would
affect dimer formation.
This phosphorylation of Ser-185 may not
'turnover', as high levels of the phospho-forms
are recovered without precautions taken to inhibit
phosphatases. Although the e and a isoforms
contain a serine residue in equivalent positions
(SPDR and SPEE respectively), they are not
known to be phosphorylated at this site. The
E isoform is particularly abundant in brain;
therefore it would have been identified by mass
spectrometri c analysis when we characterized the
a and S isoforms. We have found no evidence for a
and S phospho-forms in a wide range of tissue
types and cell lines other than brain. Inspection of
the many two-dimensional gel electrophoreto-
grams that are in the literature lend support to the
idea that this phosphorylation may be specific to
brain 14-3-3.
We identified casein kinase la (CKIa) as
the brain kinase that phosphorylated 14-3-3 f and
t isoforms on Thr- and Ser-233 respectively.
14-3-3 C is phosphorylated on Thr-233 in HEK-
293 cells [22]. Residue 233 is located within a
region involved in the association of 14-3-3 with
target proteins. In vivo phosphorylation of 14-3-3
( at this site negatively regulates its binding to
c-Raf, and may be important in Raf-mediated sig¬
nal transduction. We have also shown (S. Mackie,
T. Dubois and A. Aitken, unpublished work)
that CKIa binds to 14-3-3 isoforms in vitro.
Some isoforms of 14-3-3 have been shown to
be phosphorylated by a sphingosine-depen dent
kinase [27] and PKB/Akt [27a]. The site these
authors determined, Ser-59, is masked in the
dimer interface [16], If phosphorylation occurs,
it could be a mechanism for regulation of dimer
formation. However, it might be difficult under
physiological conditions for a kinase to gain
access, since the 14-3-3 dimer is very stable under
normal conditions (see Figure 2). Our results
have shown that while brain PKC did phosphoryl-
ate some 14-3-3 isoforms on an adjacent residue,
Ser-64, the phosphorylation did not appear to
occur to any physiologically significant extent [6],
although there is an excellent motif in this region.
In contrast, in our deletion mutants that exposed
1
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this site [28] there are very high levels of phos¬
phorylation. We also showed that large synthetic
peptides are also stoichiometrically phosphoryl-
ated at Ser-59 and there were low levels of
phosphorylation at Ser-64 [29].
Van Der Hoeven et al. [30] showed that
14-3-3 /? and z were substrates for PKC-f (sites
not determined) and Autieri and Carbone [31]
showed phosphorylation of human 14-3-3 y by
PKC isoforms on undetermined site(s). However,
their cDNA sequence was quite different from
previous y sequences (including that in the human
genome) and included changes in residues known
to be invariant.
Reuther and co-workers [32] showed that
14-3-3 r interacted with c-Bcr and with Bcr/Abl.
Their results indicated that 14-3-3 r was a sub¬
strate for the Bcr serine/threonine kinase and was
also phosphorylated on tyrosine by Brc/Abl but
not by c-Abl. On attempting to identify this site(s)
of phosphorylation on these and other 14-3-3
isoforms we have evidence (S. Clokie, S. Mackie
and A. Aitken, unpublished work) that the phos¬
phorylation is due to a co-immunoprecipitat ing
kinase at a known site of phosphorylation.
Dimerization of mammalian and yeast
14-3-3 isoforms in vivo
In many cases, interaction between 14-3-3 and
other signalling proteins shows a distinct pref¬
erence for particular isoform(s) of 14-3-3. The
existence of particular combinations of hetero-
dimeric 14-3-3 isoforms in vivo has important
implications for function as an adaptor protein in
signalling. This may allow the interaction between
signalling proteins that do not directly associate
with each other. Bcr and Raf, for example, do not
associate directly but form a complex mediated
through 14-3-3 [33]. /? and z 14-3-3 associate with
Bcr while the f and /? 14-3-3 isoforms interact
with Raf. We have shown that isoforms of 14-3-3
can form homo- and hetero-dimers in vivo and in
vitro and a specific repertoire of dimer formation
may influence which of the 14-3-3-interacti ng
proteins could in turn be brought together [34],
Since the residues involved in dimerization ex¬
hibit some isoform variation, this may limit the
possible homo- or hetero-dimer combinations and
may confer specificity on 14-3-3 function.
The dimers of 14-3-3 are stable and do not
readily exchange unless they are denatured and
renatured [34]. It should be noted that a single
recombinant 14-3-3 isoform will form homo-
dimers regardless of the actual preference in vivo
since a monomeric form would be thermo-
dynamically unstable. 14-3-3 proteins also have a
slow rate of turnover.
We analysed the pattern of dimer formation
for two of the most abundant isoforms of 14-3-3 e
and y, following their stable expression in the
neuronal pheochromocy toma PC12 cell line
(M. Chaudhri and A. Aitken, unpublished work).
This revealed a distinct preference for particular
dimer combinations that is largely independent of
cellular conditions, y 14-3-3 formed homo-
and hetero-dimers, mainly with e. In turn, the
£ isoform formed heterodimers with all the 14-3-3
isoforms tested (/?, r], y and £)> but no homodimers
were detected. This suggests that the observed
dimer combinations may be due to structural
properties of the dimer interface of the individual
isoforms. This pattern may be generally applic¬
able since the dimerization patterns of y and e
isoforms in transiently transfected COS cells were
also similar overall. The pattern of dimer forma¬
tion was not simply a reflection of the amounts of
available 14-3-3 isoform present in the cell or in a
particular subcellular location. Analysis of the two
14-3-3 homologues, BMH1 and BMH2, from the
budding yeast Saccharomyces cerevisiae also re¬
vealed that between 65 and 80 % are heterodimers
(M. Chaudhri and A. Aitken, unpublished work).
Homo- and hetero-dimers of 14-3-3 proteins
may play different roles. It is possible that homo¬
dimers of a particular isoform will function to
sequester or chaperone a protein, while hetero¬
dimers are more likely to act as adaptor proteins,
modulating the interaction of two distinct pro¬
teins, each ofwhich specifically associates with one
of the isoforms of the heterodimer. The y isoform
may be more involved in sequestration functions,
while the e isoform is more likely to function as an
adaptor protein in signal-transduction events.
Indeed, y 14-3-3 has been found to be the major
isoform in Golgi and is implicated in secretion and
protein trafficking while the £ isoform is more
generally found in association with proteins in¬
volved in signal transduction.
In conclusion, association with 14-3-3 iso¬
forms has led to the activation or stabilization of
some proteins, and the inactivation of others, while
for many proteins 14-3-3 isoforms have played an
organizational role as a 'scaffold '. In the complex
multistep process of Raf activation, 14-3-3 appears
to play several of these roles. It is likely that its
ability to form homo- and various heterodimeric
combinations is crucial and the analysis of the
exact combinations of homo- and hetero-dimers of
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14-3-3 isoforms that are present within cell com¬
partments) and that are involved in interactions
with particular proteins will be important.
The work in the authors' laboratory was supported by the Medical
Research Council.
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Survival-promoting functions of 14-3-3 proteins
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Abstract
The 14-3-3 proteins are a family of phospho-
serine/phosphothreonine-binding molecules that
control the function of a wide array of cellular
proteins. We suggest that one function of 14-3-3 is
to support cell survival. 14-3-3 proteins promote
survival in part by antagonizing the activity of
associated proapoptotic proteins, including Bad
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and apoptosis signal-regulating kinase 1 (ASK1).
Indeed, expression of 14-3-3 inhibitor peptides in
cells is sufficient to induce apoptosis. Inter¬
estingly, these 14-3-3 antagonist peptides can
sensitize cells for effective killing by anticancer
agents such as cisplatin. Thus, 14-3-3 may be part
of the cellular machinery that maintains cell
survival, and targeting 14-3-3-ligand interactions
may be a useful strategy to enhance the efficacy of
conventional anticancer agents.
Introduction
14-3-3 proteins can bind a variety of proteins that
are critical mediators of intracellular signalling
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of Phosphatidylinositol 3,4,5-Trisphosphate-binding Proteins*
Received for publication, November 2, 2000, and in revised form, February 20, 2001
Published, JBC Papers in Press, March 2, 2001, DOI 10.1074/jbc.M010005200
Thierry Dubois,""6 Preeti Kerai,' Eva Zemlickova," Steven Howell," Trevor R. Jackson,d
Kanamarlapudi Venkateswarlu,'*' Peter J. Cullen,Anne B. Theibert,' Louise Larose/
Peter J. Roach,6"' and Alastair Aitken"
From the "University ofEdinburgh, Division of Biomedical and Clinical Laboratory Sciences, Hugh Robson Building,
George Square, Edinburgh EH8 9XD, the "Division ofProtein Structure, National Institute for Medical Research, The
Ridgeway, Mill Hill, London NW7 1AA, the dRoyal Free and University College Medical School, Royal Free Campus,
London NW3 2PF, the "Department ofPharmacology and the 8Department of Biochemistry, School ofMedical Sciences,
University ofBristol, University Walk, Bristol BS8 1TD, United Kingdom, the 'University ofAlabama at Birmingham,
Neurobiology Research Center and the Department of Cell Biology, Birmingham, Alabama 35294-0021, the Polypeptide
Laboratory, Department of Experimental Medecine, McGill University, Montreal, Quebec H3A 2B2, Canada, and the
hDepartment of Biochemistry and Molecular Biology, Indiana University School ofMedicine,
Indianapolis, Indiana 46202-5122
Mammalian casein kinases I (CKI) belong to a family
of serine/threonine protein kinases involved in diverse
cellular processes including cell cycle progression,
membrane trafficking, circadian rhythms, and Wnt sig¬
naling. Here we show that CKIa co-purifies with cen¬
taurin-a, in brain and that they interact in vitro and
form a complex in cells. In addition, we show that the
association is direct and occurs through the kinase do¬
main of CKI within a loop comprising residues 217-233.
These residues are well conserved in all members of the
CKI family, and we show that centaurin-a, associates in
vitro with all mammalian CKI isoforms. To date, CKIa
represents the first protein partner identified for cen-
taurin-a,. However, our data suggest that centaurin-a,
is not a substrate for CKIa and has no effect on CKIa
activity. Centaurin-a, has been identified as a phos¬
phatidylinositol 3,4,5-trisphosphate-binding protein.
Centaurin-a, contains a cysteine-rich domain that is
shared by members of a newly identified family ofADP-
ribosylation factor guanosine trisphosphatase-activat-
ing proteins. These proteins are involved in membrane
trafficking and actin cytoskeleton rearrangement, thus
supporting a role for CKIa in these biological events.
The casein kinase I (CKI)1 family of serine/threonine kinases
is ubiquitously expressed in a range of eukaryotes including
yeast and humans as well as in plants (reviewed in Ref. 1).
Seven isoforms from distinct genes are expressed in mammals
(CKI a, p, yl, yl, y3, S, and e), four in Saccharomyces cerevisiae
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tion factor; GAP, guanosine trisphosphatase-activating protein; PH,
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(Hrr25, Yckl, Yck2, and Yck3), and five in Schizosaccharomy-
cespombe (Ckil, Cki2, Cki3, Hhpl, and Hhp2). The CKI family
is characterized by a conserved core kinase domain and vari¬
able amino- and carboxyl-terminal tails.
Yeast CKI isoforms are involved in DNA repair (2-4). Re¬
cently, many reports (5-12) indicate that they also play a role
in cytokinesis and in vesicle trafficking especially in endocyto-
sis. The functions of the mammalian isoforms are less well
understood, but based on high homology with their yeast coun¬
terparts, they may have similar biological functions. CKIe and
CKIS play a role in the regulation of p53 (13,14). CKIe has also
been implicated in circadian rhythms in Drosophila (15, 16)
and in development by transducing the Wnt pathway (17, 18).
CKI-y might play a role in cytokinesis and/or in membrane
trafficking (19). CKIa has been shown to play a role in cell cycle
progression (20) and in membrane trafficking (21, 22). Re¬
cently, CKIs have been shown to be implicated in regulating
the nucleocytoplasmic localization of some substrates (23, 24).
Several substrates, including nuclear and cytosolic proteins
and membrane receptors, have been reported to be phosphoryl-
ated at least in vitro by a CKI activity (reviewed in Ref. 1). CKI
isoforms are thought to be constitutively active and second
messenger-independent. However, it has been shown that
CKIS and CKIe are regulated by autophosphorylation (25-28).
CKIa is also autophosphorylated, but whether this has an
effect on its activity is not well defined. CKIa is negatively
regulated by PtdIns(4,5)P2 (21). Moreover, CKI isoforms have
been reported to phosphorylate some of their substrates only if
they were previously phosphorylated by another kinase two or
three residues carboxyl-terminal to the CKI phosphorylation
site. In this way, the effect of CKI is dependent on other
kinases. CKIa is present in cells in different spliced forms (1,
29) exhibiting different substrate specificities and differences
in their protein-protein interactions.
Although the yeast CKI isoforms have been well characterized,
the functions of the mammalian CKI isoforms are much less
known. Therefore, the identification of mammalian CKI sub¬
strates and CKI-binding proteins should help to clarify their
cellular function(s). CKIa interacts with NF-AT4 (23), the paired
helical filaments (30), G-protein-coupled receptors (31), and the
AP-3 complex (22). CKIa also forms a complex with certain splic¬
ing factors but these interactions may be indirect (32).
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In the present study, we have shown that CKIa interacts
with centaurm-a^. Centaurin-aj is a PtdIns(3,4,5)P3-binding
protein containing two PH domains (33-35) and a zinc finger
motif similar to the one found in a newly identified family of
ADP-ribosylation factor (ARF) guanosine trisphosphatase-acti-
vating proteins (GAP) (reviewed in Refs. 36-39). The yeast
protein that shows the highest homology to centaurm-o^, Gcsl,
also contains a zinc finger motif that confers its ARF-GAP
activity (40). Members of this family are involved in membrane
trafficking and in actin cytoskeleton rearrangement. Our re¬
sults suggest that CKIa plays a role in membrane trafficking
and/or actin cytoskeleton rearrangement, thus confirming pre¬
vious reports (21, 22).
MATERIALS AND METHODS
cDNA Cloning—The cDNA corresponding to rabbit muscle CKIa was
originally cloned in the pET 3 vector (Novagen) (41). CKIa cDNA from
this clone was amplified by the polymerase chain reaction (PCR) using
two oligonucleotides (5'-gggcatatggcgagcagcag-cggctccaagg-3') and (5'-
gggggatccttagaaacctgtgggggtttgggc-3') in order to create a 5' NdeI site
and a 3' BamUl site (both are underlined in sequences). Amplified
cDNA was inserted in a pET-16b vector (Novagen) at Ndel/BamHl
restriction sites to express CKIa: as a histidine-tagged protein. The
CKIa cDNA was inserted in a pcDNA3 vector (Invitrogen) from the
original clone after being amplified by PCR using two oligonucleotides
(5'-gggggatccgccaccatggcctacccctacgacgtgcccgactacgcccccgcgagca-
gcagcggctcc-3') and (5' -gcggcggccgcttagaaacctgtgggggtttgggc-3') in
order to create a 5' BamHI site and a 3' NotI site (both are underlined
in sequences). The Kozak sequence is shown in italics and the HA-
tagged sequence in bold. CKIa mutants were generated by PCR and
cloned in the pSP72 vector (Promega) at the EcoRI and BamHl sites
downstream of the T7 promoter. The oligonucleotides (the EcoRl and




gatgtcc-3'; 5'-gggggatccttaggtcctgaaaaggatgcgg-3'; 5 '-gggggatccttagaa-
acctgtgggggtttgggc-3'. The construction of GST-centaurin-ai has been
described previously (42). Centaurin-ai cDNA from that vector was
recovered after digestion with EcoRI and Xbal and subcloned in a
FLAG-cmv2 vector. HA-tagged CKIa(D136N) in pcDNA3 is a gift from
F. McKeon (23). FLAG-centaurin-a is from Trevor R. Jackson.
For the experiment performed in Fig. 7B, pET3c CKIa (41), pET8c
CKIS (25), pET8c CKI5 A317 (25), pET8c CKIyl (19), pSV2Zeo CKIy2
(from Louise Larose), pET8c CKIy3 (19), and pSP72 CKIe were used.
pSP72 CKIe construct was subcloned using human CKIe plasmid
(pV405) provided by Dr. David Virshup (27). CKIe cDNA was amplified
by PCR using two oligonucleotides (5'-ggaagatctatggagctacgtgtggg-
gaacaag-3') and (5'-ggaaaagctttcacttcccgagatggtcaaatgg-3') in order to
create a 5' Bglll site and a 3' HindlW site and inserted into pSP72
vector.
Identification ofCentaurin-a, by Mass Spectrometry—After the final
chromatography step during the purification of CKIa as a 14-3-3 kinase
from brain (Sephacryl S-100 gel exclusion), fractions containing this
kinase activity were pooled and loaded on 12.5% SDS-PAGE (43). Gels
were stained for 5-10 min and then destained for the minimum time.
The 45-kDa band was excised and subjected to trypsin (L-l-tosylamido-
2-phenylethyl chloromethyl ketone-treated, Worthington) digestion.
The extracts were then dried in a Speedvac vacuum centrifuge and
made up to the injection volume with water for on-line liquid chroma¬
tography mass spectrometry. Electrospray mass spectrometry of in-gel
digested protein was carried out as described (43), and the peptide map
data were used in the PeptideSearch program.
Recombinant Protein Purification—Escherichia coli carrying GST-
centaurin-a!, GST-centaurin-a, or histidine-tagged CKIa plasmid were
grown overnight at 37 °C in Liquid Broth medium containing 50 /xg/ml
ampicillin and were diluted the following day (1/10) in the same me¬
dium. Culture was then continued until the absorbance (600 nm) of the
bacterial growth reached 0.6. Expression of the tagged proteins was
induced with 0.5 mM isopropyl /3-D-thiogalactopyranoside for 3-5 h at
25 °C. The fusion proteins were purified by affinity chromatography on
glutathione-Sepharose beads or nickel columns (Amersham Pharmacia





Fig. 1. Co-purification of a 45-kDa protein with CKIa. CKIa was
purified from pig brain after four chromatography steps (43). The frac¬
tions containing CKI activity were electrophoresed on 10% SDS-PAGE
{lane 2), and the gel was stained with Coomassie Blue. CKIa was
previously identified by mass spectrometry (43). A total of seven other
proteins co-purified with CKIa (indicated by arrows), suggesting that
they may form protein complex(es). The major co-purifying band mi¬
grates at 45 kDa. Molecular mass standards {lane 1) are shown in kDa.
AKTA purifier (Amersham Pharmacia Biotech) and stored in 20 mM Tris,
pH 7.4, 1 mM EDTA, 1 mM EGTA, 100 mM NaCl, and 50% glycerol at
-20 °C. Recombinant 14-3-3 £ was purified as described previously (43).
In Vitro binding between Purified CKIa and Members of the Cen-
taurin-a Family—GST, GST-centaurin-a1} or GST-centaurin-a (0.2 /xM
final concentration) were incubated with histidine-tagged CKIa in bind¬
ing buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 10% glycerol, 1 mM DTT,
0.1% Nonidet P-40) for 2 h at 4 °C. Glutathione-Sepharose beads were
added and incubated for a further 1 h. Bead precipitates were then
washed 4 times with binding buffer and once with kinase buffer (50 mM
Hepes, pH 7.0, 10 mM MgCl2, 100 mM NaCl, 0.1% Nonidet P-40, 1 mM
DTT, and 100 /xM cold ATP). The washed beads were incubated with
kinase buffer (without NaCl and 0.1% Nonidet P-40) containing 40 pM
of a CKI-specific phosphopeptide substrate (New England Biolabs) and
[y-32P]ATP (2 /xCi/point) (Amersham Pharmacia Biotech) in a final
volume of 30 pi. Reactions were performed at room temperature for 30
min. After centrifugation, 20 /xl was spotted on P81 paper squares
(Whatman) and washed four times with 1% phosphoric acid. Radioac¬
tivity retained on the papers was quantified by liquid scintillation
counting.
In Vitro Kinase Assays—One pg of purified GST, GST-centaurin-a,
GST-centaurm-a^ and GST-14-3-3 £ were subjected to an in vitro ki¬
nase assay using purified histidine-tagged CKIa as described previ¬
ously (43). Proteins were analyzed on 10% SDS-PAGE. Gels were
stained with Coomassie Blue, dried, and autoradiographed. To study
the effect of centaurin-a! on CKIa activity, different amounts of cen-
taurin-a! (0.1, 1, or 10 pg) were preincubated with histidine-tagged
CKIa for 15 min at room temperature. The reaction was initiated by the
addition of ATP (50 pM final, 1 /xCi/point) and 14-3-3 £ or GST-14-3-3 £
or phosvitin (0.3 /xg/point) as CKI substrates. After 30 min at room
temperature, the reactions were stopped and analyzed on 10% SDS-
PAGE. Gels were stained with Coomassie Blue, dried, and
autoradiographed.
In Vitro Transcription and Translation—CKIa and 14-3-3 £ sub¬
cloned in pcDNA3 were expressed in vitro using a T7 TNT-coupled
transcription/translation reticulocyte lysate assay (Promega Corp.,
Madison, WI). The reactions (50 /xl) were performed following the man¬
ufacturer's instructions using [35S]methionine (Amersham Pharmacia
Biotech) for 90 min at 30 °C. The reactions were then diluted 4-fold with
binding buffer (containing 0.1 or 1% Nonidet P-40 as indicated in figure
legends) and split in two for incubation (as indicated in the figure
legends) with 1 or 10 pg of GST, GST-centaurin-a, or GST-centaurin-ai
at 30 °C for 15 min. Glutathione-Sepharose beads and binding buffer
(300 /xl) were added to the reactions and incubated at room temperature
for an additional 1 h. The beads were washed 5 times with 1 ml of
binding buffer and electrophoresed on SDS-PAGE. After staining/
destaining, the gels were incubated with Amplify™ (Amersham Phar¬
macia Biotech), dried, and exposed to film.
Cell Culture and Transfection—COS-7 cells were obtained from the
European Collection of Cell Cultures. They were maintained in Dulbec-
co's modified Eagle's medium (Sigma) supplemented with 10% fetal calf
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Fig. 2. Identification of the 45-kDa
protein as centaurin-o^, a Ptdlns-
(3,4,5)Pa-binding protein. A, the band
corresponding to the 45-kDa protein (Fig.
1) was excised and subjected to trypsin
digestion and electrospray mass spec¬
trometry. Nine peptides were recovered
(shown in boxes). By using the "Pep-
tideSearch" program, they all matched
with centaurin-a! and eight of them with
centaurin-a. Both aligned sequences are
from rat (33, 45). Note that the first pep¬
tide is not identical in sequence to the one
that we found (from pig brain), but for
easier interpretation of the figure, we
aligned the sequence of centaurin-a and
-aj from the same species (rat). The 45-
kDa protein was purified from pig brain,
and the actual sequence of the peptide is
VPPFYYRPSASDCQLLR (the different
amino acids are underlined). This peptide
is identical in the pig centaurin-aj (34). B,
a schematic representation of centaurin-a
and centaurin-a!. Both these proteins
contain a zinc finger motif (Zinc) related
to the one found in ARF-GAP proteins.
Centaurin-a differs from centaurin-aj by
the presence of only one PH domain (PH)
rather than two and by a 43-amino acid
extension at the carboxyl-terminal end
(the differences are shown by dashed box¬
es). The mass spectrometric analysis was
able to differentiate between these two
proteins. Indeed, one peptide (KFVLTER)
is only present in centaurin-a! (in its first
PH domain) and not in centaurin-a.
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serum (Life Technologies, Inc.) and 1% penicillin/streptomycin (Life
Technologies, Inc.) at 37 °C in a humidified chamber with 5% C02. Cells
were transfected using Fugene (Roche Molecular Biochemicals) for
24-36 h in 60-mm diameter Petri dishes with HA-tagged CKIa(D136N)
and/or FLAG-tagged centaurin-o/centaurin-ai and/or empty vectors (4
pg of total DNA).
Co-immunoprecipitation—Cells were lysed with 1 ml of lysis buffer
(25 mM Tris, pH 7.5,137 mM NaCl, 1% Nonidet P-40,10% glycerol, 1 mM
DTT) containing a mixture of protease inhibitors (Roche Molecular
Biochemicals), 1 mM sodium fluoride, 1 mM sodium orthovanadate, and
10 mM sodium pyrophosphate. Lysates were pre-cleared with Pansorbin
cells (Roche Molecular Biochemicals) and centrifuged for 20 min at
15,000 x g at 4 °C. Mouse anti-FLAG M2 antibodies (Sigma) were
added to the lysates for 2 h. Protein-A/G coupled to Sepharose (Amer-
sham Pharmacia Biotech) was then added for an additional 1 h of
incubation. The beads were washed 4 times with 1 ml of lysis buffer,
and the proteins associated with the beads were resolved on 10%
SDS-PAGE. Proteins were transferred onto nitrocellulose (Bio-Rad),
and the presence of HA-CKIa was detected by Western blotting with a
rat anti-HA (Roche Molecular Biochemicals) antibody and ECL detec¬
tion (Amersham Pharmacia Biotech).
Affinity Chromatography with the CKI Peptide—Two rat brains were
homogenized in 20 ml of lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl,
10% glycerol, 1 mM EDTA, 1 mM EGTA, 2 mM DTT) containing a
mixture ofprotease inhibitors (Roche Molecular Biochemicals). Nonidet
P-40 was then added to a final concentration of 0.1%, and the mixture
was incubated at 4 °C for 2 h with constant agitation and subsequently
clarified by centrifugation at 15,000 x g for 30 min, followed by ultra-
centrifugation at 100,000 x g for 1 h. The resulting high speed super¬
natant was loaded onto a 1-ml Sulfo-Link (Pierce) column to which 1 mg
of a peptide corresponding to residues 214-233 (C-214FNRTSLPWQGL-
KAATKKQKY233) of CKIa was coupled (according to the manufactur¬
er's instructions). A cysteine was added at the amino terminus to allow
efficient coupling to Sulfo-Link. Brain extract was also loaded onto a
control column. The columns were washed with 50 ml of lysis buffer
containing 0.1% Nonidet P-40 and with 50 ml of phosphate-buffered
saline. Bound proteins were eluted with 10 ml of 50 mM Tris, pH 7.5, 1
M NaCl, 10% glycerol, 1 mM EDTA, and 2 mM DTT. Eluted fractions and
the last 5-ml washes were concentrated on Centricon-10 (Amicon) and
analyzed by immunoblotting. The presence of 14-3-3 proteins was de¬
tected using a rabbit polyclonal 14-3-3 Pan antibody (KK1106) from our
laboratory. Centaurin-a! was detected using a rabbit polyclonal anti-
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Fig. 3. CKIa: associates physically
with centaurin-a and centaurm-o^.A,
GST, GST-centaurin-a (GST-a)t and
GST-centaurin-a1 (GST-otj) were incu¬
bated for 2 h at 4 °C with purified histi-
dine-tagged CKIa. Glutathione-Sepha-
rose beads were then added. Beads were
washed and subjected to an in vitro ki¬
nase assay using a CKI-specific phos-
phopeptide substrate. The presence of 32P
incorporated into the peptide was quanti¬
fied by liquid scintillation counting and
represents CKIa activity associated with
the beads. B, CKIa was expressed and
35S-labeled using a T7 TNT-coupled tran¬
scription/translation reticulocyte cell-free
system and incubated with 1 pg of GST,
GST-centaurin-aq (GST-ctj) or GST-cen-
taurin-a (GST-a) for 15 min at 30 °C in
the presence of 0.1% Nonidet P-40. Glu-
tathione-Sepharose beads were added
and incubated at room temperature for an
additional 1 h. Beads were washed, and
samples were analyzed by 10% SDS-
PAGE followed by autoradiography (pan¬
el Pull down assay). An aliquot of the
lysate from the in vitro transcription/
translation assay was loaded on the gel
(panel Input). C, CKIa and 14-3-3 C, were
synthesized as described above (panel In¬
put). They were incubated with 10 pg of
GST or GST-centaurin-a! (GST-at) for 15
min at 30 °C in the presence of 1% Non¬
idet P-40. Beads were washed, and sam¬
ples were analyzed by 10% SDS-PAGE
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body (J49) that was raised against an amino-terminal peptide of cen¬
taurin-a, (33).
RESULTS
A Protein of 45-kDa Co-purifies with CKIa in Brain—We
have previously reported that 14-3-3£ was phosphorylated on a
novel site (44) and identified the kinase as CKIa after four
conventional chromatography steps (43). A total of seven pro¬
teins with molecular masses ranging from 25 to 80 kDa were
shown to co-purify with CKIa (Fig. 1), and we postulated that
they may form protein complex(es) in brain. A protein migrat¬
ing at 45 kDa represented the most abundant co-purifying
protein as judged by Coomassie Blue staining (Fig. 1). The
putative association between CKIa and the 45-kDa protein
would appear to be of high affinity because the complex was
observed after elution with 0.5 m NaCl during the two cationic
exchange chromatography steps and after elution with 0.6-0.8
m NaCl from the Affi-Gel blue column (the chromatography
steps are described in Ref. 43). Experiments were performed to
identify the 45-kDa protein and to elucidate whether it associ¬
ates with CKIa.
Identification of the 45-kDa Protein as Centaurin-aj, a
PtdIns(3,4,5)Ps-binding Protein—The 45-kDa protein band
was subjected to in-gel trypsin digestion, and the mass of each
peptide was measured by electrospray mass spectrometry.
Analysis of the peptide mass map using the "PeptideSearch"
program identified the 45-kDa protein as a PtdIns(3,4,5)P3
binding protein. We identified nine peptides that matched with
centaurin-a, and eight peptides that matched with centaurin-a
(Fig. 2A). Centaurin-a, shares high homology to centaurin-a.
Centaurin-a contains an extended carboxyl-terminal tail and
only one PH domain compared with centaurin-a, (Fig. 2B).
Therefore, peptide mass analysis differentiated these two pro¬
teins and identified the 45-kDa protein unequivocally as cen-
taurin-a, (42). Centaurin-a, has been given different names in
the literature including p42IP4 (34) and PIP3BP (35). However,
for clarity in the rest of this paper, we refer to it as
centaurin-a!.
CKIa Associates Physically with Centaurin-at—We tested
the potential interaction between CKIa and centaurin-a! using
purified recombinant proteins. We show that CKIa associates
with GST-centaurin-a, and not with GST (Fig. 3A). In addition,
CKIa also binds directly to centaurin-a (Fig. 3A).
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Fig. 4. CKIa associates in vivo with centaurin-a and cen¬
taurin-a,. COS-7 cells were co-transfected with plasmids expressing
the proteins indicated at the top of the figure or empty vectors. After
36 h, cells were harvested in lysis buffer containing 1% Nonidet P-40.
Centaurins were immunoprecipitated using mouse monoclonal anti¬
body (mAb) M2 anti-FLAG antibodies (Ab), and the presence of CKIa
was detected by Western blotting with a rat anti-HA monoclonal anti¬
body (clone 3F10).
In order to confirm this interaction, [35S]methionine-labeled
CKIa was synthesized using a cell-free coupled transcription/
translation system and incubated with GST, GST-centaurin-a,
or GST-centaurin-a! (Pig. 3B). The results show that CKIa
associates with centaurin-a and with centaurin-a,.
Therefore, two distinct experiments showed that CKIa inter¬
acts physically with both centaurins. The levels of CKIa that
associated with centaurin-aj remained the same in the pres¬
ence of 0.1-1% Nonidet P-40 (data not shown).
In order to verify the specificity of this interaction, [35S]me-
thionine-labeled CKIa and 14-3-3 £ were incubated with either
GST or GST-centaurm-a, (Fig. 3C). By using higher stringency
(1% detergent), centaurin-a! indeed associates with CKIa but
not with 14-3-3 £ even though the latter is expressed at much
higher levels than CKIa (Fig. 3C, panel Input), thus showing
the specificity of the interaction between centaurin-a, and
CKIa. In conclusion, centaurin-a and centaurin-a! associate
specifically and directly with CKIa. As rat centaurin-a (except
its unique carboxyl-terminal tail) shares 94% identity with rat
centaurin-ai (Fig. 2, A and B), one could imagine that they bind
to CKIa via a common domain, thus eliminating the impor¬
tance of the first PH domain of centaurin-aj and the carboxyl-
terminal domain of centaurin-a.
CKIa Associates in Cells with Centaurin-a and Centaurin-
aj—We tested whether CKIa associates in cells with cen¬
taurin-a!. For that purpose, we transiently transfected differ¬
ent cell lines in order to check the expression of ectopically
expressed CKIa. However, the expression of CKIa was not
detectable in cell lysates of PC 12 and NIH3T3 cells, was low in
HEK 293 cells, and only really detectable in COS-7 cells (data
not shown). Therefore, we have used COS-7 cells for the tran¬
sient transfection experiments as the other cell lines were not
suitable for co-immunoprecipitation experiments due to the low
expression level of CKIa. COS-7 cells were co-transfected with
HA-tagged CKIa and with FLAG-tagged centaurin-a or cen¬
taurin-a!. FLAG-tagged proteins were immunoprecipitated,
and CKIa in the immunoprecipitates was revealed by Western
blot using HA antibodies. This experiment shows that CKIa is
pulled down in centaurin-a (Fig. 4, 3rd lane) and centaurin-ai
b 0.1 b 1 b 10
GST-J4-3-3 ;
pHosvitin
Fig. 5. Centaurins are not phosphorylated by CKIa and have
no effect on CKIa kinase activity. A, 1 pg of purified GST, GST-
centaurin-a (GST-a), and GST-centaurin-a, (GST-a,) were assessed for
in vitro phosphorylation by purified histidine-tagged CKIa as described
under "Materials and Methods." Reactions were stopped and electro-
phoresed on 10% SDS-PAGE. The gel was dried and autoradiographed.
14-3-3 £ was phosphorylated by CKIa as a positive control (lane 14-3-3).
B, 0.1, 1, or 10 pg of recombinant centaurin-a, or buffer (6) was prein-
cubated for 15 min with CKIa. The reaction was initiated with the
addition ("+") of the CKI substrate 14-3-3 £. No substrate was added in
("—") as a control in case some degraded forms of centaurin-a, would be
phosphorylated by CKIa. C, 0, 0.1, 1, or 10 pg of recombinant cen-
taurin-a, or the corresponding volume of buffer (6) was incubated with
CKIa as described above. The reaction was initiated with the addition
of GST-14-3-3 £ or phosvitin.
(Fig. 4, 4th lane) immunoprecipitates and not in the controls
(Fig. 4, 1st, 2nd and 5th lanes). Therefore, the experiment
demonstrates that CKIa associates with both centaurins in
COS-7 cells.
Centaurins Are Not Phosphorylated by CKIa—We tested
whether CKIa phosphorylates centaurin-a and centaurin-a! ln
vitro using recombinant proteins. Fig. 5A shows that GST-
centaurin-a and GST-centaurin-a! were not substrates for
CKIa in vitro. As a positive control, 14-3-3 £, a CKI substrate
(43), was shown to be phosphorylated (Fig. 5A, lane 14-3-3 £). In
addition, recombinant centaurin-aj is not phosphorylated by
CKIa indicating that the GST tag itself does not confer confor¬
mational restraint and has an effect on the result (data not
shown). However, CKI isoforms have been shown to phospho-
rylate some substrates only if they have been previously phos¬
phorylated by another kinase two or three residues carboxyl-
terminal to the CKI site. Therefore, our in vitro results do not
completely eliminate the possibility that centaurins are not
substrates for CKIa. To investigate this possibility, FLAG-
tagged centaurin-a and centaurin-ai immunoprecipitated from
COS-7 cells were subjected to an in vitro kinase assay using
purified histidine-tagged CKIa. However, immunoprecipitated
proteins were not phosphorylated by purified CKIa (data not
shown). Therefore, we conclude from our experiments that
centaurin-a and centaurin-a, either purified or immunopre¬
cipitated from COS-7 cells are not substrates for CKIa.
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164 189 817 233
Fig. 6. Centaurm-a^ associates with
the residues 217-233 of CKIo. A, sche¬
matic representation of a series of dele¬
tion mutants of CKIa {WT, wild type).
Residues 17-287 constitute the kinase do¬
main. Residues 164-189 represent a loop
containing a kinesin homology domain
(1). Residues 217-233 are found in a loop
that has been proposed to be responsible
for the interaction ofCKIawith other pro¬
teins (46). The calculated molecular
masses of wild type and deletion mutants JjJ
of CKIa are shown in kDa. B, wild type
and mutant CKIa were synthesized using
an in vitro transcription/translation as¬
say, and an aliquot of the reaction (0.5%
input) was analyzed on 15% SDS-PAGE.
C, the rest of the reaction was incubated
with 10 fig of GST or GST-centaurin-ai
using the same protocol as described in
Fig. 35. The binding of CKIa was deter¬
mined by analysis on 15% SDS-PAGE and
autoradiography. D, a longer exposure of
the experiment shown above is presented
for the mutants 217-325 and 233-325 be-
cause of their lower expression compared V->
with the other mutants, thus providing
means of a better interpretation of the
results. E, brain extracts were loaded
onto a 1-ml peptide affinity column to
which a peptide corresponding to residues
214-233 (C-214FNRTSLPWQGLKAAT-
KKQKY233) of CKIa was coupled (CKI
peptide) or a control column {control). The
columns were washed, and bound pro¬
teins were eluted with buffer containing 1
M NaCl. Eluted fractions (elut) and the
last washes {wash) were subjected to
SDS-PAGE and analyzed by immunoblot-
ting using centaurin-aj or 14-3-3 antibod-
ies. A brain extract was also analyzed as a
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Centaurin-a, DoesNotAffect CKIaActivity—As centaurm-c^
does not represent a substrate for CKIa, we have tested
whether centaurin-a, affects the kinase activity of CKIa. We
have shown that different amounts of recombinant cen-
taurin-oq (0.1, 1, or 10 pg) have no effect on CKI activity using
14-3-3 C (Fig. 5B), GST-14-3-3 f, or phosvitin (Fig. 5C) as CKI
substrates.
Centaurin-a, Interacts with Residues 217-233 of CKIa—
Mammalian CKIa belongs to a family of seven isotypes that
show a high degree of homology in their kinase domains and
have variable amino- and carboxyl-terminal tails. Therefore, it
would be interesting to identify the centaurin-a1-binding site in
CKIa in order to elucidate whether centaurin-aq associates in a
region specific to CKIa or one that is also present in other CKI
isotypes. To address this question, we constructed a set ofCKIa
deletion mutants (Fig. 6A). These mutants were synthesized
and labeled with [35S]methionine in a cell-free coupled tran¬
scription/translation system (Fig. 6B) and incubated with GST
or GST-centaurin-aj (Fig. 6C). The different mutants were
expressed in similar amounts apart from mutants 217-325 and
233-325 that were less well synthesized (Fig. 6B). The results
show that the amino- and carboxyl-terminal domains (mutants
17—325 and 17-287) of CKIa are not required for the associa¬
tion. In addition, centaurin-a! binds with high efficiency to all
mutants apart from mutant 233-325. Although the levels of
expression of mutants 217-325 and 233-325 in cell lysates
were the same, mutant 217-325 bound to centaurin-aj whereas
mutant 233-325 did not (Fig. 6, C and D), demonstrating that
the binding occurs between residues 217 and 233 within the
kinase domain of CKIa. These residues belong to a loop be¬
tween helices E and F of CKIa that has been suggested to be
the target region for protein-protein interactions (46). In order
to confirm that residues 217-233 represent the site of interac¬
tion with centaurin-aq, a brain extract was loaded onto a col¬
umn containing this peptide or a control column. Centaurin-a,
was found to associate to the peptide column (Fig. 6E). This
association is highly specific as we did not detect the presence
of 14-3-3 proteins that represent 1% of total brain proteins.
In conclusion, our results mapped biochemically the cen-
taurin-aq-interacting site on a single loop of CKIa that had
been proposed previously from the three-dimensional x-ray
structure to be the site of interaction for CKI partners.
Centaurin-a, Associates with all Members of the CKI Fami¬
ly—Residues 217-233 of CKIa are well conserved in all CKI
isoforms as indicated in Fig. 7A. Therefore, itwas interesting to
determine whether other CKI isoforms were able to associate
with centaurin-aq. To that purpose, all mammalian CKI iso¬
forms were synthesized and labeled with [35S]methionine in a
cell-free coupled transcription/translation system and incu¬
bated with GST or GST-centaurin-aj (Fig. IB). All mammalian
CKI isoforms were capable of associating with GST-cen-
taurin-a! and not with GST alone (Fig. IB). Interestingly, a
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mutant of CKIS deleted of its carboxyl-terminal domain (CKIS
A317) binds as well as wild type CKIS to centaurin-a! (Fig. IB).
This result is in agreement with data from Fig. 6C that show
that the kinase domain of CKIa is sufficient for its association
to centaurin-aj. These data have led us to strongly believe that
centaurin-a j interacts with residues 217-233 of CKIa that are
well conserved in all CKI isoforms.
DISCUSSION
In this report we have identified centaurin-U] as a novel
CKIa partner based on the following evidence: (a) they co-
purified from brain after elution from four chromatography
steps; (b) centaurin-ax associates in vitro with CKIa indicating
that the binding is direct; (c) the binding is specific as cen-
taurin-aj does not interact in vitro with 14-3-3 f under the
same conditions; (d) they form a protein complex in COS-7 cells
as shown in immunoprecipitation experiments; (e) centaurin-a!
interacts with residues 217-233 of CKIa using deletion mutants
ofCKIa; and (/) centaurin-a! elutes from a peptide affinity chro¬
matography column containing residues 214-233 of CKIa.
CKI isoforms are characterized by a conserved core kinase
domain and by variable amino- and carboxyl-terminal tails. We
report here that centaurin-a! interacts with the kinase domain
and not with the unique tails of CKIa. Moreover, a mutant of
CKIS deleted of its carboxyl-terminal domain binds to cen-
taurin-aj as well as does CKIS, suggesting that the kinase
domain of CKIS represents the centaurin-binding site. In ad¬
dition, the site of interaction within the kinase domain (resi¬
dues 217-233) is present in a loop between two helices which
has been proposed to represent an interaction domain for CKI
targets (46). The residues within that loop are well conserved
among the CKI family. Indeed, we have shown that all mam¬
malian CKI isoforms are able to associate with centaurin-a! in
vitro. This suggests that the same loop, present in all CKI
isoforms, is responsible for the interaction with centaurin-aj.
Centaurin-aj and centaurin-a have been identified as
PtdIns(3,4,5)P3-binding proteins (33-35). Phosphatidylinositol
3-kinase is mainly responsible for the synthesis of
PtdIns(3,4,5)P3 by phosphorylating PtdIns(4,5)P2 at the 3-OH
position (47). Phosphatidylinositol 3-kinase is involved in regu¬
lating various biological processes including membrane ruffling,
membrane trafficking, and actin cytoskeleton regulation (48-50).
It is interesting to note that CKIa has recently been shown to
interact with the clathrin adaptor AP-3 (22), another
PtdIns(3,4,5)P3-binding protein (51). PtdIns(4,5)P2 has been
shown to inhibit CKIa activity in vitro (21). However, the phys¬
iological relevance of the inhibition of CKIa by these two phos¬
pholipids remains to be demonstrated. Another link between CKI
and the phosphoinositide pathway has been reported in S.
pombe. The authors showed that a yeast CKI homologue, Ckil,
phosphorylates and inhibits PtdIns(4)P 5-kinase (52).
Centaurin-a]; belongs to a newly identified family of ARF-
GAP proteins (reviewed in Refs. 36—39). Members of this fam¬
ily share a cysteine-rich GAP domain and contain several other
domains such as PH domains, SH3 domains, and ankyrin re¬
peats. These proteins are involved in vesicle trafficking and in
actin cytoskeleton rearrangement. Therefore, our data support
a role for CKIa in these biological events, in agreement with
previous reports (21, 22). Indeed, CKIa interacts with and
phosphorylates the clathrin adaptor AP-3 (22), which is in¬
volved in endocytosis. It is interesting to note that a genetic
interaction between yeast CKI and AP-3 was identified previ¬
ously (8). Moreover, CKIa has been found to co-localize in
neurones with synaptic vesicle markers and phosphorylates
some vesicle synaptic associated proteins (21). Interestingly,
centaurin-a] has been shown to associate with presynaptic
vesicular structures (53). An actin-associated protein kinase
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Fig. 7. Uentaurin-a, associates with all members of the CKI
family. A, sequence alignment of residues 217-233 ofCKIa with those
corresponding to the other CKI isoforms (/3—e). B, CKI isoforms (a, S, S
A317, e, yl, y2, and y3) were synthesized as described in Fig. 3B. They
were incubated with 10 pg of GST or GST-centaurm-a, (GST-a,) as
described in Fig. 3C in the presence of 1% Nonidet P-40 and 0.1% bovine
serum albumin. Beads were washed, and samples were analyzed by
12.5% SDS-PAGE followed by autoradiography (pull down assay). Aliquots
representing 2% of total lysate were analyzed as a control (lysate 2%).
shown to be a member of the CKI family phosphorylates actin
in vitro (54). The molecular mass of the kinase (37 kDa) sug¬
gests that it could be CKIa, and we have shown that recombi¬
nant CKIa indeed phosphorylates actin.2 In addition, the pro¬
tein DAH (Discontinuous Actin Hexagon) that interacts with
the actin cytoskeleton has been shown to be phosphorylated by
CKI in vitro (55).
Members of the ARF-GAP family contain several domains for
protein-protein interactions, and they have been shown to as¬
sociate with a number of different proteins. This suggests that
ARF-GAP proteins may act as scaffold proteins in addition to
their function as GAP proteins. Whether other ARF-GAP pro¬
teins interact with CKI is not known. The ARF-GAP proteins
Gitl and Git2 have been reported to regulate the internaliza¬
tion of some G-protein-coupled receptors (56-58). CKIa has
been shown to interact with and phosphorylate these G-pro-
tein-coupled receptors (31, 59). In addition, most of the identi¬
fied ARF-GAP proteins are involved in the Pak signaling path¬
way (reviewed in Ref. 36). Intriguingly, CKI-y2 has been found
to interact with the adaptor molecule Nek (60) in a complex
with Pakl (61), thus raising the possibility that CKI may
associate with other ARF-GAP proteins. Therefore, it would be
important to investigate whether ARF-GAP proteins interact
with CKI isoforms.
Gcsl, the budding yeast homologue of centaurin-a!, also
contains a cysteine-rich domain that is necessary for its ARF-
GAP activity (40). As yet, no ARF-GAP activity has been re¬
ported for centaurin-aj, but it is able of rescuing a AGcsl strain
mutant indicating that centaurin-a] and Gcsl may have simi¬
lar function(s) (62). Gcsl has been shown to be necessary for
2 T. Dubois, S. K. Maciver, and A. Aitken, unpublished data.
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the resumption of cell proliferation from stationary phase (63)
and is involved in endocytosis (7). Gcsl also plays a role in actin
cytoskeleton regulation in vivo and binds to actin in vitro (64).
As vesicle trafficking is closely associated to actin organization
in yeast, Gcsl may link vesicle trafficking and the actin cy¬
toskeleton (64). Yeast CKIs (Yckl and Yck2) were shown to
suppress the Gcsl blockage effects on cell proliferation and
endocytosis (7). The membrane association of Yck2 was neces¬
sary for this effect (7). Yckl/2 is involved in cytokinesis, in bud
development (5, 6), and regulation of the actin cytoskeleton as
yckts mutants fail to depolarize the actin cytoskeleton during
mitosis (5). Another link between Gcsl and CKI is the ankyrin
repeat protein Akrlp. Gcsl has been shown to interact with
Akrlp in yeast two-hybrid experiments (65). Akrlp and Yckl/2
regulate yeast endocytosis, and Akrlp regulates the plasma
membrane localization of Yckl/2 (11). These authors proposed
that the Yckl/2 membrane localization may involve other pro¬
teins such as Gcsl (65).
Our data suggest that CKIa does not phosphorylate cen-
taurin-a and centaurm-a^ In addition centaurm-c^ has no
effect on CKI activity. Therefore, what is the functional rele¬
vance of the interaction between CKIa and these
PtdIns(3,4,5)P3-binding proteins? As CKIa does not contain a
lipid binding domain, it may associate with membranes
through interaction with other proteins. Centaurin-a! may rep¬
resent one of these proteins, as has been proposed for its yeast
counterpart (see above and Ref. 65). CKIa may also represent
a downstream target for centaurin-a! as suggested by the re¬
sults in budding yeast showing that CKIs suppress Gcsl mu¬
tant phenotypes.
In conclusion, we have shown an interaction between CKIa
and centaurm-a^ a member of the ARF-GAP protein family
that is involved in membrane trafficking and actin cytoskeleton
regulation. Our present results are in agreement with data
reported previously suggesting a role for CKI in membrane
trafficking and/or regulation of the actin cytoskeleton. Our
findings are further supported by evidence of a genetic link
between CKI and Gcsl in budding yeast.
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Abstract Casein kinase la (CKIa) belongs to a family of
serine/threonine protein kinases involved in membrane traffick¬
ing, RNA processing, mitotic spindle formation and cell cycle
progression. In this report, we identified several CKIa interact¬
ing proteins including RCC1, high mobility group proteins 1 and
2 (HMG1, HMG2), Erf, centaurin-ai, synaptotagmin IX and
CPI-17 that were isolated from brain as CKIa co-purifying
proteins. Actin, importin-ai, importin-P, PP2Ac, centaurin-ai,
and HMG1 were identified by affinity chromatography using a
peptide column comprising residues 214-233 of CKIa. We have
previously shown that centaurin-ai represents a CKIa partner
both in vitro and in vivo. The nuclear protein regulator of
chromosome condensation 1 (RCC1) is a guanosine nucleotide
exchange factor for Ran which is involved in nuclear transport
and mitotic spindle formation. Here we show that CKIa and
RCC1 interact in brain and in cultured cells. However, the
interaction does not involve residues 217-233 of CKIa which are
proposed from X-ray structures to represent an anchoring site for
CKI partners. Formation of the RCCl/CKIa complex is
consistent with the association of the kinase with mitotic
spindles. In conclusion, we have identified a number of novel
CKIa protein partners and their relations to CKI are
discussed. © 2002 Federation of European Biochemical Soci¬
eties. Published by Elsevier Science B.V. All rights reserved.
Key words: Casein kinase la; Regulator of chromosome
condensation 1; Mitotic spindle formation
1. Introduction
Members of the casein kinase I (CKI) family are serine/
threonine protein kinases which are widely expressed in a
number of species ranging from plants to mammals (reviewed
in [1]). Seven isoforms from distinct genes are expressed in
mammals (CKIa, (3, 5, e, yi> 72, 73). However, many more
CKI forms are generated as a result of alternative splicing.
CKI isoforms contain a highly conserved kinase domain and
variable amino- and carboxy-terminal tails. CKIs appear to be
constitutively active and are not regulated by second messen¬
gers. However, CKI8/e activities are modulated by autophos-
phorylation [2-5]. CKI isoforms preferentially phosphorylate
proteins on residues that occur two to three residues down¬
stream of an acidic or a phosphorylated residue.
'Corresponding author. Present address: Institut Curie - Section
Recherche, CNRS UMR 144, 26 rue d'Ulm, 75 248 Paris Cedex 05,
France. Fax: (33)-1-42 34 63 77.
E-mail address: thierry.dubois@curie.fr (T. Dubois).
Mammalian CKI isoforms are involved in various biologi¬
cal functions. For instance, CKIe and CKIS play a role in the
regulation of p53 [6,7]. CKIe has also been implicated in
circadian rhythms [8] and in the Wnt signalling pathway
[9,10], CKIS/e are also implicated in membrane trafficking,
in the regulation of centrosome and in spindle formation
[11-13]. CKIY2 appears to play a role in actin cytoskeleton
organisation [14,15], CKIa has been shown to play a role in
cell cycle progression [16], in membrane trafficking [17-19]
and in RNA processing [20]. CKIs have also been shown to
regulate the nucleo-cytoplasmic localisation of some of their
substrates [21,22],
CKI isoforms contain a putative nuclear localisation signal
(NLS), a kinesin homology domain and exhibit a high degree
of variation in their subcellular localisations [1]. CKIa has
been shown to localise to synaptic vesicles, to the centro-
somes, with spindle microtubules at mitosis and also to nu¬
clear structures such as speckles [17,20,23]. CKIy2 is present at
the plasma membrane where it associates with membrane re¬
ceptors, Pakl and Nek [14,15,24]. CKIS is associated with
post-Golgi structures, microtubules and the spindle apparatus
[11-13],
Although the yeast CKI isoforms have been well character¬
ised, the functions of the mammalian CKI isoforms are much
less known. Therefore, the identification of mammalian CKI
substrates and binding proteins should help us to clarify their
cellular function(s). CKIa has been shown to interact with the
transcription factor NF-AT4 [21], G protein-coupled recep¬
tors [25], the AP3 complex [18], DARPP32 [26] and centaur-
in-a; [19], In this report, we have identified numerous novel
CKIa protein partners. One of these CKIa interacting pro¬
teins is the regulator of chromosome condensation 1 (RCC1).
RCC1 is a guanosine exchange factor for the small G protein
Ran which plays a role in nuclear transport and in mitotic
spindle formation (reviewed in [27-29]). We show that RCC1
co-purifies with CKIa in brain. RCC1 associates with a CKI
activity in brain and in cultured cells. Moreover, RCC1 inter¬
acts with ectopically expressed CKIa in COS-7 cells. Our data
suggest a role for CKIa in mitotic spindle formation which is
in agreement with its association with mitotic spindles [23].
2. Materials and methods
2.1. Identification of the CKIa co-purifying proteins from brain lysate
by mass spectrometry
We have previously identified from brain CKIa as a kinase which
phosphorylates 14-3-3 t and [30] and we found that several proteins
co-purified with CKIa [19,30]. The identification of these ckla co-
purifying proteins was performed by electrospray mass spectrometry
after trypsin digestion as described previously [19].
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2.2. Cell culture
COS-7 cells were obtained from the European Collection of Cell
Cultures. They were maintained in Dulbecco's modified Eagle's me¬
dium (Sigma) supplemented with 10% foetal calf serum (Life Tech¬
nologies, Inc.) and 1% penicillin/streptomycin (Life Technologies,
Inc.) at 37°C in a humidified chamber with 5% CO2.
2.3. Kinase assays on the immunoprecipitates
Brain tissue and cells were lysed as described [19], Lysates were pre-
cleared with Pansorbin cells (Roche Molecular Biochemicals) and in¬
cubated with an affinity-purified goat polyclonal RCC1 antibody
(Santa Cruz Biotechnology, Inc.). A mixture of protein A and G
(Pharmacia) was then added to precipitate the antibody. A kinase
assay was performed on the bead precipitates as described [19] using
14-3-3 C, wild-type or T232A (purified as in [30]) or the phosphopep-
tide KRRRALSpVASLPGL (where Sp is a phosphoserine; New Eng¬
land Biolabs) as CKI specific substrates. 14-3-3 C, T232A was used as a
control. Kinase assays using 14-3-3 proteins were analysed by SDS-
PAGE followed by autoradiography. In contrast, the phosphopeptide
substrate was spotted on P8I paper squares (Whatman) and washed
four times with 1% phosphoric acid. Radioactivity retained on the
papers was quantified by liquid scintillation counting [19].
2.4. Transfection and co-immunoprecipitation
COS-7 cells were transfected using Fugene (Roche Molecular Bio¬
chemicals) for 24-36 h in 60-mm diameter petri dishes with 4 pg of
DNA (HA-tagged CKIa wild-type or with the empty vector,
pCDNA3.1). Cells were serum-starved for 16 h and were either stimu¬
lated for 10 min with 100 nM insulin (Sigma) or left untreated. The
cells were lysed and RCC1 was immunoprecipitated as described
above. Proteins were transferred onto nitrocellulose (Bio-Rad) and
the presence of HA-CKI was detected by Western blotting with a
rat anti-HA (Roche Molecular Biochemicals) antibody and ECL de¬
tection (Amersham Pharmacia Biotech).
2.5. Identification of proteins which interact with residues 214-233 of
CKIa by affinity chromatography
This experiment was performed as described [19]. Briefly, rat brain
lysate was loaded onto a 1 ml Sulfo-Link (Pierce) column to which
1 mg of a peptide corresponding to residues 214-233 (C-214FNRTSL-
PWQGLKAATKKQKY233) of CKI was coupled. Brain extract was
also loaded onto a control column. Both columns were washed
extensively and bound proteins were eluted with 1 M NaCl. Eluted
proteins were revealed by mass spectrometry after in-gel trypsin di¬
gestion [19] or by Western blotting using high mobility group protein
I (HMGI; Pharmingen), RCC1 (Santa Cruz Biotechnology, Inc.),
centaurin-ai [19] and pan 14-3-3 [19] antibodies.
3. Results and discussion
3.1. Identification of CKIa co-purifying proteins in brain
During the purification of CKIa from brain as a protein
kinase which phosphorylates 14-3-3 proteins [30], several pro¬
teins co-purified with the kinase after four conventional chro¬
matography steps (SP-Sepharose, Blue Affi-gel Blue, Mono S
and gel filtration) [19]. These co-purifying proteins may rep¬
resent novel CKI-partners and we therefore attempted to
identify them by mass spectrometry. These proteins were iden¬
tified as Erf, RCC1, synaptotagmin IX, HMG1/2, centaurin-
ai and CPI-17 (Table 1). It should be noted that the in vitro
and in vivo association of CKIa with centaurin-ai has been
shown by our laboratory previously [19].
Some of the proteins that we have identified here have
previously been implicated in CKI functions. For instance,
HMGI, an architectural DNA binding protein [31,32], has
recently been shown to be phosphorylated by CKI [33], Erf
is a transcription factor of the Ets family [34] and Etsl has
been used as an in vitro CKI substrate [3], Moreover, we have
found that Erf is also phosphorylated in vitro by CKIa and
preliminary data indicate that it occurs within the serine/
threonine-rich domain of Erf (T. Dubois, G. Mavrothalassitis,
and A. Aitken, unpublished data). CPI-17, a protein phospha-
control RCC1 IP RCC1 Ab - + _ +
protein A/G T T~ *E T"
Fig. 1. RCC1 associates in vivo with CKI. A: Brain lysate was incubated with (RCC1 IP) or without (control) RCC1 antibodies and a mixture
of protein A and G was then added. A kinase assay was performed on the precipitates without (open bars) or with a CKI specific phosphopep¬
tide as the substrate (closed bars). The presence of radioactivity (32P) incorporated into the peptide was quantified by liquid scintillation count¬
ing and represents CKI activity associated with the beads. B: COS-7 cells lysate from insulin-stimulated cells or unstimulated cells was immu¬
noprecipitated with RCC1 antibodies. A kinase assay was performed using no CKI substrate (—), 14-3-3 ^ wild-type (14-3-3 C, WT) or a
mutant of 14-3-3 £ whereby the CKI phosphorylation residue was mutated to alanine (14-3-3 t, T232A). The kinase assay was analysed on
SDS-PAGE and the gel was autoradiographed. The position of 14-3-3 is indicated as well as the molecular weight markers (kDa). C: COS-7
cells were transfected with a plasmid expressing HA-tagged CKIa (+, top of the figure) or with the empty vector (—, top of the figure). Cells
were lysed and incubated with (+) or without (—) RCC1 antibodies followed by the addition of a mixture of protein A and G. The presence
of CKIa in the immunoprecipitates was detected by Western blotting using a rat anti-HA monoclonal antibody. The position of HA-CKIa is
indicated.
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Fig. 2. RCC1 does not associate with residues 217-233 of CK.Ia.
Brain extracts were loaded onto a 1 ml peptide affinity column to
which a peptide corresponding to residues 214-233 (C-
214FNRTSLPWQGLKAATKKQKY2") of CKIa was coupled (CKI
peptide) or onto a control column (control). The columns were
washed, and bound proteins were eluted with 1 M NaCl. Eluted
fractions (elut) and the last washes (wash) were subjected to SDS-
PAGE and analysed by immunoblotting using RCC1 or FIMG1
antibodies. Antibodies against centaurin-ai or 14-3-3 were used as
positive and negative controls, respectively [19]. A brain extract was
also analysed as a positive control for the antibodies (brain lysate).
tase 1 inhibitor [35], associates with and regulates the activity
of members of the CKI family (E. Zemlickova, F.J. Johannes,
A. Aitken, and T. Dubois, manuscript in preparation). Syn-
aptotagmin IX has been shown to associate with a mRNA
binding protein [36], The association of synaptotagmin IX
with CKIa is interesting in light of evidence which suggests
that CKIa may regulate certain steps of mRNA metabolism
[20],
Therefore, it appears that all the co-purifying proteins we
have identified are related in some way to the function(s) of
CKI. It also means that the affinity of these proteins is strong
enough to withstand four different chromatography steps. It is
noteworthy that the interactions between CKI and the co-
purifying proteins may represent in vivo complex(es) as they
were identified from brain. Whether these proteins interact
simultaneously or in a mutually exclusive manner with CKI
is not known. It is interesting to note that some of the pro¬
teins are mainly localised in the nucleus (RCC1, HMG1/2,
centaurin-ai and Erf). This may explain the observed associ¬
ation of CKIa with mitotic spindles and speckles within the
nucleus [1].
3.2. CKIa and RCC1 co-purify in brain
We also identified RCC1 as a protein which co-purified
with CKIa (Table 1). RCC1 is a guanosine exchange factor
Table 1
Identification of CKIa co-purifying proteins in brain
CKI co-purifying Function
proteins
HMG1/HMG2 DNA binding proteins
RCCI mitotic spindle formation, nucleo-cytoplasmic
shuttle
Synaptotagmin IX associates with a mRNA binding protein
Erf transcription factor of the Ets family
(repressor)
CPI-17 protein phosphatase 1 inhibitor
Centaurin-ai membrane trafficking
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for Ran, a small G protein of the Ras superfamily. RCC1 has
been involved in nuclear transport and mitotic spindle forma¬
tion (reviewed in [27-29]). Importantly, CKIa has been found
to be associated with mitotic spindles [23], Other members of
the CKI family (CKI5 and CKIe) have been proposed to play
a role in the regulation of centrosome or spindle function
during cell division. Both have been found to be recruited
to the centrosomes and to the spindle apparatus [11-13]. In
addition, yeast CKIs have been linked to chromosome segre¬
gation and cytokinesis [1]. Moreover, members of the CKI
family contain a kinesin homology domain [37], Kinesin,
which possesses this domain that has been proposed to be
involved in microtubule interactions, plays a role in the as¬
sembly of mitotic spindle and the segregation of chromo¬
somes. Therefore, experiments were carried out to characterise
the interaction of RCC1 with CKIa.
3.3. RCCI associates with a CKI activity in brain
We tested whether RCCI associates with CKI in brain. For
that purpose, endogenous RCCI was immunoprecipitated
from brain lysate using RCCI antibodies. A kinase assay us¬
ing a specific CKI phosphopeptide substrate was performed
on the RCCI immunoprecipitates. Results showed that RCCI
associates with a kinase which is capable of phosphorylating
the specific CKI phosphopeptide substrate (Fig. 1A, 'RCCI
IP'). The CKI activity is detected only in the RCCI immuno-
precipitate and not in the control, thus validating the experi¬
ment (Fig. 1A, 'control'). Therefore, results from Fig. 1A
indicate that a CKI activity specifically associates with
RCCI in brain.
3.4. RCCI associates with a CKI activity in cultured cells
In order to further confirm the endogenous association be¬
tween CKI and RCCI, we immunoprecipitated RCCI from
COS-7 cells and performed a kinase assay using another CKI
substrate. We have previously shown that CKI phosphory-
lates 14-3-3 £ on Thr-232 [30]. We have used 14-3-3 ( as a
substrate because the CKI phosphopeptide substrate may be
more prone to non-specific phosphorylation. Endogenous
RCCI associates with a kinase which is able to phosphorylate
14-3-3 £ WT but not 14-3-3 C in which the CKI phosphory-
control CKI peptide

















* actin + PP2Ac
We have identified six proteins by mass spectrometry that we found
to co-purify with CKIa in brain. These proteins are listed in the ta¬
ble and their functions are indicated.
Fig. 3. A number of brain proteins associate specifically with resi¬
dues 217-233 of CKIa. Brain extracts were loaded onto a peptide
column comprising residues 214-233 of CKIa as described in Fig.
2. Eluted proteins were analysed by SDS-PAGE and were visualised
by Coomassie blue staining. The bands were excised and subjected
to trypsin digestion and electrospray mass spectrometry. The peptide
map analysis identified some of the proteins as importin-ai, impor-
tin-p, actin, tubulin and PP2Ac. The positions of these proteins are
indicated as well as the molecular weight markers (kDa).
170 T. Dubois et al./FEBS Letters 517 (2002) 167-171
lation site has been mutated to an alanine (14-3-3 t, T232A)
(Fig. IB). In addition, the kinase activity associated with
RCC1 was not sensitive to insulin stimulation. This is consis¬
tent with CKI activity which is proposed to be second mes¬
senger-independent. In conclusion, Fig. IB indicates that en¬
dogenous RCC1 associates with an endogenous CKI activity
in COS-7 cells.
3.5. RCC1 associates with ectopically expressed CKIa in
cultured cells
To further demonstrate the association between RCC1 and
CKIa, we have transfected COS-7 cells with HA-CKIa. We
have used COS-7 cells as CKIa was found to be expressed
poorly or not at all (not detectable) in other cell lines tested
(discussed in [19]). Endogenous RCC1 was immunoprecipi-
tated and the presence of CKIa in the immunoprecipitate
was detected by Western blot analysis using an anti-HA anti¬
body. The results showed that endogenous RCC1 forms a
protein complex with ectopically expressed CKIa in COS-7
cells (Fig. 1C).
3.6. RCC1 does not associate with residues 217-233 from
CKIa
We have previously mapped the centaurin-a; binding site
within residues 217-233 of CKIa using several approaches
[19]. These residues belong to a loop between helices E and
F of CKIa that have been proposed to be the target region
for protein-protein interactions [38]. A brain extract was
passed through a column to which a peptide comprising res¬
idues 217-233 from CKIa was coupled [19]. We tested
whether RCC1 eluted from the peptide column by Western
blotting using RCC1 antibodies. However, we were unable to
identify RCC1 in any of the fractions eluted from the CKI
peptide column (Fig. 2), thus indicating that residues 217-233
of CKIa do not represent the RCC1 binding site. Centaurin-
ai and 14-3-3 antibodies were used as positive and negative
controls, respectively [19],
3.7. Identification of HMG1, importin-ail/3, catalytic submit
of protein phosphatase 2A (PP2Ac), tubulin and actin as
putative CKI partners interacting with residues 217-233 of
the kinase
Several proteins from brain specifically eluted from the CKI
peptide column as judged by Coomassie blue staining (Fig. 3).
We attempted to identify these putative CKI protein partners
by mass spectrometry. Proteins were digested with trypsin and
peptide mass map analysis identified them as HMG1, impor-
tin-ai, importing, PP2Ac and actin (Fig. 3). Therefore, these
proteins represent novel putative CKI partners interacting
with residues 217-233 of CKIa.
Intriguingly, the roles of importins are closely related to
those of RCC1. Indeed, RCC1 activates Ran which uses im-
portin-a/p as effectors in both nuclear transport and spindle
assembly (reviewed in [28]). The finding that importins bound
to the CKI peptide column emphasised a function for CKI in
these biological events and further supports our present re¬
sults regarding the CKI/RCC1 association. In addition, im-
portin-a recognises NLS-bearing proteins, and importin-P as¬
sociates with the importin-a-NLS complex to facilitate the
transport to the nucleus through the nuclear pore. Interest¬
ingly, residues 217-233 of CKIa contain a putative NLS (ami¬
no acids KKQK) [1] and we show that these residues repre¬
sent the CKI importin binding site. As CKIa is also expressed
in the nucleus, our results suggest that the transportation of
CKI to the nucleus is via its interaction with importin-ai/p.
We also identified PP2Ac as a protein which specifically
associates with residues 217-233 of CKIa (Fig. 3). In yeast,
a genetic link has been found between CKI and PP2A [39], In
addition, phosphorylation/dephosphorylation events by the
CKI/PP2A complex are important in endocytosis and actin
cytoskeleton organisation in yeast [40]. PP2Ac and CKI
may form a complex in which the two activities may regulate
each other [40], Supporting the existence of such a complex,
PP2A has been shown to associate with several protein ki¬
nases including casein kinase II [41], calcium-calmodulin-de-
pendent kinase IV [42], p21-activated kinase [43], p70 S6 ki¬
nase [43], Raf-1 [44] and cyclic adenosine monophosphate-
dependent protein kinase [45], Our data suggest that PP2A
also associates with CKI within residues 217-233 but further
experiments are required to characterise the interaction.
Actin was also found to interact with residues 217-233 of
CKIa (Fig. 3). This result is consistent with a report showing
that a protein having CKI activity and a molecular weight of
37 kDa associates with and phosphorylates actin [46]. The Mx
of the kinase suggested that it could be CKIa and we have
found that CKIa phosphorylates actin in vitro (T. Dubois,
S.K. Maciver, and A. Aitken, unpublished data). Taken to¬
gether, this suggests that CKIa associates with and phosphor¬
ylates actin, and we have mapped the site of interaction to
residues 217-233. Tubulin associates also specifically to the
peptide column (Fig. 3) and it is interesting to find this protein
in the context of the association of CKI with mitotic spindles.
Finally, we have identified HMG1 as a protein which asso¬
ciates specifically with residues 217-233 of CKIa by Western
blot analysis (Fig. 2). This result strongly supports the idea
that they form a protein complex after our finding that they
co-purified from brain (Table 1). In support of this finding,
HMG1 has recently been shown to be phosphorylated by CKI
[33].
4. Conclusions
We have identified numerous potential CKI protein binding
partners including RCC1. Our findings are consistent with a
role of RCC1 in mitotic spindle formation and the association
of several CKI mammalian isoforms with the mitotic spindle.
However, we do not know whether the association is direct or
via another molecule, and the possibility for RCC1 to be a
substrate for CKI has not been tested yet. In conclusion, the
association of CKI with RCC1 supports a role for this kinase
in mitotic spindle formation. The identification of RCC1,
HMG1, importin-ai/fl, PP2Ac, tubulin, actin, Erf, synapto-
tagmin IX, centaurin-ai and CPI-17 as CKI protein partners
gives a further insight into the biological roles of CKI. Indeed,
these interactions need to be fully characterised in order to
better understand the role of CKI in mammalian cells.
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